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I. GENERAL INTRODUCTION
1. Proteins and the need for adequate delivery systems
Proteins, nucleic acids, polysaccharides and lipid assemblies are the four major biopolymers. 
Among them, because of their variety of important biological functions, proteins and nucleic 
acids have attracted much more attention from biological scientists than the other 
biopolymers. Proteins are an integral part of the body as they carry out all important 
physiological and biological processes like enzyme reactions, acting as receptors for 
hormones or antibodies in the immune system. Due to these facts, protein pharmaceuticals 
have gained significant importance in the treatment of many severe diseases e.g. hormonal 
disorders, cancer, autoimmune diseases [1]. Naturally occurring proteins all consist of only 21 
??????????- and L-amino acids. Protein structure can principally be described at four different 
levels. The primary structure pertains to the linear arrangement of amino acids residues along 
a polypeptide chain or disulfide bonds between and within a chain. Secondary structure refers 
??? ???????????????????????? ??????????????????????????????????????????????-?????????????-sheets. 
???? ??????????? ?????????????????-???????? ?????-sheets leads to the tertiary structure, which 
also includes all of the non-covalent interactions that ensure the proper folding of a single 
polypeptide chain, such as hydrogen bonds and hydrophobic, electrostatic and van der Waals 
interactions. The quaternary structure finally refers to the non-covalent interactions that bind 
several polypeptide chains into a single protein molecule, as seen in most proteins [2].
It is understood, that the specific function of proteins is reflected by its tertiary structure [3] 
which is a consequence of the mentioned substructures. This complex architecture of proteins, 
the tertiary structure with labile bonds and side chains with chemically reactive groups offers 
some serious limitation for their use as drug substances. They can undergo non-chemical 
changes i.e. physical instability e.g. unfolding (denaturation).This leads to loss of native 
structure resulting in interaction with surroundings by adsorbing to surfaces or aggregating 
with other protein molecules. Protein aggregation often leads to immunogenicity [4-6]
Chemical degradation e.g. oxidation, deamidation and disulfide exchange causes disruption of 
substructures or modification of side chains leading to loss activity. Above all, the most 
challenging task is their delivery. In contrast to conventional molecules, which are mostly 
stable with low molecular weight reasonable lipophilic properties and hence can be 
transported through cellular barriers and membranes, proteins require a sophisticated delivery 
system. Due to their hydrophilic nature and high molecular weight, proteins have poor 
intrinsic permeability across biological membranes.
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Another barrier a protein has to overcome in the human body is the enzymatic equipment of 
the gastro intestinal tract: various enzymes (e.g.  pepsin), intestinal pancreatic proteases (e.g. 
trypsin), elastases, brush border proteases (e.g. aminopeptidases) leading to degradation [2]. 
To avoid contact with these degrading enzymes, proteins can be delivered by several different 
ways: 
? By parenteral injection: e.g. subcutaneous, intramuscular and i.v.
? Pulmonary: by inhalation
? Nasal: sprayed or inhaled
? Transdermal: via liposomes or patches
Nasal delivery: there are a few nasal products approved by the EMEA, e.g. nasal salmon 
calcitonin marketed by Novartis, nasal desmopressin marketed by Ferring and partners.
The major advantage of the nasal administration is the avoidance of protein degradation 
resulting from acidic, enzymatic and first pass metabolism. But there are also some serious 
disadvantages that limit the potential of the nasal drug delivery. First of all the volume that 
can be delivered is restricted to 25-200µl. The most important factor limiting the nasal 
absorption of large molecular weight drugs, such as proteins and peptides is the low 
membrane permeability. Only molecules with a molecular weight under 1000 Da can pass the 
membrane [7, 8].
Pulmonary delivery: Many proteins are absorbed from the deep lung surprisingly well. 
Protein bioavailabilities (relative to subcutaneous administration) of at least several percent 
and (in rare cases) up to almost 50% have been recorded [9]. An inhalable insulin preparation 
(ExuberaTM) invented by biotech startup Nektar Therapeutics and shepherded to market by 
Pfizer has been approved in January 2006 by the FDA.  However in October 2007 Pfizer 
announced to take Exubera off the market and returned all rights to Nektar Therapeutics [10].
According to Pfizer Chief Executive Jeffrey Kindler Exubera has failed to gain acceptance of 
patients and physicians and therefore was not economically successful.
Transdermal delivery: Due to the anatomy of the skin, especially the horny layer, the so 
called stratum corneum, which prevents the entry of most pathogens and most chemicals 
when undamaged, bigger molecules like proteins, can hardly enter the deeper layers of the 
skin. The FDA has approved, throughout the past 22 years, more than 35 transdermal patch 
products, spanning 13 molecules, but none of them were proteins. This does not mean that 
there is no adequate method for transdermal protein delivery. There are a few promising 
techniques for protein delivery into the skin. These transdermal technologies are iontophoresis 
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(which uses low voltage electrical current to drive charged drugs through the skin) [11] and 
sonophoresis (which uses low frequency ultrasonic energy to disrupt the stratum corneum 
[12]. These systems can achieve significant skin permeation enhancement, enabling more 
effective delivery of proteins, such as insulin and calcitonin. A newer and potentially more 
promising technology for macromolecule delivery is microneedle-enhanced delivery [13]. 
These systems use an array of tiny needle-like structures to open pores in the stratum corneum 
and facilitate drug transport. Macroflux® from Alza or 3M’s Microstructured Transdermal 
System (MTS).
2. Parenteral delivery and polymeric systems
Parenteral injection is the most often used route of drug administration. Since most 
pharmaceutical proteins, given by injection, must be administered in several doses to reach 
therapeutic useful concentrations in the blood plasma, resulting in low patient compliance and 
high hospital costs are resulting. To avoid the disadvantages of multi dose injections, the 
technology of retarded release was developed. The first controlled-release technology was 
developed in 1962 and was based upon diffusion of small molecules through the wall of 
silicone rubber tubing [14]. Although the molecular mass was not allowed to be bigger than 
600 Daltons, to diffuse through the rubber, it was a first promising step into a new land. Only 
a few years later Langer showed that it is possible to release big molecules from polymers as 
described in the following part of this paper.
Controlled release of macromolecules from nondegradable polymers
As already mentioned earlier, most polymers, e.g. ethylene vinyl acetate copolymer (EVAc), 
are impermeable to molecules larger than 600 Daltons (e.g. polypeptides and proteins) since 
most of these macromolecules are too large to penetrate through the linked polymer chains, 
even after polymer swelling. In 1976, while working on tumor angiogenesis, Langer and 
Folkman discovered their need for a device that could provide steady diffusion of tumor 
angiogenese factor (TAF) into rabbit cornea from a depot source. After failing to deliver the 
TAF with poly(acrylamide) pellets (they were often highly inflammatory), Langer and 
Folkman tried another polymer, ethylene vinyl acetate copolymer, which turned out to be very 
useful. They prepared the pellets by mixing the bioactive agents with a solution of EVAc in 
methylene chloride. The resulting dispersion was poured into a mold, allowing the solvent to 
evaporate under vacuum over night. Their pellets provided a zero order release between 20 
and 100 days for several proteins e.g. lysozyme, catalase and soybean trypsin inhibitor. They 
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also used the ethylene vinyl acetate copolymer to release insulin, heparin and DNA. For 
periods up to 60 days nearly 1µg of each drug was released per day through these systems 
[15]. As explanation for the sustained release of macromolecules, Langer quoted the 
formation of a tortuous, interconnected pore network, through which the molecules can 
diffuse. These pores originated from dissolving embedded polypeptide powder within the 
polymer matrix. By varying the particle size and the loading of the matrix, rate of release can 
be controlled. If the matrix is low loaded, not all the polypeptide is released from the polymer. 
This can be easily explained: If the loading of the polymer matrix is low, the chance that 2 
particles have contact or that they are embedded at the surface is low. These particles will be 
completely surrounded by the impermeable polymer matrix. They are trapped, since the 
water, dissolving the macromolecules and thus releasing them, isn’t able to permeate through 
the polymer. Pores within the polymer matrix are the key for drug release. In contrast a highly 
loaded matrix is able to release almost all the embedded molecules, since more particles are 
embedded and the chance that they have contact with each other and the surface of the matrix 
is increased. Particles build clusters which can extend from the surface deep into the matrix. 
When dissolved by the releasing medium, these clusters leave a connected pore network 
behind, allowing the water to infiltrate through the pores deep into the matrix and dissolving 
all particles it contacts. There is also an increase of the released molecules if the polypeptide 
particle size is increased. This is because the larger the polypeptides are, the more they touch 
the surface and the bigger are the resulting pores when dissolved [16]
Figure 1: Schematic of EVAc-polypeptide matrices before release
a. Low loading – most drug is trapped by surrounding polymer
b. High loading – almost all drug is connected to surface via other drug particles, and is therefore 
releasable.[16]
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Although the particles are dissolved in water and thus released through aqueous filled pores, 
the relevant diffusion coefficient isn’t the diffusion coefficient of polypeptides in water. In 
this case the releasing times durations should be much shorter. Even assuming that the 
network within the matrix, containing pores (space evacuated by a drug particle) and channels 
(space connecting two pores), is highly tortuous, this would not explain a release continuing 
for months. It is also unlikely that retardation of release is due to absorption of polypeptides 
onto the pore walls. Assuming a monolayer of absorbed drug on the pore walls would only 
consist of an insignificant part (less than 1%) of the entire drug within the pores. Langer
postulated that the sustained release is dependent to a geometrical feature of the pore structure 
within the polymer matrix. Scanning electron micrograph showed that pores are connected by 
channels whose radii are substantial smaller than the pore radii. Thus nature of sustained 
release is due to the random walk of drug molecules in the pores and due to the time a 
molecule takes until it exits the pore.
Figure 2: Schematic of pores through which a diffusing drug molecule must pass [16].
In addition to the already mentioned parameters influencing the sustained release there are a 
few more. Dissolution properties of polypeptides are variable. For instance native insulin, 
consisting of three dimers associated around two zinc ions, has a high solubility compared to 
Ultralente-insulin, one of the most protracted insulin analogs [17]. It is therefore understeood 
that the resulting dissolution rate in the depot matrix leads to different releasing rates. 
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Concentrations of polypeptide and drug-excipient ratio are as well a parameter, influencing 
the releasing rate. If there is a high concentration of drug embedded within the matrix, 
resulting solution becomes very viscous, leading to a diffusion coefficient decrease, resulting 
in prolonged release [16]
Biodegradable polymers and their classification
After all the years of research associated with protein drug delivery with polymer devices, one 
major problem still persisted: The polymer systems were non-biodegradable and required 
surgical removal after drug delivery was complete, otherwise inflammation- and toxicity-
problems could occur. Thus, there was a need for biodegradable polymers. Biodegradable 
polymers are synthetic or natural polymers which degrade in vivo, either enzymatically or 
non-enzymatically i.e. by hydrolysis or solubilization, to produce biocompatible or non toxic 
by-products along with the progressive release of dissolved/ dispersed drug. In general 
degradation is understood as the chain scission process by which polymer chains are cleaved 
into oligomers or monomers [18]. A variety of synthetic and naturally occurring polymers 
have been intensively studied over the last 30 years.
Table 1: Classification of biodegradable polymers/materials [19]:
Polyorthoesters
Polyanhydrides
Polyamides
Polyalkylcyanoacrylates
Polyesters: Lactides/Glycolides, Polycaprolactones
Polyphosphazenes
Synthetic
Pseudopolyaminoacids
Proteins
Polysaccharides 
Starch
Alginate 
Natural
Lipids
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Biodegradable synthetic polymers and the preparation techniques used for the 
manufacturing of drug delivery systems 
Synthetic polymers used for the preparation of drug delivery systems fulfil the following 
requirements: In general they are biologically inert, compared to natural occurring polymers 
they have more predictable properties and batch-to-batch uniformity in addition to that, they 
offer the advantage of having tailored property profiles for specific applications.. The 
successful application of the first synthetic polymer based biodegradable suture system in the 
late 1960s [19] was followed by a tremendous increase of design and development of a new 
series of biodegradable polymers used for the preparation of implants and related medical 
applications. Since then research has concentrated on the custom design of biodegradable 
polymer systems with predictable erosion kinetics as drug/gene delivery carriers or as 
materials scaffolding tissue and cells in several bio engineering applications. 
PLGA
???? ??? ???? ???? ?????????? ?????????? ??? ??????????? ?? ??????????? ????????? ????? ??????????? ?????
and/or  polyglycolic acid- i.e. poly(D,L-lactide) (PLA), polyglycolic acid (PGA) and 
copolymers of lactide and glycolide (PLGA) have found the most widespread use [20]. 
??????? -ester)s are thermoplastic polymers with hydrolytically labile aliphatic ester linkages 
in their backbone. Attractive features of these polymers are:
Largely abundant toxicological and chemical data, biocompatibility/histocompatibility, 
predictable biodegradation kinetics, ease of fabrication, versatility in properties, variety in 
copolymer ratio and molecular weights. However, the most important feature is the regulatory 
approval. Employing these polymers, a broad spectrum of performance characteristics can be 
obtained by manipulating four key variables:1)monomer stereochemistry, 2)co-monomer ratio 
3) polymer chain linearity and 4) polymer molecular weight. Varying co-polymer ratios 
results in different crystallinities, affects the glass transition temperature and the polymer 
hydrophilicity. A change in chain linearity influences as well the polymer hydrophilicity 
which directly influences the water influx into the polymer. This water influx has a great 
effect on the polymer degradation rate as highlighted later in the respective section of this 
introduction. Nowadays most PLGA drug release systems consist of drugs embedded in 
microparticles; however there are a few systems consisting of implants of various shapes and 
sizes. In the following section most PLGA drug release systems and their preparation 
techniques are presented.
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PLGA-microparticles: 
By definition microparticles are spherical devices with a size within the range of 1-1000 µm.
They can be divided into 2 categories: microcapsules and microspheres. Microcapsules 
contain a core in which the drug is embedded, surrounded by a polymeric membrane [21].
In microspheres the drug is embedded in the whole polymeric matrix. The ideal size of 
microparticles, for parenteral use is less than 125µm. Several methods are suitable for 
producing microparticulate systems, all of them have to include following the requirements:
? stability and activity of the protein should not be adversely affected by the 
production   method      
? drug encapsulation efficiency should be high
? the drug release profile and the microsphere quality should be reproducible 
Manufacturing techniques of PLGA Microparticles
There are two different types of methods to produce PLGA microparticles:
Chemical and physical preparation techniques. The former method deals with Polymerisation 
of the PLGA, complexation, emulsifying and altering the properties of the solvent. Physical 
methods involve working with a gas phase, which helps to congeal the polymer. Of course the 
author is aware that this nomenclature is somewhat confusing since all presented methods are 
based on physical processes and do not involve changes in the chemical structure of the 
polymers. However, this nomenclation has grown historically and therefore shall be still 
applied in this introduction:
So called Chemical procedures are: 
Single emulsion method: This process involves oil-in-water-emulsification in which 
micronized protein powder is dispersed into the organic solvent phase containing dissolved 
polymer. The organic phase then is emulsified in an aqueous phase, leading to microcapsules 
[22]. Double (multiple) emulsion process: This is a water-in-oil-in-water (w/o/w) method 
and is best suited to encapsulate water-soluble drugs like peptides, proteins, and vaccines.
Disadvantages of the emulsion methods are the existence of diverse interfaces which are 
destabilize the fragile structure of the proteins. This adsorption step can induce protein 
unfolding, inactivation and aggregation. Morlock et al. showed that during the procedure of 
microencapsulation of rh-erythropoetin using PLGA, the first processing step namely the 
formation of W/O emulsion was mainly responsible for epo-aggregation. The following steps 
didn’t seriously increase the total amount of aggregates [23, 24]
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Phase separation (coacervation): This encapsulation process was discovered and developed
by Barrett K Green of the National Cash Register Corporation (NCR) in the 1940's and
1950's. Coacervative encapsulation (or microencapsulation) is a three part process: particle or 
droplet formation; coacervative wall formation; and capsule isolation. In the field of drug 
microencapsulation into PLA/PLGA, the term coacervation is commonly used for polymer 
phase separation induced by the addition of a coacervating agent to the polymer solution. 
Typically, addition of poly(dimethylsiloxane) (PDMS, silicone oil) to PLA/PLGA dissolved 
in methylene chloride (DCM) yields the so-called coacervate droplets, which are solidified in 
a hardening agent, such as hexane or octamethylcyclotetrasiloxane (OMCTS), to produce the 
final microspheres. It is a non aqueous method and hence is suitable for encapsulating both 
water soluble and water insoluble proteins [25]
Physical Procedures: 
Spray drying: The dissolved polymer (possible solvents are acetone, methylene chloride) 
therein the protein, suspended as solid or emulsified as aqueous solution, is atomized through 
a heated nozzle [26].
Varied spray drying techniques: A novel low-temperature spraying method for preparing 
PLA and PLGA microspheres has been reported by Herbert et al.  PLGA solution with 
suspended or emulsified Protein was sprayed into a vessel containing liquid nitrogen 
overlaying a frozen extraction solvent like ethanol. The liquid nitrogen is subjected to 
evaporation causing the polymer solvent from the frozen droplets to be extracted then by 
liquid ethanol. The produced microspheres were then filtered and the residual solvents 
evaporated by filtration. Advantages of this spray freezing method include maintaining the 
proteins stability and activity as well as achieving very high encapsulation efficiency [27]
Techniques using supercritical fluids (SCF):
This method has the advantage of working without organic solvents since it replaces the 
solvents with carbon dioxide involving very low temperatures. Supercritical means the area 
above the critical point, which is defined as the point where the boundary layer between liquid 
and gas in a phase transition curve vanishes. Carbon dioxide is one of the most commonly 
used supercritical fluids for SCF processing of drug compounds, owing to the fact that it 
reaches super-criticality at a relatively mild temperature (~31°C). These fluids, the properties 
of which can be tuned by changing the fluid density between those of liquid and gases, have 
been adopted or are being explored as: alternative solvents for classical separation processes 
such as extraction, fractionation, adsorption, chromatography, and crystallization, as reaction 
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media as in polymerization or depolymerization, or simply as reprocessing fluid as in 
production of particles, fibers, or foams. Some of the extraction processes, such as 
decaffeination, and some polymerization and foaming processes, have become commercial. 
Because SCF processing conditions do not strictly necessitate temperature extremes, 
operational parameters may be developed that are more suitable for temperature-sensitive 
protein species besides lyophilization or spray-drying [28]. Presently several modified 
processes exist which use various mechanisms for precipitating particles:
Rapid expansion of supercritical solutions (RESS): 
This process is based on the solubility difference of the polymer in SC in high and low 
pressures; it is used when the polymer has some degree of solubility in the SCF. The polymer 
is dissolved in the supercritical fluid. As this high-pressure solution is rapidly depressurizing 
through a nozzle, polymer is precipitating.
Gas antisolvent process (GAS):
The supercritical fluid is used as an antisolvent, due to the fact that many polymers aren’t 
soluble in SCF. The polymer first is dissolved in a suitable solvent e.g. ethanol. For 
precipitating the polymer gas (not necessarily supercritical gas) is injected into the solution in 
a chamber. With increasing gas concentration in the solution, the polymer precipitates.
Supercritical antisolvent process (SAS):
In this technique a supercritical fluid acts as an antisolvent for polymer solutions like in the 
GAS process, but the contacting mechanism is different. Dissolved polymer is sprayed in a 
chamber in which a supercritical fluid, the antisolvent, already exists, causing rapid contact 
between the two media. Contact causes supersaturating leading to fast nucleation growth and 
hence smaller particles.
PLGA implants
Compared to the countless publications dealing with the manufacturing of PLGA 
microparticles there are only a few publications describing PLGA implants for protein 
delivery. There are several methods manufacturing PLGA implants:
Solvent casting method [29] Firstly an aqueous solution of the drug was poured into a Teflon 
mould and freeze-dried. A solution of the polymer was then poured on the cake. The solvent 
was allowed to evaporate at 4°C for 48h. The resulting drug-polymer cake was vacuum dried 
until all residual solvent was gone. This procedure leads to laminar implants with a thickness 
about half a millimetre.
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Injection-molding method [30] A special adapted molding machine was used. Melted 
polymer-drug dispersion (100°C) was injected into the mold with a pressure of about 130 bar, 
then it was cooled at 14°. One of the implant ends was round shaped for injection for 
facilitation under the skin. The rods had a diameter of 4,6mm. Surely, due to the high 
temperatures and the pressure, this method isn’t suitable for temperature-sensitive protein 
drugs.
Extrusion-techniques [31]: Using a ram extruder, implants were gained by extruding 
mixtures of polymer and drug. Extrusion temperatures range between 80°C and 175°C. 
Extrusion techniques are the most convenient ways of producing PLGA implants for protein 
delivery. Apart from the ram extruder, the screw extruder’s also suitable for manufacturing 
implants. The goserilin acetate implant Zoladex© is produced with an extrusion technique: A 
lyophylisation cake containing the polymer and the drug is formed into implants by extruding 
????? ??????????????????????????????????????????????????-radiation [32]. 
Polyanhydrides
In 1980, Langer was the first who exploited the hydrolytically unstable nature of the 
Polyanhydrides for sustained release of drug in controlled drug release applications, using 
poly[bis(p-carboxyphenoxy)methane], as a bioerodible matrix for controlled drug delivery 
[33]. Matrices fabricated from this material and containing cholic acid showed a period of 
nearly zero-order erosion kinetics during which this steroid was released at nearly the same 
constant rate. Five years later, Langer and his group developed Poly[bis(p-
carboxyphenoxy)propane (P(CPP)) anhydrides with copolymers of sebacic acid (SA), 
(P(CPP:SA)) [34]. This biodegradable compound, which breaks down to dicarboxylic acids 
by spontaneous reaction with water, exhibits several important properties [35]:
? The macroscopic breakdown of the polymer is limited to its surface.
Zero order kinetic releasing rates can thus be achieved.
? The rate of breakdown of PCPP:SA polymers can be varied by altering the ratio of the  
monomers CPP and SA.
? The matrix is completely degradable.
? The degradation products of these polymers are nonmutagenic, noncytotoxic, and have 
a low teratogenic potential [34].
In 1996 Gliadel® , a PCPP:SA wafer carrier containing carmustine for the treatment of brain 
tumour, entered the U.S. market [35]. In the last few years, investigations have expanded to 
newer polymers and other drugs such as 4-hydroperoxy cyclophosphamide (4 HC), cisplatin, 
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carboplatin, paclitaxel and several alkaloid drugs in an effort to develop a better system for 
treating brain tumors incorporated into poly(FAD-SA), prepared by mixing the drug in the 
melted polymer, has been evaluated for the treatment of brain tumors in laboratory animals 
[36] Disadvantages of the Polyanhydrides may be the need for special fabrication techniques 
for controlled release devices. The temperature required for the fabrication of polyanhydride 
matrices is too high for sensitive molecules like proteins, thus a solvent extraction technique 
derived from the standard W/O/W emulsion method for PLGA microspheres had to be used 
[37].
Poly(ortho esters)
Over the last 30 years, poly(ortho esters) have evolved through four families, designated as 
POE I, POE II, POE III and POE IV. Of these, only POE IV has been shown to have all the 
necessary attributes to allow commercialization [38]. Therefore, only the POE IV will be 
outlined in this short review.
POE IV is a modification of POE II (as shown in Fig.3) 
Figure 3: [38]
POE IV was created by incorporating short segments based on lactic acid or glycolic acid into 
the polymer backbone of POEII. These segments act as latent acids, because they readily 
hydrolyze to glycolic or lactic acids, which then catalyze hydrolysis of ortho ester linkages in 
the polymer backbone. By controlling the concentration of such segments in the polymer, rate 
of erosion can be accurately controlled. POE IV possesses 3 major features of protein release 
kinetics: First, there is either no drug burst or only a minimal burst, even when very 
hydrophilic drugs are incorporated in the polymer matrix. Second, a significant lag time was 
monitored. Finally, polymer weight loss and drug release occur concomitantly, due to the 
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surface erosion controlled protein release [30] [39]. The lag time can be reduced by admixing 
the monomethyl- polyethylene-glycol-ether to the polymer-protein mixture. Obtained 
extrudates liberated the protein for a 2 months period following zero order kinetics [30] n 
summary, poly(ortho esters) for protein and peptide delivery are very promising, but due to 
the fact that bulk degradation cannot be completely inhibited some questions about erosion 
properties have to be answered [38]
3. Erosion of polymers
Polymer erosion can be defined as a process of material loss of the polymer from the initial 
bulk weight [18]. This process usually is driven by degradation processes. Degradable 
polymers are classified in surface-eroding and bulk-eroding polymers. In addition to that, 
polymers can be defined as hydrolytically degradable polymers and enzymatically degradable 
polymers.
Hydrolytically degradable polymers are materials with hydrolytically labile chemical bonds 
in their back bone. The functional groups susceptible to hydrolysis include esters, orthoesters, 
anhydrides, carbonates, amides, urethanes, ureas [40].  Although all polyesters are 
theoretically degradable as esterification is a chemically reversible process, only aliphatic 
polyesters with reasonably short aliphatic chains between ester bonds can degrade over the 
time frame required for most of the biomedical applications. Hydrolytically degradable 
polymers can undergo both surface- and bulk-eroding processes. In general the basic 
composition of the polymer determines the erosion behaviour to some degree. Reactive 
groups such as anhydrides tend to fast degradation and therefore show surface erosion 
whereas polymers containing less reactive groups i.e., esters tend to bulk erosion [18]. In the 
case of surface eroding polymers, erosion proceeds at constant velocity. For bulk eroding 
polymers such as poly(d,l-lactic acid) (PLA) and poly(d,l-lactic-co-glycolic acid) (PLGA), 
however, things are more complicated as they have no constant erosion velocity [41]. Usually 
they do not erode for a long period of time. This time of constant mass is followed by a 
spontaneous loss of mass during a short period of time. When polymer areas within the 
polymer bulk degrade, they cannot erode if they have no connection to the erosion medium 
via pores. When the polymer is degraded to a critical degree, these degraded areas form a 
continuous cluster that stretches to the surface of the matrices and cause their spontaneous 
erosion. How a polymer matrix erodes depends on the size of the matrix, the diffusion 
coefficient of water inside the matrix and on the degradation rate of the polymer’s functional 
groups. If the degradation rate of the polymer backbone is faster than the diffusion of water 
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into the polymer matrix, erosion will primarily occur at the surface. In contrary, a polymer 
matrix system undergoes bulk erosion, if water diffuses faster into the matrix than the 
degradation rate of the polymer backbone [41].
Figure 4: Schematic illustration of the changes a polymer matrix undergoes during surface erosion 
and bulk erosion [42]
Enzymatically degradable polymers comprise natural or synthetic materials like proteins, 
polysaccharides and lipids. These materials can undergo degradation in the presence of 
enzymes. The enzymes e.g. lipases exhibit an amino acid sequence consisting of serine, 
histidine and aspartad called the catalytic triad. This functional centre of the enzyme is buried 
under a short helical segment, termed the lid [39, 40]. When the enzyme adsorbs on a 
hydrophobic surface a conformational change opens the lid, activating this structure and 
enabling its enzymatic function [43, 44]. Due to this activation mechanism enzymatic 
degradation of polymers is a strict surface erosion process. The degradation velocity is mainly 
based on the enzyme activity therefore the rate of in vivo degradation can vary significantly 
with the site of implantation [19]. In addition to that degradation rate exhibits great 
differences when compared between different species. Enzyme activity and erosion velocity 
can be controlled to some degree by the addition of non-degradable polymers. Blending 
enzymatically degradable polymers with materials such as polystyrene alters the properties of 
the polymer surface i.e., the surface free energy. In that way the material life-time of such 
blended materials can be controlled in a reproducible manner [45]. In contrary to the above 
mentioned method non-degradable polymers can be processed into materials susceptible to 
enzymatic degradation by blending with biomaterials easily degraded by enzymes [46].
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4. Polymer erosion and its influence on the entrapped drug
As a consequence of the erosion process the interior of polymer drug delivery systems can 
change dramatically involving changes in pH, osmotic pressure, polymer crystallinity and 
hydration [24]. Especially bulk eroding polymers show distinct pH-shifts in the release 
medium dropping down to pH-values of about 3 [47]. This acidification of the release 
medium has its origin in the inner part of the polymer material where the hydrolytic 
degradation of the polymer chains leads to a tremendous pH shift creating a micro 
environment with pH-values between 1.5 and 4.7 [21, 46-49]. Polymer cleavage and the 
accumulation of soluble oligomers and monomers lead to an increase of the osmotic pressure 
within the particles. This change in osmotic pressure and the pH shift can strongly affect the 
stability of the entrapped drug. Especially proteins – due to their biochemical structure – are 
susceptible to these changes in the microenvironment. Many publications [19,20,48-50] report 
on the negative effects of polymer bulk erosion on the stability of the entrapped peptides and 
proteins. Potential pathways leading to protein inactivation or incomplete protein release due 
to polymer bulk erosion are as followed:
Protein adsorption on polymer interfaces: Due to ionic interaction and non-covalent 
binding incomplete protein molecules adsorb on polymer interfaces leading to incomplete 
protein release and protein aggregation [19, 20]. 
Protein degradation induced by pH-shift and high osmotic pressure: As described above 
polymer erosion changes the microenvironment in the drug delivery systems and lead to low 
pH-values and high osmotic pressure. Since proteins are susceptible to changes in pH protein 
unfolding and aggregation are consequences of these changes [48]. But not only physical 
instability but also chemical degradation can result from the acidic environment in the 
polymer [49]. Deamidation and acid catalyzed hydrolysis of the amino acid chain has been 
reported to be one major chemical reason for protein instability within PLGA drug delivery 
systems [50].
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5. Lipids as alternative drug delivery systems
In comparison to the vast number of papers about polymer-based drug delivery systems for 
sustained release of bioactives, especially PLGA-polymers, there are only a few publications 
which deal with lipid carriers for parenteral controlled drug delivery. Since the late 70s lipids 
i.e. fatty acids, triglycerides, cholesterol and lecithin have been used as excipients for the 
preparation drug delivery systems designed for the sustained release of drugs like steroids and 
morphine derivates [51, 52]. In the past 30 years there have been many advances in the field 
of drug delivery systems based on lipids. Nowadays we know more than 10 different lipid 
based drug delivery systems resulting in numerous methods for the preparation thereof. These 
methods exhibit different approaches answering the complex questions one is faced with 
when dealing with the need for controlled release of bioactive substances. The term lipid
comprises a diverse range of molecules and to some extent is a catchall for relatively water-
insoluble or nonpolar compounds of biological origin, including waxes, fatty acids, fatty-acid 
derived phospholipids, sphingolipids, glycolipids and terpenoids, such as retinoids and 
steroids. They all show a good solubility in organic solvents such as acetone or methylene 
chloride. In our case, lipids are defined as esters made of glycerol and certain fatty acids like 
stearic acid, oleic acid, myristic acid. They are physiological, cheap and can be purchased in 
bulk. On the following pages the author attempts to highlight the unique properties of lipid 
materials in terms of drug delivery systems preparation and outlines the most important 
techniques for their production. 
Polymorphic behavior of lipids
Lipids, like almost all other substances especially long-chain components can exhibit different 
three dimensional molecular arrangements resulting in different unit cells as modules in the 
higher order crystalline structures. This phenomenon of different long range order and 
crystalline structure of a single and pure component is called polymorphism. In fat 
polymorphism, the triglyceride molecules can be packed in solid state in three different ways 
so that each crystal form has a different melting point. The main polymorphic forms in 
??????????????????????????????????????????m [53, 54]. This property is explained by the Ostwald 
step rule [55]: A crystallizing system first will form a sequence of available metastable phases 
before finally forming the stable phase. Such behaviour is observed in crystallization 
sequences in systems as diverse as aqueous solutions and silicate melts. 
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The hydrocarbon chains in all the forms are arranged as “chairs” with the chains in the 1 and 
?????????????????????????????????????????????????????????????????????????????????????????????????
form have a loosely packed hexagonal sub cell structure. By quickly cooling a melt, the form 
????? ???? ?????????????????????? ???????????????????????????????????????????? ???? ????????? ???
????????????????????????????????????????????????????????????????????????????????????????????
chains are arranged according to the orthorhombic sub cell structure. Its transition to the most 
?????????????????????????????????????????????????????????????????????????????????????????????????
??????????? ???? ??????????? ????????? ??? ????????? ?????? ?????????????????? ?? ?????????? sub cell
structure [56].These transformations may also occur during the production of releasing dosage 
forms such as microparticles or nanoparticles made of lipids. This surely can influence the 
structure; i.e. the stability [59, 60] and the property of the dosage form and hence the release 
of the embedded drugs. It has been shown that it is possible to conserve the state of 
modification of lipids used for producing sustained releasing forms by avoiding melting as 
workstep during the manufacturing. The melting points of tristearin implants loaded with 10% 
IFN/HP-h-CD lyophilisate obtained by compression, showed no differences when compared 
to the melting points of unprocessed tristearin bulk [57]. In contrast, tristearin implants 
obtained by melting which showed different thermodynamic behaviour. For instance lipid 
microparticles produced by melt dispersion method showed typical ?? ????????????????????????
contrast to microparticles produced by the solvent evaporation method, which had the same 
modification as the bulk material [58].
Figure 5: The molecular arrangement of a monoacid triglyceride trilaurin in the ?-state as seen along the short 
unit cell axis [59]. 
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Today there are several lipid drug carrier systems for the controlled release of bioactive 
substances: Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), lipid 
Microparticles (MP), lipid drug conjugates (LDC), liposomes and liposomal gels, oil 
suspensions, lipd depot foams, lipid-based microbubbles, lipid extrudates and lipid implants.
6. Lipid based drug carrier systems
Solid lipid nanoparticles
In the middle of the 1990s, the attention of different research groups has focussed on 
alternative nanoparticles for intravenous injection made from solid lipids, the so-called solid 
lipid nanoparticles (SLNs, also called lipospheres or nanospheres). SLNs are particles with a 
solid lipid matrix with an average diameter in the nanometre range, they are made of solid 
lipids in contrary to mikroemulsion. SLNs formulations for various application routes 
(parenteral, oral, dermal, ocular, pulmonar, rectal) have been developed and thoroughly 
characterised in vitro and in vivo. The first product has recently been introduced to the Polish 
market (Nanobase, Yamanouchi) [60] as a topically applied moisturiser. The main 
characteristics of SLN with regards to parenteral application are the physical stability, good 
tolerability, controlled drug release and their ability to protect sensitive drugs of degradation. 
Disadvantages are their low drug loading capacity (normally up to 25 %), their affinity to 
polymorphic transition leading to drug expulsion, and the high water content of the SLN 
dispersion (70-99%)[61].
Preparation of SLN
Preparation by High Pressure Homogenisation (HPH).
This preparation method can be divided into the cold HMP and the hot HPH: The cold HPH is 
suitable for all temperature sensitive drugs. Lipid and drug are melted together and then
rapidly ground under liquid nitrogen forming solid lipid microparticles. A pre-suspension is 
formed by high speed stirring of the particles in a cold aqueous surfactant solution. This pre-
suspension is then homogenised (3 cycles at 500 bar) at or below room temperature forming 
SLNs. Hot HPH: Lipid and drug are melted together (approx. 5 C° over the melting point of 
the lipid). The melt is then combined with an aqueous surfactant solution having the same 
temperature. After high speed stirring for instance with an Ultra Turrax® machine, a hot pre-
emulsion is obtained. This pre emulsion is processed in a heated homogeniser, generally a 
maximum of 3 cycles at 500 bar are sufficient [62].
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Preparation via microemulsion
Gasco et al developed a method of producing SLNs via microemulsion. In the first step a 
microemulsion is prepared. This heated microemulsion is continuously injected through a 
needle which is placed a few centimetres beneath the surface of an ice cooled water bath, and 
stirred until the SLNs solidify [63]. 
Preparation by w/o/w double emulsion method
This method consists in the solubilization of the drug to be encapsulated in the internal 
aqueous phase of a w/o/w double emulsion, along with a stabiliser able to prevent loss of drug 
to the external phase during solvent evaporation. The aqueous drug solution is emulsified in 
the melted lipid using an Ultra Turrax®. This primary emulsion is stabilized by adding 
Poloxamer (polyoxyethylene–polyoxypropylene block copolymer). This primary emulsion is 
then dispersed into a heated aqueous solution containing PVA. The resulting double emulsion 
is stirred at 300 rpm by a four-blade turbine impeller. After 3–5 h, SLNs can be isolated by 
filtration [64].
Preparation by high speed stirring
Microparticles, produced by spray congealing, are high speed stirred or sonicated to obtain 
SLN. Generally high speed stirring and sonication should be combined to avoid producing 
SLNs with a diameter within the micrometer range. This broad particle distribution can lead 
to particle growth upon storage [61].
Lipid Microparticles
To avoid problems such as lack of biocompatibility, residual solvents and detrimental effects 
on incorporated drugs when handling polymers for drug carriers, micro particles made of 
natural occurring lipids can be a promising alternative. Lipid microparticles are solid particles 
with a size residing in the micrometer range. Like SLN they can be produced without 
solvents, but also their production includes the possibility of polymorphic transition during 
storage time. Using a model peptide during the melt dispersion method, Reithmeier et al 
showed that the encapsulation efficiency was higher than 80%, leading to a drug content of 
about 16.4% [58]. Different methods for the production of microparticles shall be introduced:
Melt dispersion method
After dispersion of the protein drug (as solid or as solution) into the melted lipid 
(temperatures should be 5°C higher than the melting point of the lipid) by vortex-mixing, the 
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resulting mixture is emulsified into a small amount of heated water containing a surfactant. 
This emulsion is poured into a bigger volume of ice cooled water, allowing the lipid particles 
to solidify. The hardened microparticles are filtrated, rinsed with water and vacuum dried over 
night. Microparticles produced with the melt dispersion method showed a medium diameter 
of 92.8 µm [58].
Solvent evaporation method
When preparing somatostatin loaded lipid microparticles, Reithmeier et al used a modified 
solvent evaporation method, widely used for the preparation of polymeric microparticles.
The lipid was dissolved in a suitable solvent (for instance methylene chloride), the drug was 
incorporated into the lipid by vigorous vortex-mixing (whether as a solid or as solution). Due 
to the surface ability of somatostatin acting as a surfactant, no stabilizer was added to this 
emulsion. The resulting preparation was further emulsified into a small volume of an aqueous 
phase containing stabilizer. After this workstep, the emulsion was poured into a bigger 
volume of ice cooled water and stirred, to allow the organic solvent to evaporize. 
Microparticles produced with the solvent evaporation method showed a medium diameter of 
56.9 µm [58].
Spray congealing
Spray congealing is a technique of making microparticles by atomizing a solution or 
suspension of a drug in a melted carrier. The carrier can be a lipid as well as a polymer. The 
atomization or prilling process leads to the formation of melted droplets, which then solidify 
when in contact with cold air [65].
As there is no possibility for the drug to diffuse into an aqueous phase during preparation high 
encapsulation efficiencies can be achieved with this method. Maschke et al reported 
encapsulation efficiency for somatostatin and insulin of up to 100% [66].
Lipid microparticles formation with supercritical carbon dioxide
In 2000, a novel supercritical-fluid based process for the coating of proteins particles with 
lipids (e.g. trimyristate or glyceride esters of PEG, Gelucire©) was invented by the group of 
Benoit. This process has been applied to serum albumin as well as to sugar granules. In 
contrary to the Gas antisolvent method (GAS) and the Supercritical antisolvent Process 
(SAS), this method completely avoids the use of organic solvents. The method consists of 
dissolving the coating material in supercritical CO2 in an autoclave and then adjusting the 
conditions of temperature and pressure so that the coating material becomes insoluble in the 
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carbon dioxide. This insolubilization step causes a coating to deposit on the surface of 
suspended particles. Scanning electron microscopy revealed that trimyristate precipitates as 
micro-needles of very large sizes. It was difficult to obtain uniform coating on the surface of 
the proteins since it mainly generates large non film-forming flakes. In contrast Gelucire, due 
to its multi component nature (Gelucire50-02 is a solid material composed of a complex 
mixture of mono-, di- and tri-glycerides, mono- and di-glyceride esters of poly(ethylene 
glycol) (PEG)) can form a smooth coating on BSA particles. The release of BSA from these 
coated microcapsules was sustained over 5 hours for crystals coated with trimyristate and over 
24 hours coated with Gelucire [67-69].
Lipid microparticles preparation by cryonic micronization
In 2002, Del Curto described a novel method for manufacturing lipid microparticles as an 
alternative to the standard methods previously mentioned. He produced antide-(gonadotropin 
release hormone (GnRH) antagonist) loaded microparticles. The drug was either added to the 
lipid melt and stirred until a clear solution appeared (co-melting) or the antide and the lipid 
(glycerol monostearate, or glycerol monobehenat) were dissolved in a benzyl alcohol-ethanol 
mixture (solvent stripping) before being poured into a Petri dish for solvent evaporation. 
Resulting lipid matrices were micronized in a milling apparatus with liquid nitrogen. The 
obtained powders were sieved through a 125µm sieve in an automatic sieving apparatus [70].
Liposomes and liposome gel preparations
Liposomes are vesicular concentric bilayered structures with an aqueous core, usually 0.05-
5.0 µm in diameter which form spontaneously when certain lipids – i.e.  amphiphilic 
substances like lecithin - are hydrated in aqueous media [71]. Liposomes may also contain 
other bilayer constituents such as cholesterol and hydrophilic polymer conjugated lipids. The 
drug can be encapsulated in the aqueous core or in the lipophilic shell during the preparation 
or after preparation by certain means like freeze drying in an aqueous drug solution [72]. 
Liposomes can control the delivery of drugs by targeting the drug to the site of action or by 
prolonged circulation of drugs [73]. The physicochemical properties of the lipids used for the 
liposome preparation can control the properties of the liposomes, such as membrane fluidity, 
charge density, steric hindrance, and permeability. All these factors can determine the 
interactions of these drug carriers with blood components and other tissues after systemic 
administration. The method commonly used for the preparation of liposomes is the thin-film 
hydration procedure in which a thin film of lipids is hydrated with an aqueous media at 
temperatures above the transition temperature of lipids. After the spontaneous formation of 
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the liposomes extrusion or sonication is necessary to reduce and unitize the particle size. 
Beside the film-method the injection method is the method used most often for the 
preparation of liposomes [74]. Derived from liposomes, liposomal gel or vesicular gel 
preparations have gained great interest in the last years. Based on phospholipids dispersed in 
water by high pressure homogenization or other suitable methods these systems form 
semisolid pastes with vesicular microstructure [75]. With this gels prolonged therapeutic drug 
levels at the site of action is achievable with almost no systemic side effects. Upon contact 
with the release medium the entrapped drug is slowly released by two different release 
mechanism: (1) erosion of the matrix with burst open of drug filled liposomes and (2) 
diffusion of dissolved drug out of the swollen phospholipid matrix [76]. 
Lipid microbubbles
Lipid microbubbles (LMB) are gas-filled spherical carriers derived from conventional 
ultrasound contrast agents and were initially used for improving image quality in sonography 
[77]. In this system the gas core – a physiological inert gas is used – is surrounded and 
stabilized by phospholipids. The drug is usually distributed in the material surrounding the 
core. LMB respond to the ultra sound field of their resonance frequency by oscillation. High 
ultra sound energies can cause high amplitude oscillations leading to MBs’ destruction. Drug 
loaded LMBs can be used as ultra sound targeted carriers to locally deliver and release the 
bioactive substance [78]. LMB can be loaded during bubble preparation or after preparation 
by simple incubation with the desired bioactive substance. Due to electrostatic or weak non 
covalent binding the substance can be attached to the microbubble shell [79]. LMB can be 
produced by several methods: (1) the emulsification method uses an inner emulsion phase 
typically composed of a lyophilizable hydrophobic organic solvent, such as p-xylene or 
toluene, a volatile solid compound, such as camphor, and the lipid shell material. After freeze 
drying and evaporation of the organic phase the emulsion matrix can be treated with the MB 
core gas – immediately filling the free space. After reconstitution, the MBs instantly form in 
the injection medium [80]. The spray drying method is another approach to prepare LMB. 
During this preparation process the liquid droplet- consisting of phospholipids and volatile 
organic solvents - shrinks during solvent evaporation. Subsequently the dissolved shell-
material accumulates at the air–water interface which leads to the formation of an elastic film. 
Finally, the lipid material solidifies to form the shell and the solvent inside evaporates leaving 
pores [81].
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Lipid implants and extrudates
Implants, in our case, are small monolithic devices developed for parenteral delivering of 
bioactive substances into the human body in a controlled manner for a prolonged period of 
time. To avoid problems with their application (should be injectable with current canula) they 
should feature an average diameter of about one millimetre and an average length of about 10 
millimetres [82]. In 1984, Kent et al described a technique of manufacturing a cholesterol-
based implant matrix for the controlled release of macromolecules[83]. Matrix systems have 
therefore proven incapable of delivering large molecules at useful rates, due to the extremely 
low diffusivity of these molecules in known matrix materials. Exceptions to these theses are 
the polymeric matrix delivery systems disclosed in U.S. Pat. No. 4,164,560 to Folkman and 
Langer [84]. They function by simple diffusion through a flexuous pore network. Three years 
later Wang et al dispersed Insulin in a pellet disk by compressing it in mixture with 
cholesterol. It was found to reduce hyperglycemia in streptozocin-induced diabetic Wistar 
rats, by releasing the hormone for 24 days [85]. Opdebeeck et al manufactured an implant by 
compressing bovine serum albumin into cholesterol. These pellets, injected in mice, delivered 
the albumin for 77 days[86]. Pure cholesterol implants showed no erosion, but cholesterol 
mixed with lecithin in different ratios showed characteristic erosion behaviour. Increasing the 
concentration of lecithin enhanced the rate of release of the incorporated drug and lead to a 
higher grade of erosion. The lecithin provided the formation of aqueous pores due to its 
amphiphilic properties [87]. In 2004 Mohl et al prepared tristearin implants for the controlled 
release of rh-INF by compressing the powdered components using a hydraulic press. The 
resulting tablet-shaped implants released rh-INF for more than 4 weeks with a distinct linear 
release phase of 2 weeks. In addition to that, these implants showed remarkable stabilizing 
effect on the encapsulated protein [57, 88]. A few years later Herrmann et al could show that 
the addition of PEG within the lipid matrix leads to a reversible precipitation of the embedded 
therapeutic protein thus the equilibrium of dissolution and precipitation drives the unique 
release mechanism [89, 90]. Sustained release of rh-INF for more than 60 days from 
extrudated implants was reported by Herrmann et al in 2007. Implants were prepared using a 
twin screw extrusion device and consisted of two lipid components: a low melting lipid 
component which was partially melted during the extrusion process and a high melting lipid 
component which melting temperature was above the extrusion temperature [91]. 
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7. Degradation and swelling behaviour of lipid particles
As biodegradation of drug release systems is highly desirable, investigations on the 
degradation behaviour of lipid based drug delivery systems has come into focus of many 
research teams. In 2003 Vogelhuber et al investigated matrix swelling and erosion behaviour 
of glyceryl trimyristate matrices as a function of the cholesterol content. Their matrices 
(height was about 2 mm) were eroded at 37°C in 10 ml 0.08 M phosphate buffer solution (pH 
7.4) containing 0.02% sodium azide to suppress the growth of bacteria and fungi. Matrices 
made of triglycerides alone showed no significant water uptake for more than 6 months. 
These matrices took up less than 3 % water and showed no erosion, proved by the constant 
mass of the matrices after drying. This was not surprising because triglycerides are known to 
be very stable in the absence of lipases – enzymes which would allow cleavage of the 
triglycerides into fatty acids and more water soluble degradation products such as mono- or 
diglycerides. When different glyceryl trimyristate/cholesterol mixtures were investigated there 
was again no significant mass loss noticeable, but the swelling behaviour changed 
significantly. The biggest mass gain of approx. 30% was recorded for matrices with equal 
amounts of triglyceride and cholesterol, whereas matrices containing 80-100% cholesterol 
showed only moderate water uptake i.e. less than 10%. This behaviour can be explained by 
the melting point depression of the triglyceride/cholesterol mixture, leading to a more soften 
structure with an increased possibility of water diffusing into the matrices [92]. In contrary to 
the lack of erosion of these matrices in vitro, Reithmeier et al showed a degradation of 
somatostatin  triplamitate microparticles  dispersed in the  release medium [PBS-buffer pH 
7.4, 0.05% w/v Pluronic F 68, 0.05% (w/v) NaN3] and incubated at 37°C in a horizontal 
shaker water bath. The morphology of the microparticles changed significantly compared to 
the morphology of the microparticles shortly after the preparation, they were partly degraded 
and showed an eroded surface. Reithmeier et al also found a vanishing of tripalmitate 
microparticles 7 days after implantation in the subcutaneous tissue of mice a phenomenon 
which may give evidence to degradation processes at the implantation site [58]. In numerous 
papers, the group of Müller dealt with the effect of the particle size, lipid matrix, surfactants 
and crystallinity on the degradation behaviour of SLNs. They incubated their SLNs in a 
pancreatic lipase/colipase solution and measured the content of generated free fatty acids (as a 
result of the enzymatic saponification) using the NEFA (non-esterified-fatty-acid) C testkit 
[93-95]. 
GENERAL INTRODUCTION
___________________________________________________________________________
27
Effect of surfactant on the degradation velocity:
It has been shown, that the degradation velocity is substantially affected by the stabilizer used 
for the preparation of SLNs. Some stabilizers such as cholic acid sodium salt (bile salt) have 
degradation accelerating effects, while others such as Poloxamer 407, distinctly slow down 
the degradation velocity. Degradation velocity can be modulated by changing the surfactant 
ratio. Phospholipids for instance are known to inhibit the activity of lipase. Since lipase needs 
contact with water-lipid interfaces to work properly, preventing their adsorption on the lipid-
water interface leads to reversible enzyme inactivity. In vivo, hydrolysis products (i.e. fatty 
acids and monoglycerides), which could stop the enzyme reaction by accumulation in the 
interface, are removed by bile salts. It is presumed, that bile salts, used as stabilizers, facilitate 
the lipase-induced degradation of SLNs in the same way as they support the lipase in vivo. 
Furthermore, due to their amphiphilic properties as ionic surfactants, bile salts increase the 
exposed surface area of SLNs, through erosion, when they migrate from the particle into the 
aqueous phase. In contrast to the bile salt’s promoting influence on the degradation ability of 
SLNs, Brokman explains the inhibitating effect on degradation of Poloxamer with surface 
effects such as steric-hindrance  [94] [96] [97].
Effect of particle size
Size is expected to have a pronounced effect because lipid particles are degraded by surface 
erosion (lipase/colipase complex anchors on particle surface). By varying the homogenization 
parameters (pressure and number of cycles) Dynasan 114 (glyceryl trimyristate) SLNs with 
different size distributions were produced by Müller et al. One formulation had a distinct PCS 
diameter of about 800 nm. The other formulations had a diameter size range of 180-300 nm. 
Müller et al could not observe a difference in rate of degradation within the size range of 180-
300 nm but a distinctly slower degradation rate of 800 nm SLNs could be detected. All of the 
SLNs (180-300nm) prepared with sodium cholate as surfactant degraded within 2 hours, 
whereas the microparticles prepared by Reithmeier (with a diameter size range of 57-95µm), 
using poly vinyl alcohol instead of sodium cholate, took more than 7 days to degrade [93].
Effect of crystallinity on the degradation velocity 
To study the effect of crystallinity on the degradation velocity, Müller et al produced SLNs 
with different degrees of crystallinity. These SLN were produced by using glycerides with 
different length of fatty acid chains and known differences in crystallisation velocity 
(Dynasan 114, i.e. glyceryl trimyristate and 116, i.e. glyceryl palmitate), and using stabilisers 
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interfering differently with the crystallisation process of the lipid matrix (cholic acid sodium 
salt (NaCh), Poloxamer 407 (Plx 407)). After production, SLN with a lower crystallinity 
matrix (Dynasan 114 and 116, NaCh) degraded faster than higher crystalline particles (all 
SLN with Plx 407), and showed a decrease in degradation velocity with increasing 
crystallinity during storage [93-95]. Studies from Herrmann et al showed that the lipid
modification has strong effect on the protein release kinetics from lipid implants. Lipid 
devices comprising the instable ?-polymorph exhibited a high burst and a significant faster 
release compared to the same device composition formulated with the stable ?-form lipid 
??????????????????????????????????????????????????????????????????????????????????????????????????
to a more soften structure of the implant with a larger surface area. This increased surface area 
influences the growing possibility of pore formation, through which the protein can be 
liberated quicker. It further can be hypothesized, that this polymorphic modification has a big 
influence on the degradation velocity. Due to the increased exposed surface area, lipids 
?????????????????? ???? ?-modification should degrade faster than lipids containing the more 
stable ?-modification [98]. 
8. Silk proteins 
Since early times people have been fascinated by spiders and by the material produced by 
these arthropods for web construction and numerous other purposes. Already the publications 
from ancient scientist like Pliny the Elder convey the fascination for this material praising the 
extraordinary strength of this fiber [99]. But not only the physical properties but also the 
medical use was described by this early roman scientist. According to Pliny the placement of 
a spider web in open wounds and ulcers would promote healing [100]. This use as wound 
dressing has been conserved from roman times to modern era: In the wars of the 16th century 
packages of spider silk have been the constant companion of surgeons carried for the 
treatment of battle injuries [101]. This application has been immortalized by Shakespear’s 
romantic comedy A Midsummer Night's Dream (Act II, 1) where the use of cobwebs is 
described as bandage material [102]. With the rise of modern medicine in the 19th century 
spider silk has fallen into therapeutic disregard. In the original Wood’s dispensatory of the
USA from 1870 only a few lines are devoted to its discussion, narrating about the use and 
success as filling material for a socket of an extracted tooth [103] but overall in those days the 
use of spider silk was declining and eventually terminated. Now, after so many years of 
disregard modern science is, once again, dealing with this fascinating material. 
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Today there are many hundred publications available investigating on silk protein properties 
for their application in material science and for medicinal use. In the last few years an 
understanding has emerged the reasons for the unique mechanical properties that silk 
possesses. In 1907 the protein nature of the silk fibres could be demonstrated [104] Since then 
it is known that all the different kinds of silks are composed principally of proteins (fibroin in 
silkworm silk, spidroin in spider silk) [105] but it took until the late 1980s that scientists 
concentrated on the structural properties of the different fibres [106] and the processes during 
the fibre spinning which are responsible for the unique combination of high strength, high 
elongation and extreme fineness. The process of spinning the fiber is surely one of nature’s 
most exciting phenomena. Orb weaver spiders normally exhibit up to seven different 
specialized silk glands – evolutionary derived from limb glands [107] - each producing silk 
with a different amino acid composition. The silk protein is spun at ambient temperature and 
pressure from an aqueous solution to form a fiber. The state of the protein in the lumen of the 
gland is believed to be a liquid crystal [108], thus preventing fiber aggregation until passage 
down the duct. This is probably accomplished by a combination of   protein structure and 
concentration that prevents formation of silk proteins into large protein arrays. The shear 
alignment during spinning induces the final assembly of the b-sheets rich structure into 
crystalline blocks [109]. Once formed, silk fibers are insoluble in most solvents such as water, 
ethanol, dilute acids and bases. Suitable solvents for silk materials, converting the ß-sheet into 
a water soluble random coil conformation are highly concentrated sulphuric acid, formic acid, 
hexafluoroisopropanol (HFIP), calcium nitrate, guanidinium thiocyanate or LiBr. After 
dialysation from concentrated salt solutions silk proteins exhibit the water-soluble ?-helical 
rich structure which can be converted into the water-insoluble ß-sheet rich structure by 
addition of methanol or - in case of certain spider silk proteins- with phosphate solution [110-
113]. Due to the numerous amounts of spider species spider silks are only partly 
characterized, but it is generally agreed that the secondary spidroin protein folding 
arrangement is similar to that of fibroin in Bombyx. mori – the common silk worm-silk. There 
are four different motifs: (a) elastic ?-spirals; (b) crystalline ?-sheets rich in alanine; (c) tight 
amino acid repeats forming helical structures; and (d) spacer regions [114-116]. While their 
structure is similar to B. mori silkworm silk, spider silks do not have an immunogenic sericin 
coating. Sericin which serves as glue, holding together the fibres to form the cocoons of silk 
worms was identified as a source of immunogenic reactions in vivo [117].
There are two main areas of interest for the application of silk – derived from spiders or other 
organisms like Bombyx. mori - in the modern human medicine:
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Biomedical applications, i.e. tissue repair and tissue engineering and the use of spider silk 
proteins for the preparation of drug delivery systems. 
9. Biomedical application of silk proteins
Since more than 20 years the application of silk and isolated silk proteins for application in 
tissue engineering i.e., the regeneration and restoration of various tissue types like bone and 
cartilaginous tissue with scaffolds and other appliances can be reported. Already 1989 Sakabe 
et al. tested silk fibroin proteins for their blood biocompatibility and thrombogenic behaviour. 
They implanted silk fibroin into a jugular and femoral vein of a dog. According to their in 
vivo studies, there was no thrombogenic activity of the silk proteins detectable [118]. In the 
same year Minoura et al prepared silk fibroin membranes and treated them with methanol for 
different amounts of time. Methanol treatment leads to a conversion into the water insoluble 
ß-sheet conformation thus stabilizing the silk film. This methanol treated silk fibroin 
membranes had high oxygen permeability, high water vapour permeability, high transparency, 
good mechanical property and biodegradability [119]. All these properties make silk derived 
scaffolds ideal for the application in tissue engineering. In 1995 Minoura et al. conducted 
fibroblast cell studies on silk fibroin gained from silk worms. As a result they could conclude 
that the presence and the properties of silk proteins are ideal for the viability, growth and 
function of the used cells [120, 121]. In 2000 Yeo et al. prepared different dressings from 
polyvinylalcohol (P), chitosan (C) and fibroin (F) or used blends thereof, in order to test the 
resulting spongy sheets as wound dressing in an in vivo experiment. From all different wound 
dressing prepared a blend consisting of polyvinyl alcohol, chitosan and fibroin (PCF) 
promoted the best wound healing conditions by facilitating collagenization [122]. Petrini et al 
investigated in 2001 the interactions between silk fibroin coated polyurethane membranes and 
foams, and four different strains of normal human adult fibroblasts (HAF). Their results 
indicate that silk fibroin coated PU substrates promote cell adhesion and growth compared to 
unprocessed PU substrates [123]. In 2002 Cai et al. published that - when combined with 
poly(d,l-lactic acid) (PDLLA) - silk proteins like fibroin can improve the interaction between 
osteoblasts and the PDLLA films [124]. In the same year Vollrath et al. tested the 
biocompatibility of spider silk. In their study they used four types of spider silks: 1) dragline 
silk – also known as major ampullate silk - from Nephila clavipes, 2) native (unsterilised) silk 
reeled from a Brachypelma spider, 3) native silk taken from this spider's web and 4) its web 
silk thermally treated at 80 degrees C°. They compared these silk materials with fibrous silk 
analogue protein polymers and four already marketed wound dressings (polyurethane film, 
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collagen dressings, gauze pads) all these materials were implanted in epicutaneous split 
wounds. After 14 days the implanted silk wound stuffing were analyzed macroscopically and 
histological tests were conducted. Overall all sites healed rapidly. Nevertheless, marked 
inflammatory reactions in all sites with lympho-plasmacellular infiltrations could be detected, 
thus giving evidence to phagocytosis and granuloma formation but there were no distinct 
differences between all wound dressings [125]. In 2003 Chiarini et al tested silk coated 
membrane materials for their use in cell culture. Cell adsorption of adult fibroblasts was 2.2 
fold higher than on uncoated polymer membranes. In addition to that, the seeded cells didn’t 
release any major inflammatory cytokines in the culture media compared to cells seeded on 
normal uncoated polymer membranes [126]. It could be shown that the use of silk scaffolds 
resulted in advanced mineralization, with an increase of newly formed bone material, 
compared to collagen scaffolds which couldn’t generate a similar outcome because of the 
rapid degradation rate [127]. Similar results could be achieved in experiments dealing with 
the production of cartilage-like tissue derived from human mesenchymal stem cells (hMSC) 
on silk scaffolds. The scaffolds – prepared from silk worm cocoons – allowed a continuous 
cartilage-like tissue formation applicable in clinical cartilage-repair [128].  In 2006 Jokuszies 
et al. published data dealing with the use and biocompatibility of spider silk fibres as a new 
material in nerve tissue engineering. In this study Schwan cells were cultivated on 
reconstituted spider silk fibres. These cells formed distinct columns a long the spider fibre 
scaffold. These columns indicate that nerve cell reconstruction is possible with the application 
of this superior fibre serving as endoneural graft construction [129]. The results of this on in 
vitro experiments based study was verified by a consequent in vivo study in rats with sciatic 
nerve defects. Once again, using spider silk fibres as nerve graft newly produced axons were 
aligned regularly and had a healthy appearance. In addition to that, a good histological 
evaluation and a diminishing degeneration of the gastrocnemius muscle proved the 
extraordinary applicability of spider silk fibres as material enabling Schwan cell migration for 
nerve regeneration [130]. Overall it can be concluded that silks are materials with superior 
mechanical and physico-chemical properties such as high oxygen permeability, high water 
vapour permeability and biodegradability. In contrast to native silk from Bombyx mori spider 
silk exhibit no immunogenic potential. All these properties make spider silk proteins ideal for 
the preparation of drug delivery systems.
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10. Silk as a material for the preparation of drug delivery systems
The extraordinary properties of silk allow the use of a broad spectrum of preparation 
techniques resulting in several drug delivery systems for parenteral as well as for oral 
administration. In the following pages the authors concentrates only on drug delivery systems
for parenteral application. Silk proteins can be processed resulting in: Silk hydrogels, silk 
based micro and nanoparticles, silk films processed as coatings and implantable matrices.
Silk films and matrices for the controlled delivery of drugs
One of the first silk based drug delivery system was developed by Tsukada et al. in 1994.
This research team prepared porous silk matrices suitable for the preparation of matrix-
controlled drug delivery systems. The matrices were produced either by freeze drying of 
aqueous silk solutions at different temperatures, by freeze drying of coagulated silk solutions 
at different temperatures or by mixing the silk solution with methanol-water solutions with 
different ratio resulting in coagulated silk solutions followed by a freeze-drying step. The 
results of this study showed that the addition of methanol is the most effective method to 
control the pore size of the resulting porous systems. By rendering the concentration of the 
used silk solutions and the temperature of freeze drying packing and the density of the 
matrices is controllable. In vitro release studies of acetylsalicylic acid entrapped in porous silk
fibroin matrices showed a drug burst for the first 2 hours followed by a constant drug release 
for almost 3 days [131]. The need for methanol treatment inducing structure conversion can 
possibly endanger the stability of the entrapped drug. To investigate on the effect of this 
alcohol treatment Hofmann et al. conducted studies with respect to the bioactivity of the 
entrapped drugs. Interestingly they found out, that when using lysozyme as model drug 
methanol stabilization of the films resulted in significant loss of lysozyme activity whereas 
using horseradish peroxidase wasn’t affected negatively by the methanol treatment but by the 
treatment with water vapours [132, 133]. Another aim of this study was the evaluation of the 
drug size/molecular weight impact on release patterns therefore dextrans with increasing sizes 
and molecular weights were used. The authors could show that the higher the molecular 
weight of the drug the higher was the retention in the matrix. Changes in the crystallinity of 
the silk in consequence of the methanol treatment and a decrease of the water solubility of the 
films are the explanation for that phenomenon. Nevertheless, horseradish peroxidase – a 44 
kD molecule - was released in a linear manner for more than 22 days.
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In 2007 Uebersax et al. published the results of their studies dealing with the preparation of 
silk fibroin matrices for the controlled delivery of Nerve Growth Factor (NGF). With this 
system Uebersax et al. could achieve a sustained release of NGF for more than 22 days. To 
prepare the silk films aqueous silk solutions were cast into Teflon moulds and – after water 
evaporation – stabilized with methanol to induce structure conversion. The obtained silk 
matrices had a pore free surface morphology. Bioactivity of NGF was assessed using an in 
vitro assay system. Uebersax et al. could show that although the total fraction of NGF 
released from the silk-based system was rather low – ranging from 0.3% to 13.0% - NGF 
activity was unaltered. In addition to that SEC-HPLC couldn’t detect any NGF aggregation 
induced by methanol treatment or silk-NGF interaction [134].
Silk film coatings
Coatings of silk materials provide the possibility of enabling and controlling the release of 
bioactive substances from drug carrier systems or medicinal devices. Nanoscaled silk fibroin 
coatings on quartz slides produced by an all-aqueous stepwise deposition process were
prepared for the controlled delivery of model compounds rhodamine B, Evan’s blue and 
azoalbumin representing small molecules drugs and therapeutically relevant proteins. In these 
experiments Wang and co-workers could show a cumulative release of azoalbumin for more 
than 32 days from six layers of silk fibroin [135]. In other studies metallic stents used in 
angioplasty were coated with drug-loaded silk fibroin. Heparin, paclitaxel and clopidogrel 
were used as pharmacologic components and their antiproliferative effects on smooth muscle 
cell proliferation and endothelial cells was evaluated in this system. Human aortic endothelial 
cells (HAECs) and human coronary artery smooth muscle cells (HCASMCs) were used as an 
in vitro control system to evaluate the cellular responses to the drug-incorporated silk 
coatings. The conducted in vitro experiments could prove the capability of silk proteins in 
terms of controlling the adhesion, viability and growth of HAECs. Results from the in vivo 
experiments showed that the silk coatings promote the viability of the endothelial cells and 
reduce the platelet adhesion on the stent surface [136]. Another application of silk proteins 
was the coating of theophylline tablets using an aqueous coating process. As coating materials 
heat treated silk fibroin, fibroin-PEG mixtures and cross linked silk fibroin were applied. A 
sustained release for over 5h with zero order release kinetics was obtained using crosslinked 
silk fibroin and PEG-fibroin mixtures, whereas the heat treated possessed a brittle structure 
resulting in a rapid release of the drug from the tablet [137].
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Silk hydrogels
Hydrogels prepared from bombyx mori fibroin were demonstrated to control the release of 
entrapped model drugs e.g., fluorescein isothiocyanate (FITC), buprenorphine and dextran 
conjugated with FITC with an average molecular weight of 4.4 kD. By rendering the fibroin 
concentration during gel preparation mechanical properties and drug release could be varied. 
Gels showed linear drug release for several hours indicating that silk fibroin hydrogels can 
serve as a rate-controlling barrier and may be used as a drug carrier system for the controlled 
delivery of drugs like buprenorphine [138]. Silk hydrogels prepared from genetically 
engineered proteins based on the sequence of b. mori fibroin were used to control the in vitro 
release of model drugs with molecular weights ranging from ca. 400 D to 500 kD. Release 
kinetics could be described as first order, high molecular drugs showed a constant release for 
over 10 days. In vivo biocompatibility was tested by implanting the hydrogels in guinea pig. 
After sacrification of the animals no clinical signs of tissue reactions due to toxicity, allergy 
or irritancy were observed [139]. Hydrogels consisting of silk-like elastine-like polymers 
(SELP) were produced by the group around Ghandehari. By combining silk-like and elastin-
like protein blocks in various ratios and sequences, it is possible to produce biomaterials with 
excellent material properties. In their publications they could show that hydrogels consisting 
of SELP can form injectable in situ forming depot systems for the release of bioactive 
substances such as DNA for gene delivery. Over 28 days almost 80% of the entrapped 
plasmid DNA was released by the prepared hydrogels [140]. Using the gel as a depot system 
for adenoviral release in vivo bioactive viruses could be delivered over a period of 4 weeks 
leading to a prolonged and localized expression of the viruses [141].
Preparation of silk protein microparticles by spray drying
?????????????????????????????-sheet rich structure and the possibility of stabilizing silk proteins 
by converting their secondary structure into the water insoluble ß-sheet rich structure allow 
the use of organic-solvent-free preparation techniques such as spray drying. Silk microspheres 
generated by spray drying of aqueous silk solutions were prepared by Nakai, Shimabayashi 
and Kim. Whereas Nakai et al. and Shimabayashi [132] produced silk microparticles which 
maintained their helical structure after the drying treatment [142] the particles produced by 
the group around Kim changed their structure towards the water insoluble ß-sheet structure 
during the drying [143]. Shimabayashi reported a structural conversion of their microparticles 
after spray drying upon an exposition to an atmosphere of 89% RH. These results indicate that 
it is possible to control the speed of structure conversion by means of the spray drying 
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parameters. Stabilized secondary structure is a prerequisite for the application of spider silk as 
a parenteral dosage form. 
Recombinant spider silk proteins
Since all sorts of natural silk need to be harvested either from b. mori cocoons or from spider 
silk filaments followed by several processing steps involving the removal of the sericin 
coating on the bombyx. mori fibres [117], several research teams have been concentrating on 
facilitating the process of silk harvesting. The collection of silk from spiders is a time 
consuming and expensive procedure since spiders don’t produce any cocoons with larger 
amounts of silk. Instead the desired drag line has to be harvested from living and fixed 
animals which have been refrigerated for a few minutes in order to tranquillize them. Then, 
after manual stimulation of the major ampullate gland the silk can be collected on spools 
using a winding machine. This procedure allows the collection of approx. 150 m an hour 
resulting in a few milligrams of silk protein [130]. A recombinant production of silk proteins 
overcomes disadvantages typical for natural materials such as differences in quality, 
variations of material structure due to genetic reasons and a limitation of the total amount of 
polymer harvested. Today in the era of recombinant proteins and genetic engineering there are 
many approaches to produce recombinant spider silk proteins but until today no dragline silk 
gene has been cloned in its entirety [144, 145]. In most cases there is only some sequence data 
available [110]. As a consequence of this, all recent studies used partial cDNA constructs of 
dragline silk genes to produce recombinant silk proteins in E. coli [146] in bovine and 
hamster cells [147] or in insect cells using the baculovirus expression system [148]. In 2004 
the research group around Scheibel recombinantly produced synthetic spider silk proteins 
based on two major dragline silk proteins of Araneus diadematus called ADF-3 and ADF-4. 
The amino acid sequences of these proteins were back translated into nucleotide sequences. 
The modules were connected resulting in controlled assembly of synthetic genes.  In this way 
the repetitive part C of the natural occurring silk protein ADF-4 comprising the sequence
GSSAAAAAAAASGPGGYGPENQGPSGPGGYGPGGP was multimerized and finally 
expressed in escherichia coli bacteria to obtain the repetitive synthetic 48 kD spider silk 
protein C16.
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Properties of recombinant spider silk protein C16
The genetically engineered C16 protein can be processes into nanofibers, nano- and 
microparticles, hydrogels and films using several techniques. Perhaps on of the biggest 
advantages of this synthetic silk material is the possibility to use both, aqueous and non-
aqueous solvents for the preparations of all these different systems. A simple preparation 
technique for the production of spider silk films uses a casting method. Films can be cast from 
aqueous C16-solution or from HFIP respectively formic acid solutions. Using aqueous or 
HFIP solutions leads to the generation of water soluble films – a conversion of the protein 
structure is necessary to stabilize the film and avoid dissolution. These structural conversions 
can be achieved by treating the films with methanol or potassium phosphate solutions. This 
treatment induces the conversion of ???? ?-helical rich structure into the semi-crystalline ß-
sheet structure – a process similar to the proceedings occurring in the spider silk duct during 
spinning [109]. Films prepared from formic acid solutions self-assemble into the water 
insoluble ß-sheet structure during solvent evaporation. The change in secondary protein 
structure can be monitored using circular dichroism (CD) and FT-IR-spectroscopy. Processed 
films show remarkable chemical stability after stabilization with methanol or potassium 
phosphate. Most known solvents are incapable of dissolving stabilized C16 films, only 
guanidinium thiocyanate solutions with high molarity can lead to a complete disintegration of 
the film [149]. If a special functionality is necessary the C16 film surface can be modified with 
respect to the desired feature. For instance enzymes like ?-galactosidase and other 
macromolecules can be coupled to surface exposed carboxyl groups of the C16. In 2007 
Scheibel et al could show that the conversion of water soluble C16 can be triggered by the 
interfacial adsorption of the protein. When emulsifying C16 solution with toluene insoluble 
silk microcapsules form around the toluene droplets. These silk microcapsules were 
mechanical stable and permeable for smaller molecules possessing a molecular weight cut off 
of approx. 70kD molecules [150] [151]. Admixing aqueous solutions of C16 with potassium 
phosphate solution initiates the change in secondary protein structure leading to the 
generation of water insoluble silk microparticles. The formation of C16 microparticles involves 
a phase separation into a hydrophobic protein-rich phase and an aqueous phase. This process 
allows an encapsulation of hydrophobic substances participating in this phase separation and 
thus accumulating in the hydrophobic protein-rich phase. In 2008 Liebman et al could show 
ß-carotene was encapsulated successfully in spider protein particles during the microparticle 
formation yielding in an encapsulation of 5% (m/m) [152].
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Similar to fibroin proteins spider silk proteins can spontaneously form hydrogels which are 
physically stable for several weeks. The self assembling process leading to the gel structure 
can be disrupted by agitation or shearing and chemical cross-linking of the hydrogels yielded 
in elastic hydrogels probably applicable in medical applications [144, 149, 150]. 
In summary spider silk proteins especially genetically engineered C16-proteins are very 
versatile. Due to their unique physicochemical properties they enable the use of a great variety 
of preparation techniques resulting in a diverse set of systems with a great potential for 
various medical and technical applications.
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II. AIM OF THE THESIS
When the area of controlled release was starting in the early 70ties of the last century no one 
would have assumed that the development and research associated with this field of science 
would have such major influence on the therapeutic medicine. Today we know that the 
employment of controlled release devices crucially enhances the therapeutic success of 
treatments requiring multi dose injections or infusions of bioactives. Starting with rather 
simple materials such silicone rubber tubing the primary substance used to develop and 
manufacture controlled release devices such as implants and microparticles have traversed a 
remarkable pathway of scientific evolution. Today there are numerous materials applicable 
reaching from natural materials over semi-synthetic to fully synthetic substances. The 
application of these materials depends on their featured properties as well as on the bioactive 
drug to be released from the final depot system. Despite of the vast numbers of materials used 
for the preparation of drug depot systems there are only a few materials which are approved 
by regulatory agencies for this application in human medicine. Today these approved systems 
based on polymeric materials such as PLGA are state of the art. However, as it has been 
detailedly reviewed in the previous pages, these polymeric systems can interact with the 
encapsulated bioactive substance and – especially in case of therapeutic proteins – can lead to 
inactivation of these active agents. The aim of the work presented in this publication was to 
concentrate on lipid substances used for the preparation of drug depot systems. Controlled 
release from lipid based drug delivery systems is a very promising way to overcome obstacles 
associated with the use of approved polymeric systems, i.e. PLGA such as protein instability 
during encapsulation and release. Lipid based drug delivery systems have proofed their 
capability in terms of biocompatibility, release properties and stabilization of the encapsulated 
bioactive substances upon preparation and storage [57, 58, 70, 85, 88, 92, 153-158]. However, 
the question whether parenteral lipid drug delivery devices – especially implants - are 
biodegradable is still unanswered as there is no data available from application in humans. 
Despite the capabilities of some currently existing products based on non degradable 
polymers such as Implanon® [159], which can remain in the body and continuously deliver 
drugs for up to 3 years, it is highly impractical because these implants carry the risk of 
intoxication [160, 161] when left in the body thus surgical removal is required. In addition to 
that drug depot systems which remain in the body for years will lead to poor patient 
compliance especially in case of palpable implants since these systems are psychologically 
perceived as foreign body. 
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It was therefore an aim of this thesis to investigate on the biodegradation of lipid based drug 
delivery systems. Especially implants systems consisting of naturally derived triglycerides 
such as glyceryltistearate and other simple or mixed triglycerides consisting of glycerol 
esterified with fatty acids (C12 to C18) are in the focus of this research work. Special interest 
lies on lipid based depot systems prepared by simple compression of the lipid matrix and 
extruded implants. Micro-particular systems such as microparticles are also within the scope 
of this thesis. In this presented work the author wanted to investigate on the behaviour of lipid 
based drug carrier systems in vivo. Especially the influence of physiological enzymes on the 
physical properties of the employed implant systems is of great interest. It was therefore a 
further aim of this thesis to develop an in vitro model for the simulation of biodegradation 
processes. Such a system would allow to be more independent of animal experiments and to 
fully characterize degradation and erosion processes. It was a further goal to analyze lipid 
degradation and erosion processes occurring in vivo and in vitro in a profound manner using 
different analysis techniques such as chromatographic and spectrometric techniques. 
Summarizing, the major aim of the thesis associated with lipid depot system degradation was 
to arrive at a conclusion about the composition, the preparation technique, the dimensions and 
the time frame of degradable lipid-based drug depot systems.
In addition to the project of lipid based drug depot degradation this publication deals with the 
application of spider silk proteins in pharmaceutical technology.
Spider silk and silk derived from other arthropods such as the silk worm has gained a lot of 
attraction in recent years not only due to their outstanding physical properties exhibiting a 
tensile strength exceeding that of steel or Kevlar but also for its remarkable qualities in the 
application of biomedical tissue engineering. Although the application of spider silk in 
medicine goes back to ancient times, today there are only few modern publications describing 
the use of silk material for the preparation of drug depot systems. This may be contributed to 
the fact that silk is mostly collected as it was hundreds of years ago: by harvesting the 
cocoons of the silk worm and carefully and tedious reeling its precious and sensitive fibre. In 
case of spider silk the filament has to be collected from the living animal, a fact making its 
quarrying even more time consuming and expensive. Since silkworm silk is always coated 
with special proteins causing immunogenic reactions when brought into the human body, 
isolation of the pure silk proteins is necessary. Spider silk proteins don’t exhibit such 
detrimental coating. Nevertheless, in general the harvesting and isolation of this natural 
polymer and the existence of natural occurring dissimilarities in silk compositions leading to 
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different protein properties is a major obstacle thus impeding the thorough investigation and 
development of drug depot systems based on these fascinating proteins. Only when 
genetically engineered spider silk proteins were producible in lab scale resulting in 
reproducible silk qualities of high purity, efficient investigation and production of silk-based 
sustained release devices was possible. 
It was therefore the second major aim of the presented work to develop and thoroughly 
characterize micro particulate carriers consisting of genetically engineered spider silk proteins 
using preparation techniques which allow a controlled and reproducible upgrade towards 
batch sizes greater than lab-scale. Consequently, it was an aim to analyze the prepared silk 
particles with respect to their release behaviour of drug substances with different charges and 
properties. As already described, biodegradation of implanted drug depot devices is highly 
desired thus the biodegradation properties of the employed silk based systems should be 
evaluated towards their degradation behaviour.
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1. Chapter One: In vivo studies of rh-?????????????????????????????
1.1. Introduction
The following chapter deals with the investigation on the release of a therapeutic protein from 
compressed triglyceride discs which was implanted into rabbits. As already highlighted in the 
introduction of this dissertation, the potential of lipid implants for parenteral delivery of 
bioactives - although first investigations started already in the late 70ies – is still not 
exhausted. It is therefore not surprising that in vivo data of drug release from lipid based 
implants and even more data dealing with the physical changes of lipid implants upon in-vivo 
incubation are very few. . The release mechanism of the employed implant-drug systems was 
clarified previously in several in vitro experiments: the release of the protein out of the 
prepared triglyceride implant is controlled via proceedings comprising precipitation, and 
dissolution of the encapsulated protein followed by subsequent diffusion processes occurring 
within an interconnected pore network. However, it was not clear if this highly sophisticated 
mechanism would be possible under different conditions such as in vivo conditions. It was 
therefore of special interest if this mechanism may be influenced by potential immunogenic 
foreign-body reactions or by degradation processes occurring around or within the implant. 
Simultaneously this animal experiment offered the opportunity to examine the influence of 
the animal organism on the employed lipid implant. Accordingly, this chapter is organized 
with respect to the emphasis of the results of the conducted work. Some results of the above 
described animal experiment are already published whereas other results may be understood 
as impulses leading to subsequent experiments. In the following sections of this first chapter 
the published data is reprinted, followed by a little discussion about the content of the article. 
Finally, further studies related with this work are closing this chapter.
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Abstract
Previous in vitro experiments had shown that rh-????? ?????????? ??????????? ????????? ????????
promising properties making them an excellent tool for the delivery of therapeutic proteins. 
Sustained release for periods up to one month could be achieved, associated with high protein 
stabilization. The objective of this study was to investigate for the first time the in vivo release 
properties of these implants in rabbits and to establish an in vivo-in vitro correlation. 
Computer modeling was used to simulate rh-????? ?????? ?????? based on pharmacokinetic 
data. Protein serum concentrations on therapeutically relevant nearly constant levels could be 
detected for 9 days. Modeling revealed that in vivo release correlated closely with the release 
monitored in vitro.
Keywords: Protein release; Lipid implants; Computer modelling; In vivo-in vitro correlation;
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Introduction
Since pharmaceutical proteins given by injection must be repeatedly administered in short 
intervals to reach and maintain therapeutic useful concentrations in the blood plasma, low 
patient compliance and high hospital costs are resulting. To overcome these problems 
polymer based delivery systems for therapeutic proteins have been developed. Although 
application of these new delivery devices is very promising most of the used polymer systems 
such as poly(lactic-coglycolic acid) (PLGA) (1) show some major drawbacks i.e. interference 
with the protein stability like protein-polymer interaction, pH-shift and interface formation 
during formulation (2). Recently a new model depot system for the controlled delivery of rh-
????? ???? ????? ?????????? ??? ???? ???????? ?????? ????? ????? ???????? ????????? ??? ?? ??????
component, rh-?????? ?????????????-?-cyclodextrin (HP-?-CD) or trehalose as a stabilizer 
and PEG 6000 as release modifier. The use of lipids known as matrix materials with a high 
biocompatibility (4,5,6) allows to generate implants capable of a sustained protein release. 
The application of solvent-free processing techniques like compressing the lipid mass satisfies 
the necessity for both a high biocompatibility and high protein stabilization. For long-time 
storage especially HP-?-CD can provide a high stability of the embedded therapeutic protein 
within the matrix (7). In vitro release experiments have shown a continuous release over 30 
days with a close to linear release phase for the first 2 weeks. Overall protein liberation up to 
95% can be achieved within 4 weeks. This controlled release is a consequence of the 
interaction of PEG with the incorporated rh-???????????????????????????le precipitation of the 
???????????????????????????????????????????????????????????????????????????????????????????????
contributes to the controlled release (8). The aim of this work was to elucidate whether the 
release profile of the implants in vitro can be verified in vivo, i.e. in rabbits. We wanted to 
confirm whether the release mechanism was under total physiochemical control, independent 
of enzymes, and other components of body fluids and mechanical stress. Further we wanted to 
proof the expected excellent biocompatibility of the lipid implants.
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Materials and Methods
Rh-??????????? ?-2a-(rh-?????? ?????? ????????????? ?????????? ????????? ???????? ?????? ????
mg/ml in a 25 mM acetate buffer of pH 5.0, 120 mM sodium chloride) was lyophilized in a 
1:3 ratio with hydroxypropyl-?-cyclodextrin (HP-?-CD, Merck, Darmstadt, Germany).
Tristearin (Dynasan 118) was purchased from Condea Chemie, Witten, Germany and 
polyethylene glycol 6000 (PEG 6000) is a product from Clariant, Gendorf, Germany.
All other materials (from Merck) were of high purity grade.
Implant manufacturing:
Implants were prepared by using a 5 ton hydraulic press (Maassen, Eningen, Germany).
The implant components-?????????????????????????????????????????????-lyophilisate 10%-
were ground in an agate mortar. The resulting mixture was compressed with a pressure of 2 
tons for 30 seconds. The obtained implants had an average weight of 50 mg and an average 
height of approximately 2.3 mm. The drug load of the implant was 2.5% of the implant 
weight, accounted for the rh-??????????
Animal experiment setup
In order to investigate the rh-????? ???????? ????? ??? ???? ????????? ???????? ?????? ??????????????
administered to a group of 5 young female rabbits. Rabbits were chosen as experimental 
animals, because in contrast to rats or mice rabbits show a distinctive subcutaneous fat tissue 
which is quite similar to the human one. Under ketamin/xylazin anaesthesia one implant per 
animal was placed subcutaneously between the omoplates and the insertion site was sewn up. 
Samples of approx. 0.5-1ml blood-gained from the ear vein-were taken daily for the first 
week, afterwards every three days. Blank values were taken before the implantation. To gain 
basic pharmacokinetic data, another group of 3 rabbits received an injection of unretarded rh-
????? ????????? ???7 I.U. i.e. 37µg rh-????? ???? ??? ???????????? Samples were taken every 
hour for at least 9 hours and after 12 and 24 hours.
In vivo release studies:
Blood samples were centrifuged and the resulting serum frozen at -80° until analysis.
??????????????????????????????????????????-ELISA (Bender MedSystems, Vienna, Austria).
Rh-???????????????????????????????????????????????oncentrations (8.0-1600.0 pg/mL) were 
used to generate calibration curves. Analysis was conducted according to the ELISA test 
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protocol. The absorbance of the colored product was measured using a CS-930-1PC 
platereader (Shimadzu, Kyoto, Japan). The detection limit of the rh-????-ELISA was 4pg/ml.  
Rabbit anti-rh-????-antibody determination
Repeatedly administered injections of rh-????????????????????????????????????????????????????
rabbits (9). As no rabbit anti-rh-????-antibody-ELISA was available spiking experiments 
with serum samples were conducted in order to investigate whether rabbit antibodies against 
rh-??????????????????????????????? Aliquots of the samples drawn at day nine or later were 
????????? ??? ????-ELISA and showed no detectable amount of rh-I???????? ?????? ???????
(1.600 or 3.200 ng/mL) of rh-?????????????????????????????????????????????????????????????
the mixture was incubated for one hour at 40 rpm in a horizontal shaker. After such spiking 
the recovery of the added rh-????????????????????????the rh-????????????????????????????
It was expected that the antibodies generated in the rabbits against the recombinant human 
protein can also capture the added rh-???????????????????????????????????????????????????????
of the added rh-?????
Histological studies
At the end of the animal experiment (after 28 days) the implants were surgically removed. 
Slices of the implant and surrounding tissue were stained with a hematoxylin and eosin 
(H&E) stain. Image data were collected through a Leica DFC 320 camera (Leica 
Microsystems, Wetzlar, Germany) mounted on an Orthoplan microscope (Leica, Wetzlar, 
Germany).
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In vitro release studies 
Studies were conducted by incubating the implants (n=3) at 37°C in TopPac® vials 
containing 2.0 ml isotonic 0.01 M phosphate buffer pH 7.4. The samples were shaken at 40 
rpm (Certomat ® IS, Braun Biotech International, Melsungen, Germany). Samples were taken 
daily the first 7days afterwards every 3 days. Sample volumes were replaced with fresh 
buffer. Analysis was conducted using a Thermo Separation Products HPLC system equipped 
with a Tosoh TSK-Gel G3000 SWxl column. 120 mM disodium hydrogen phosphate 
dehydrate, 20 mM sodium dihydrogen phosphate and 4 g/L sodium chloride, adjusted with 
hydrochloric acid to a pH of 5.0 was used as mobile phase. The flow rate was set to 0.6 
mL/min, UV detection was performed at 210 nm wavelength.
Computer modeling
Basic pharmacokinetic data and data gained by the in vitro release studies were collected to 
calculate virtual rh-???????????????????????????the release curve as input function and the 
basic PK data for modeling distribution and elimination. Calculations were conducted with a 
self-programmed program and obtained data transferred into Microsoft Excel® for diagram 
generation. The pharmacokinetic analysis program WinNonlin® was used to determine half-
life and elimination rate of rh-??????
Results and Discussion 
Pharmacokinetic data:
The reference group with non retarded rh-????-solution applied as s.c. injection provided 
basic pharmacokinetic data. The Cmax was reached after 2.5 hours. Rh-??????????????????
eliminated with an average terminal elimination half life of 3.4 hours. After 12 hours no rh-
??????????????????????????????????????-????????????????????????????????????????????????????
shown in Fig. 1. The modeled curve covering the rh-???????????????????????????????
functions: an inverted Gaussian function describing the inflow and a first order kinetics curve 
describing the elimination of rh-???????????????????????????????????? This pharmacokinetic 
data revealed high similarity to data gained in human clinical trials with rh-????????????????
releasing systems. The human half life of rh-??????????????????????????????????????????
therefore the chosen model is considered as appropriate and plausible.
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Figure 1: rh-????-serum levels after injection of 37µg rh-??????????????????????????????????????????????????
rabbits. The obtained curve was covered with a modeled curve providing necessary PK-data.
In vitro release studies and modeling
As shown in Fig. 2 the implants revealed continuous sustained protein release for 4 weeks. 
The initial drug release was below 25% of the incorporated protein for the first 24 h.
Over 14 days the protein release was almost linear and overall protein liberation from the 
implant was higher than 90%. An inverted Gauss function was generated covering the in vitro 
release curve. This function served as an input function for the calculation of virtual rh-?????
serum levels. 
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Figure 2: Cumulative rh-??????????????????????????????????????????????????????????????????????????????????????
inverted Gauss function serving as input function for computer modeling.
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In vivo release studies and modeling
Serum samples revealed high rh-????-contents on an almost constant level over 9 days after 
insertion of the implant. Fig. 3 shows the obtained protein serum curves. High and therapeutic 
rh-????????????????????????etectable at day 9, protein levels abruptly wear off from day 10 on. 
This phenomenon is most likely attributed to antibodies generated in rabbits against human 
???????????? ????? ???????? ???????? ??? ?????? ????? ???? ???? ??? ????? ?????? ?????? ?????? ??? ????
histology data allows any other explanation. In order to corroborate this hypothesis spiking 
experiments with serum samples after day 9 were conducted in a way that has already been 
described in the methods section. These experiments clearly revealed that serum components 
i.e. antibodies captured large amounts of the spiked rh-??????From data shown in Fig. 4 it can 
be concluded that a massive production of antibodies against the rh-????????? ?????? ???????
Presumably these antibodies were capable of masking all protein released from the implants. 
This leads to the presumption that rh-????? ??? ?????? ????????????? ?????????? ????? ???? ????????
after 9 days but released rh-????? ??? ???? ?????? ???? ??????????????? ????????? ??? ???? ???????
antibodies In order to calculate virtual rh-??????????? ????????? ?????????????????????l was 
developed. This model consists of a serum compartment with an inflow function described as 
an inverted Gauss distribution and first order kinetics for the outflow. The values necessary 
for the inflow function were provided by the in vitro release experiments. First order kinetic 
data i.e. the elimination rate was obtained by the analysis of the rh-????-injection experiment 
of the control group. 
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Figure 3: In vivo rh-???????????????????????????????????????????????????????
Curve was covered with the simulated rh-?????????????????????????????????????????
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The modeling of the rh-??????????????rum levels revealed that the theoretical rh-???????????
levels were in accordance with the experimentally obtained serum levels. Both the curve 
progression and the quantity of the modeled rh-?????????????????????????????????????????????
experimentally obtained rh-?????????????????????????????????????????????????????????????????
outrun of the in vivo data after 9 days does not allow correlations after that time point but it 
can be presumed that without the interference of rabbit antibodies against the rh-??????release 
of rh-?????????????????????????????????????????? ?????????
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Figure 4: Spiking experiment data: analysis revealed an increasing rabbit-anti-??????-antibody titer masking 
large amounts of rh-??????????????????????????
Biocompatibility and degradation
After implantation of the device rabbit’s body temperature, the behavior, as well as the eating 
habit was under steady observation. However, no fever or other signs of inflammation and 
illness like food repulsion could be noticed. Already after a few days the tissue at the 
insection site was healed and it was hardly visible that an implantation had taken place there 
(Fig. 5). At the end of the animal experiment the implants were surgically removed whereas 
no macroscopic encapsulation of the implant was noticeable (Fig 6). The surrounding tissue 
was unaffected by the implant and showed only low signs of inflammation. The implant 
maintained its structure and appeared to be intact and not eroded; migration of immune cells 
into the lipid matrix did not appear. 
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Figure 5: The implantation site before surgical removal of the implant for histological studies.
The imprint of the implant is visible through the subcutaneous tissue.
Figure 6: Dissection of the implantation area: The implant maintained its structure and was located 
loosely beneath the sub cutis without any macroscopic noticeable encapsulation.
Microscopic investigations and tissue staining (Fig. 7) revealed that the implantation 
provoked only weak immune reactions leading to a migration of granulocytes into the 
surrounding tissue at the insection site. Cicatrisation of the sub cutis was noticed indicating a 
quick healing rate and low irritation of the tissue.
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Figure 7: 25 times magnified immune-histological H&E staining of the subcutaneous tissue 
surrounding the implant: The tristearin implant is located on the lower half of the picture, surrounded 
by some collagen fibres.   
Conclusion
The rh-???????????????????????????????????????????????????????????????????????????????????????
rabbits, a relevant model for the potential s.c. application in humans. It can be stated that 
during the first 9 days protein release in vivo is in surprisingly quantitative accordance with 
data gained by in vitro experiments. Computer modeling using PK data obtained in injection 
experiments revealed that the release properties observed in the animal experiment are in very 
close causal correlation to the simulated data. The modeled rh-???????????????????????????
same curve progression for the first 9 days like the rh-??????????????????obtained in this 
animal experiment. Further on the quantity of the modeled rh-??????????????????????????????
with the measured rh-????????????????????????????????????? ??????????????????????????????
the quality and the quantities of the rh-??????????????????allows us to presume that without 
rabbit-rh-????-antibodies the rh-??????????????????????????????????????????????????????
therapeutic relevant levels for several days. The virtual elimination half life of rh-???????????
be extended from approx. 4h up to more than 50hours by means of the depot system.  Thus it 
can be stated that in terms of biocompatibility and controlled release the implant used in these 
experiment is a very suitable device for the delivery of rh-???????????????????????????????
pharmaceutically relevant drugs too. Studies to adjust the geometrical form of such devices 
towards convenient rod-like or micro particulate application forms are under way as well as 
studies for other protein drugs incorporated into depots of the presented type. Biodegradation 
studies are under way too. Based on the in vivo experience presented here the clinical use in 
animals and humans may be achievable in the near future.
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1.3. Discussion of the published correlation data
The data presented in the preceding article proves that the release mechanisms featured by the 
employed implant was not negatively influenced by body fluids and immune reactions of the 
animals. Although the implant was surrounded by fibrous tissue, release wasn’t affected by 
this sub acute response of the animal immunogenic system. Additionally, it was shown that 
there was macroscopically no hint for any degradation or erosion processes occurring at the 
implanted triglyceride disc. As light microscopy analysis didn’t reveal any hints on implant 
erosion it was assumed that the employed triglycerides are not susceptible to any kind of
agents secreted by immune cells or other protection mechanism of the animal body. At the 
first moment this outcome was rather disappointing, meaning that triglycerides can be used as 
stable drug release carriers but exhibiting properties comparable to that of many other 
substances known and already used for the preparation of drug depot systems. Eventually 
their disability of disintegration in vivo results in surgical removal. Of course, this explanation 
and conclusion is somewhat premature as we were observing only one sort of triglyceride 
incubated for a rather short period of time - 4 weeks – in one animal model. This set of data 
therefore may not be sufficient for consecutions regarding a broad spectrum of substances and 
circumstances which need to be taken into account. Therefore, it may be time to take a look at 
the literature and to spot the field of polymer degradation occurring when incubating these 
materials into a living organism. This short review is followed by a closer look at the surface 
of the implants excised from the rabbits in the animal experiment described in the article 
above. Maybe, after taking all these new facts into account this new set of unpublished data 
can change the view on this area of research.
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1.4. Short review on cellular activity at the implant tissue interface
Within a few seconds to minutes after contact to living tissue or blood, surfaces of implanted 
biomaterials are covered with a strongly adherent proteinaceous layer [1]. Probably due to the 
properties of the hydrophobic surface of most applied biomaterials, the adsorbed proteins 
undergo structural changes; unfold themselves by exposing their hydrophobic core, usually 
buried inside the spherical protein structure [2]. This protein denaturation at the interface of 
implanted materials triggers procoagulant and inflammatory responses [3-5]. The most 
abundant adsorbed proteins on the surface of hydrophobic biomaterials comprise albumin, 
fibrinogen and immunoglobulin G (IgG) [6-8]. Especially fibrinogen adsorption seems to be a 
crucial factor in the genesis of inflammatory response [5]. Tang et al could show that the 
presence of fibrinogen at the implantation site is a major factor promoting the accumulation of 
phagocytes in the fibrous tissue surrounding the implant [9]. This accumulation of phagocytes 
leads to histamine associated morphology of the tissue, featuring hyperaemic and oedematous
characteristics [4, 10, 11]. In order to fight against the alleged bacterial intruders, the 
accumulated monocytic macrophages release an abundance of enzymes from their lysosomes, 
mostly belonging to the families of hydrolases and oxidoreductases [12]. In particular, 
lysosomal hydrolases comprise acid and alkaline hydrolases and non-specific esterase as 
predominant enzymes. The family of oxidoreductases is represented by several hydrogenases 
and oxidases. Acid and alkaline phosphates - enzymes responsible for the hydrolysis of 
phosphate esters – are the most prominent hydrolases found in association with leucocytes 
such as monocytic macrophages and mast cells [13, 14]. Further effective weapons in the 
battle initiated by the implantation of the “foreign body” are highly active peroxide species, 
such as hydrogen peroxide, hydroxyl radical, hydroperoxyl radical and super oxide anion [15-
17]. It is understood that this cocktail of different substances such as enzymes and peroxide 
species released from different leukocytes accumulated at the implant/tissue interface may 
influence the structure and the stability of the biomaterial. Thus, it is not surprising that even 
materials classified as stable and unsusceptible to hydrolysis undergo degradation in the living 
tissue [18]. Several papers report on the biodegradation of materials used for long term 
application in human tissue such as polyether polyurethanes (PEU). PEU has been used as 
insulation for cardiac pacemaker leads. However, in some cases, surface crazing has occurred, 
sometimes progressing to deeper cracks and breach of the insulation. It is hypothesized that 
biodegradation of these polymers might involve attack by chlorine- based and/or nitric oxide 
(NO)-derived oxidants, as major oxidative products of activated phagocytes [19-21]. For 
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implants prepared from polyesters and polycarbonates enzymatic surface degradation has 
been reported in many cases [22-24]. Implantation of copolymers of caprolactone and 
valerolactone implanted in rabbits, lead to a total biodegradation within 16 weeks due to 
enzymatic activity [25]. In additional studies it could be shown, that the breakdown of the 
polymeric material into particles in the µm-range leads to accelerated biodegradation due to 
phagosomal degradation [26]. Nowadays, after several decades of extensive clinical research 
on the medical application of polymeric materials, the development of polymeric biomaterials 
has resulted in the preparation of synthetic materials with controllable properties in terms of 
biodegradation. Rendering the surface properties and the hard segment chemistry of specific 
polyesters enables the control of cell adsorption and thus the control of biodegradation rate 
and velocity [3, 23, 27, 28]. Summarizing, it can be stated that materials implanted in living 
tissue have to face many attacks from different adversaries such as low pH level due to 
inflammation processes [29], enzymes and reactive peroxide species. Depending on the 
chemical and physical nature of the applied material complete biodegradation may take only 
several days or may take years. However, it seems that there is no material insusceptible to 
biodegradation processes, since even durable materials like stainless steal show signs of 
degradation after implantation [30]
Materials and methods 
Implant manufacturing
Implants were prepared as described in chapter 1. The implants used in the animal 
experiments were surgically removed from the animals and washed 3 times with distilled 
water in order to remove loosely attached organic material. Reference implants were taken 
from the same batch of implants prepared for the animal experiment. The reference implants 
were incubated in PBS pH 7.4 at 37°C for 4 weeks with and without addition of lipases (100 
U of Lipoprotein lipase and 100 U of lipase from rhizoma oryzae per 2ml PBS). After 3 days 
the buffer media was changed and new lipase-containing buffer was added. 
Scanning electron microscopy
Surface morphology of all implants was analyzed using a Field Emission Scanning Electron 
Microscope Joel JSM-6500F (Joel Inc., Peabody, USA). Implants were fixed with adhesive 
carbon tape (BAL-TEC AG, Balzers, Principality of Liechtenstein) to a custom made brass 
stub, carbon-sputtered and analyzed.
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Results and discussion 
Tristearin implants (Fig. 1) incubated for 4 weeks in PBS without lipase addition showed a 
smooth surface morphology and exhibited pores with an average diameter of about 100µm. 
Pore generation was a result of rh-INF and PEG 6000 release. Higher magnifications of the 
implant revealed the flaky structure typical for crystalline lipids.
When incubated in lipase solution for 4 weeks implant structure was slightly changed. At 
lower magnifications surface morphology was almost comparable to the untreated tristearin 
tablets. However, due to triglyceride cleavage, crystalline microstructure was clearly visible at 
higher magnification. Presumably the detected rosette-like structure – somehow reminding at 
desert rose minerals – is resulting from the lipase affinity towards low ordered structures [31]. 
Regions with lower degrees of crystallinity are preferentially cleaved; regions with a higher 
degree of crystallinity remain - for the time being - untouched by the enzymatic hydrolysis. 
The implant removed from the animal after 4 weeks certainly shows the most distinct change 
in morphology compared to the untreated reference implant. Already at low magnification 
rates it is visible that the former smooth surface is traversed by numerous rips and pores. Most 
prominent is the fact that the microcrystalline structure seems to be completely eradicated. At 
higher magnifications the surface morphology has changed dramatically: the flaky crystalline 
structure seems to be molten generating a scurf-like pattern.
Figure 1: Tristearin implant after incubation in PBS for 4 weeks. a) overview (25Xmagnification) b) pore in the 
implant structure due to drug release (150X magnification) c) microstructure of the lipid tablet (2700X 
magnification)
Figure 2: Tristearin implant incubated for 4 weeks in lipase containing buffer media. a) overview of the tablet 
(25X magnification) b) pore in the implant structure due to drug release (150X magnification) c) microstructure 
of the lipase incubated lipid tablet (2700X magnification)
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Figure 3: Tristearin implant after incubation in the animal body for 4 weeks. a) overview of the tablet (25X 
magnification) b) porous surface of the implant (150X magnification) c) change in microstructure (2700 X 
magnification)
Conclusion
Most biomaterials implanted in human or animal tissue have to face serious attacks from all 
sides such as physical stress and immunogenic attacks including contact with various 
enzymes and highly reactive peroxide species. These combined forces can lead to changes in 
the structure of the implanted biomaterials resulting in cleavage of hydrolytically or 
enzymatically sensitive bonds in the polymer. In our case tristearin implants were implanted 
for 4 weeks in rabbits, after excision the implants were analyzed with scanning electron 
microscopy for changes in the microstructure. These observations revealed that distinct 
changes in the structure of the implants had occurred. Especially the formation of numerous 
pores and rips in the surface of the implants can be assessed as a result of enzymatic or 
peroxide-derived degradation processes. 
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2. Chapter Two: In vitro degradation studies of lipid based drug depot 
systems
2.1.  Introduction
In the first chapter which was divided in two major parts - a set of  in vivo-release data 
already published, followed by results from subsequent SEM-analysis – we saw that 
triglycerides especially the employed glyceryl tristearate exhibit a great potential for the 
preparation of drug depot system controlling the release of sensitive bioactives such as 
therapeutic peptides and proteins. It was further shown that release mechanism based on a 
complex interaction of precipitation, diffusion and dissolution processes were unimpeded by 
the physiological system of the animal model. However, the hope that the used triglyceride 
implants would show distinct biodegradation behaviour i.e., by macroscopic visual 
disintegration wasn’t fulfilled. Although SEM-analysis of the excised implant could proof that 
degradation processes had occurred on the surface of the compressed lipids, e.g. by changing 
the implants microstructure presumably resulting from attacks of reactive peroxide species, 
these humble signs were not suitable to undergird the allegation that triglyceride-based 
implants undergo complete degradation in vivo. One major argument for the biodegradation 
of parenteral applied lipids is their susceptibility towards lipases. However under normal 
condition the human body digests triglycerides in form of small oily droplets. Until today 
there was no data available concerning the lipase degradation of relatively large monolithic 
systems such as the implants applied in the described animal experiment. It was therefore 
necessary to go adrift from simple visual inspection of implanted triglycerides implants in 
vivo and concentrate on methods which bring out quantifiable results and thus enable 
statements on the degradation quantity of the employed lipid. The intended method 
development made it necessary to transfer the incubation and analysis of the lipid depot 
systems from in vivo systems towards in vitro incubation. It is understood that, if 
concentrating on the lipase-related degradation of lipid implants, these enzymes have to be 
included in the in vitro system. 
Chapter two is dedicated on the implementation of this new method, simulating the in vivo 
incubation of triglyceride based drug depot systems within the presence of lipases. In the first 
part of this chapter the analytical method is detailedly described and first results of 
investigation on triglyceride degradation are presented. After a little discussion, additional 
data dealing with the development of the presented methods are displayed. 
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Abstract
The question whether lipid based - especially triglyceride based - depot systems can undergo 
biodegradation is despite many in vivo studies still unanswered. In this paper we studied 
biodegradation processes in vitro by incubating these lipid based systems in buffer media 
containing lipases. The main degradation product the free fatty acids (FFA) were isolated 
from the drawn samples and after derivatization analyzed with RP-HPLC. Lipid 
microparticles showed a rapid biodegradation whereas the complete degradation of 
compressed implants would take several months or years. For theses two systems surface 
degradation can be stated.  Surprisingly lipid based extrudates changed their structure 
dramatically upon lipase incubation resulting in a breakdown of the lipid matrix and 
formation of small lipid particles in the µm-range. This sort of bulk-degradation may enable 
the use of lipid-based extrudates for the long term delivery of drugs. However additional in 
vivo experiments will be necessary to fully characterize these degradation processes.
Keywords: lipid based depot systems, biodegradation, erosion, extrudates, implants
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Introduction
In recent years great efforts have been made in the development of lipid-based parenteral drug 
delivery devices. Although approved polymers like poly(D,L-lactide–co-glycolide-acid) 
(PLGA) are still state of the art for the preparation of parenteral drug delivery devices, depot 
systems based on lipid materials arouse much interest among protein formulators since 
biocompatibility, release and effect on the stability of the entrapped bioactive drug appear 
advantageous. Since the late 70s lipids i.e. fatty acids, triglycerides, cholesterol and lecithin 
have been used as excipients for the preparation of implants designed for the sustained 
delivery of drugs like steroids and morphine derivates [1, 2]. In the late 80s Wang and 
coworkers prepared implants for the controlled delivery of insulin consisting of fatty acids or 
cholesterol. Implants made of fatty acids showed erosion in vivo; however it was reported that 
administration of fatty acids as matrix material lead to inflammation and formation of blisters 
in the animal tissue. Further on, the use of fatty acid-monoglycerides is limited due to the fast 
erosion of these systems [3-5]. In 2001 Reithmeier et al prepared glyceryltripalmitate 
microparticles and PLGA-based microparticles and compared their biocompatibility after 
implanting both formulations in mice. After 7 days the amount of PLGA-microparticles as 
well as lipid microparticles at the site of implantation was reduced most probably due to 
degradation in the subcutaneous tissue [3].  In 2003 Vogelhuber et al produced cylindrical 
matrices consisting of triglycerides or triglyceride/cholesterol mixtures which allowed a 
release of pyranine, a model compound, for more than 120 days. In vitro no erosion was 
detectable [4]. In 2006 Mohl et al developed a tristearin implant for the controlled delivery of 
rh-INF over 1 month. In further studies the stability of the entrapped protein in the lipid 
matrix could be verified [5, 6]. Stability and bioactivity of the encapsulated protein was also 
confirmed by Appel regarding release of insulin from tripalmitate cylinders in cell culture [7]. 
In 2006 Guse et al conducted an animal experiment with the aim to investigate on the 
biocompatibility of glyceryltripalmitate and on the effect of cholesterol and distearoyl-
phosphatidyl-choline (DSPC) on the erosion behaviour of the lipid matrices. It could be 
shown that DSPC is quickly eroded leading to a residual porous lipid structure consisting of 
triglycerides [8]. In order to prove the biocompatibility and to investigate on the in vivo in 
vitro correlation of the rh-INF release from tristearin implants an experiment with rabbits as 
animal model was conducted by Schwab et al [9]. In this study, once again, triglyceride 
implants showed a good biocompatibility but signs of bioerosion couldn’t be detected. 
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In summary, depot systems based on lipids – especially triglycerides – are a valuable 
alternative to already approved polymeric systems. Especially for long term drug delivery 
lipids seem to be superior to the commonly used polymers, due to their ability to maintain the 
stability of the entrapped proteins for a long period of time and due to their excellent 
biocompatibility. However, the question whether parenteral lipid drug delivery devices –
especially implants - are biodegradable is still unanswered as there is no data available from 
application in humans. Biodegradation of lipid depot systems surely is one major parameter 
for the future success of these materials concerning an approval for their use in human 
medicine. Therefore we decided to systematically study the degradation of various lipid drug 
delivery devices incubated in lipase solution under physiological conditions. As lipases are 
present in human subcutaneous fat tissue [10-12] in muscle tissue [13] as well as in serum 
fluids [14] they therefore exhibit the possibility to hydrolyze lipid based drug delivery 
systems. Our aim was to investigate whether lipid based depot systems would undergo 
degradation in the presence of lipases. Further on, we wanted to elucidate the influence of the 
lipid composition, the size and the manufacturing process of the implants on the degradation 
kinetics. Little is known about the activity of lipases and their ability to degrade exogenous 
lipids brought in the body by injection or infusion [15] since research is mostly concentrating 
on the relationship of lipase activity - i.e. hormone sensitive lipase, lipoprotein lipase and 
serum hepatic lipase - and lipid metabolism in the context of obesity [10, 12, 14, 16-23]. In 
general one can state that the average lipase activity in the human serum and subcutaneous fat 
tissue has approximately an activity of 0.01 U/ ml.  In these studies higher lipase activities 
were chosen with respect to the analytical sensitivity and time frame of the experiments. It is 
therefore understood that the results of the described experiments should be viewed with some 
caution as the employed lipase levels are 5000-15000 times higher than the activities present 
in human tissue.
Materials and Methods
Materials
All lipids (Glyceryltristearate, -tripalmitate, -trimyristate –trilaurate, lipidmixture E85, 
lipidmixture H12) used in this study were purchased from Sasol GmbH, Witten, Germany. 
Lipases (Lipoproteinlipase from pseudomonas sp. and Lipase from Rh. Oryza) and all other 
chemicals were purchased from Sigma–Aldrich, Deisenhofen, Germany.
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Methods
Preparation techniques
Preparation of microparticles
Placebo lipid microparticles either consisting of glyceryltripalmitate or glyceryltristearate 
were produced resulting in 2 different particle sizes (10µm and 100µm mean particle size).
The production techniques are described as followed:
Lipid Microparticles preparation
Placebo Lipid Microparticles were produced using 2 different preparation techniques widely 
used for the preparation of polymeric or lipid based microparticles [3, 25]:
Solvent Evaporation method: 300 mg lipid powder was dissolved in 1.0 ml organic solvent 
(e.g. methylene chloride). The resulting solution was further emulsified at 40°C into a small 
volume (3.0 ml) of a 1% (w/v) aqueous PVA solution using an Ultra-Turrax® (IKA Werke 
GmbH & Co. KG Staufen, Germany). Particle size was controllable by adjusting the rotation 
speed of the emulsification tool. The emulsion was poured into a larger volume (150 ml) of an 
ice-cooled (5°C) aqueous phase (PVA 0.1% (w/v)) and stirred with a propeller stirrer to allow 
for the evaporation of the organic solvent. The hardened microparticles were separated from 
the aqueous phase by filtration, rinsed with 40 ml of water and vacuum dried overnight at 
room temperature.
Melt Dispersion method
With this preparation technique, a lipid melt was used instead of the solution of the lipid in an 
organic solvent. The lipid melt (300 mg lipid powder heated above its melting point was 
poured into the PVA solution and emulsified as described for the solvent evaporation method. 
The following steps were the same as for the solvent evaporation method. The stirring time 
was reduced from 30 min to 5 min since this method is solvent free.
Implant manufacturing
Implants were prepared by using a 5 ton hydraulic press (Maassen, Eningen, Germany).
The implant component, i.e. tristearate-powder was ground either with or without pore builder 
and compressed with a pressure of 2 tons for 30 seconds. The obtained implants had an 
average weight of 50 mg a diameter of 5mm and an average height of approximately 2.3 mm. 
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Preparation of twin-screw extrudates (tsc-extrudates)
Lipid based tsc-extrudates were prepared using a MiniLab® Micro Rheology Compounder 
(Thermo Haake GmbH Karlsruhe, Germany). Extrusion temperature was set to 43°C to 48°C 
which was slightly above the melting temperature of the respective low melting triglyceride. 
As pore forming agent PEG 6000 was used either alone or in combination with 
hydroxypropyl-?-cyclodextrin lyophilisate (lyo). After application of the lipid powder mixture 
into the extruder barrel and subsequent softening of the mixture, extrusion was performed 
through the extruder outlet dye (diameter 2.0 mm). The rotation speed of the extruder screws 
was set to 40 rpm and the bypass channel was closed to inhibit material circulation within the 
extruder.
Degradation studies setup
In this study, solid lipid drug depot formulations i.e., microparticles, compressed implants, 
and extrudated rods were incubated at 37°C in PBS (2.0 ml isotonic 0.01 M phosphate buffer 
pH 7.4) containing the lipases mentioned above in different activities (100, 200 and 300 
U/2ml respectively). After 3 days of incubation the buffer media with the lipases was 
exchanged with fresh medium. FFA were isolated from the drawn samples and, after 
derivatization, analyzed. The amount of FFA released during the incubation was used to 
compare the different formulations in terms of biodegradation. Degradation of the lipid mass 
was calculated as percentage of the total amount of saponifiable lipid mass. 
Microparticles
10mg of microparticles were incubated at 37°C in 2 ml PBS pH 7.4 containing 100 U of both 
lipases. After 3 days 100µl of the supernatant were drawn and the volume was replenished 
with fresh lipase solution. FFA were isolated from the drawn samples and, after 
derivatization, analyzed. 
Compressed lipid implant study
In order to investigate on the degradation behaviour of compressed lipids tristearate implants 
were prepared from tristearate powder applying compression forces used for the preparation 
of the implants established in previous experiments [5, 9]. The relationship between lipase 
activity and FFA-rate was analyzed using 3 different lipase activities (100, 200 and 300 U 
/2ml respectively).To analyse the influence of pores in the lipid implants tristearate implants 
were produced with increasing amount of pore builder (PEG 6000). Amount of pore builder 
used was 0,  20, 30, 40 and 50%. Prior to the start of the degradation experiments the implants 
were incubated in PBS for 4 weeks to allow the pore building agent to dissolve. 
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Lipid extrudate degradation study
10 different formulations of lipid based extrudates have been produced for this study. The 
prepared lipid extrudates always consist of a low melting and a high melting lipid component. 
Glyceryltristearate (D118), glyceryltripalmitate (D116) and glyceryltrimyristate (D114) 
served as high melting lipid component, whereas glyceryltrilaurate (D112) and two 
triglyceride-mixtures (H12 and E85) served as low melting component. H12 and E85 are 
synthetically produced triglycerides consisting of different fatty acids (lauric-, myristic- and 
palmitic acid) esterified in different ratios with glycerol. Due to the specific composition H12 
has a melting point of approx. 35 °C and E 85 melts at 41°C. In Table 1 the different 
formulations of the produced lipid extrudates are listed. Aim of this study was to investigate 
on the effect of the high melting lipid composition, the effect of the low melting lipid 
composition, the effect of the ratio of the lipid composition and the effect of different amounts 
of pore builder on the degradation behaviour. Results of preliminary experiments (data not 
shown) showed that the presence of PEG can interfere with the lipase induced lipolysis in an 
unpredictable manner therefore lipid extrudates have been incubated in 2ml PBS pH 7.4 for 4 
weeks to allow the pore builder to dissolve. These extrudates were used for the lipase 
incubation. A second batch of extrudates has been incubated in PBS for 2 months without the 
addition of lipase solution to investigate on the stability under non lipolytic conditions
Table 1: Formulation of lipid based extrudates: D118 (glyceryltristearate), D116 (glyceryltripalmitate), D114 
glyceryltrimyristate), D112 (glyceryltrilaurate), H12 (lipid composition consisting of different fatty acids (lauric, 
myristic and palmitic acid) esterified in different ratios with glycerol; melting point 34°C), E85 (mixture of 
different fatty acids (lauric, myristic and palmitic acid) esterified in different ratios with glycerol; melting point 
41°C)
Batches High melting lipid 
component (HMLC)
Low melting lipid 
component (LMLC)
Ratio of lipid 
components
HMLC:LML
Amount/type of 
pore builder
E1 D118 H12 80:20 0% PEG
E2 D118 H12 80:20 20% PEG
E3 D118 H12 80:20 40% PEG
E4 D118 H12 90:20 10% lyo, 10% 
E5 D118 H12 80:20 10% lyo, 10% 
E6 D118 H12 70:30 10% lyo, 10% 
E7 D118 E85 80:20 10% lyo, 10% 
E8 D118 D112 80:20 10% lyo, 10% 
E9 D116 H12 80:20 10% lyo, 10% 
E10 D114 H12 80:20 10% lyo, 10% 
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Characterization Methods
FFA Extraction method
FFA were extracted from Lipase activity assays samples and samples drawn in the 
degradation experiments. Extraction provided quick analysis time and avoidance of 
derivatization interference with buffer components. The extraction method is based on the 
Dole and Meinertz extraction procedure [27]. The extraction solvent was prepared by mixing 
isopropanol–heptane–phosphoric acid (2 M) (40:10:1, v/v) and was thoroughly stirred before 
use.  Extraction solvent (2.5 ml) was added and the tubes were thoroughly vortexed. The 
tubes were then immersed in a sonicator water bath (Branson Ultrasonic, Danbury, CT, USA) 
and the samples were sonicated in 30 s intervals for 2 min. Care was taken to avoid heating 
the samples during sonication. The samples were then vortexed vigorously and allowed to 
incubate at room temperature for 10 min. Heptane (1 ml) and water (1.5 ml) were added and 
the tubes were thoroughly vortexed and sonicated again for one min. Tubes were centrifuged 
at 1000 g for 10 min at 4°C. After centrifugation the top organic layer was seen to separate 
cleanly from the aqueous layer. A 1.5 ml aliquot (88% of the total organic layer of 1.7ml) of 
the top layer was transferred carefully using a pipette to 1.5 ml HPLC vials and dried under a 
stream of warm nitrogen. These samples were then used for derivatization.
Free fatty acid determination
As free fatty acids (FFA) are the major cleavage product of lipase induced triglyceride 
degradation, a quantifiable analysis was based on FFA-release upon lipid degradation. 
Phenacyl esters of fatty acids were prepared by the method described by Wood and Lee [26]. 
Briefly, samples were placed in HPLC-vials with closed silicone/PTFE screw caps (VWR 
international, Darmstadt, Germany), then 25 ml of a phenacyl bromide solution (10 mg/ml in 
acetone) and 25 ml of a triethylamine solution (10 mg/ml in acetone) were added, capped 
under N and heated in a boiling water-bath for 5 min. The excess of phenacyl bromide was 
reacted with acetic acid (40µl of a 2 mg/ml solution in acetone) and, after evaporation of 
solvents under a stream of N2 at laboratory temperature, the derivatization products were 
reconstituted in methanol. FFA solutions of known concentrations (5-200.0 µg/ml) in 
methanol were used to generate calibration curves. Samples were analyzed using a Thermo 
Separation Products HPLC system (Thermo Fisher Scientific, Inc. Waltham, U.S.A.) 
equipped with a LiChrospere RP C18 column (4.6 mm i.d. x 250 mm, 5 µm) ( Merck, 
Darmstadt, Germany). Mobile phase was a mixture of MeOH-AcCN-water (80: 10: 10 (v/v)). 
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Elution of phenacyl esters was monitored by absorbance at 254 nm. The detection limit was 
about 5µg FFA per ml, accounted for stearic acid, i.e. approx. 20 nmol of fatty acid.
Lipase activity assay
In order to determine the activity and stability of the used lipases enzyme activity assays were 
carried out. For each assay a trioleate emulsion was prepared by mixing 4.5 ml polyvinyl 
alcohol solution (2% w/v) with 1.5 ml triolein. This mixture was then emulsified at 0°C with 
an Ultra Turrax®  for 2 min at 15,000 rpm. 500µl of this emulsion and 400µl PBS buffer 0.01 
M pH 7.4 then were incubated in a 2 ml Eppendorf cap for 10 min at 37°C in a water bath. 
100µl of lipase solution was added and the mixture was incubated again at 37°C. After 10 min 
the reaction was stopped by adding 1 ml of a methanol:acetone:methylene chloride mixture 
(1:1:1 v/v).  Before derivatization and HPLC analysis FFA produced in the triglyceride 
cleavage were extracted using the method described below. 1 U of enzyme activity was 
defined as the release of 1µmol FFA per min at 37°.
Scanning Electron Microscopy (SEM)
To investigate whether degradation of lipid drug delivery devices is visible SEM 
measurements were carried out. Samples were analyzed using a Field Emission Scanning 
Electron Microscope Joel JSM-6500F (Joel Inc., Peabody, USA). Therefore samples were put 
on adhesive carbon tape (BAL-TEC AG, Balzers, Principality of Liechtenstein) and attached 
to a custom made brass stub, carbon-sputtered and analyzed.
Particle size distribution
Particle size was determined using a Horiba LA 950 laser diffraction particle size distribution 
analyzer (Retsch Technology GmbH, Haan, Germany).
Determination of Lipase adsorption on lipid surface
In order to analyse the amount of lipase adsorbed on the surface of the lipid devices, i.e. the
amount of lipase which is hydrolytically active at the lipid-water interface, adsorption studies 
were carried out using a modified method after Brockmann [28]. Briefly, after incubation of 
lipid implants in lipase solutions for a defined amount of time at 37°C, implants were washed 
in water and then incubated for 15 min in PBS pH 7.4 containing 0.15% Brij 35® to desorb 
bond lipase. Aliquots of the resulting solution were assayed for lipase concentration 
determination via fluorescence spectroscopy. A calibration curve of known lipase 
concentrations was prepared for each adsorption test. 
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Results and Discussion 
Microparticles
Samples drawn from the incubated microparticles revealed steady generation of free fatty 
acids due to the lipase activity (Fig. 1). For D118 microparticles a distinctive differentiation 
can be made concerning the degradation velocity of microparticles produced with different 
preparation techniques: microparticles produced with the solvent evaporation technique show 
faster degradation than microparticles prepared with the melt dispersion technique.  
Regarding the influence of the particle size on the FFA-release from the microparticles it was 
found that it has a bigger influence for longer chain length triglycerides than for shorter chain 
lengths. For the particles made from D116 no such distinction can be made. All particle 
batches showed comparable degradation velocities. After 48 days degradation of the total 
lipid mass reached 80 % for D116 whereas D118 microparticles showed a degradation 
ranging from 45 to 65%. Over the time degradation velocity was decreasing in both studies 
probably due to the lipases inhibition by the cleavage products, i.e. by the accumulation of 
fatty acids in the incubation tubes as reported in literature [29]. To investigate whether 
degradation of lipid drug delivery devices was visible SEM measurements were carried out. 
SEM photographs revealed strong differences in the surface morphology prior and after the 
degradation period. As seen in Fig. 2a-b the surface of the microparticles before lipase 
incubation was smooth whereas microparticles incubated with lipase changed their 
morphology towards a rough and uneven surface. However cracks or pores couldn’t be 
detected indicating that the degradation is only happening at the lipid water interface.
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Figure 1: Degradation study of lipid microparticles over 48 days (Average + S.D., n = 3). 
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Implants degradation study
Compressed tristearate implants showed a constant and linear FFA release during lipase 
incubation. After 60 days of incubation only 0.7 % of the total lipid mass was degraded by the 
enzymes. Compared to the fatty acid release from the microparticles, degradation kinetics of 
the implants were very slow most probably due to the small surface area exhibited by the 
implants. When extrapolating the applied lipase activity to a level found in human tissue 
(approx. 0.01 U/ml) the total degradation of these systems would surely exceed the average 
life span of a human being (>100 years). Macroscopically analyzed implants showed no 
change in surface morphology. However, SEM photographs did show changes in surface 
morphology but revealed no cracks or holes in the lipid matrix (Fig. 2c-d). Typical lipid 
crystals were visible after lipase incubation in high magnification. As expected, these findings 
confirm the interfacial activity of the lipases [30-32] resulting in a strict surface degradation 
and erosion of the compressed lipid implants. In this study we can assume the substrate 
concentration, i.e. the lipid, to be very low and the enzyme being not saturated, thus resulting 
in linear fatty acid release over several days. To analyze whether an increase in surface area 
could increase lipid hydrolysis porous implants were prepared. 
Figure 2: SEM-pictures of lipid microparticles and compressed implants: a) D116 Lipid microparticle 
prepared by melt dispersion (MD) method before incubation (magnification 2000X). b) D116 lipid 
microparticle (MD) after incubation with lipase (magnification 2000X). c) D118 implant surface before 
incubation (magnification 2000X). d) D118 implant surface after lipase incubation (magnification 
2000X).
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With increasing amount of pore builder fatty acid generation was increased in a linear 
manner. Implants with 50% of pore builder partially collapsed upon lipase incubation 
probably due to the physically instable porous structure. These fragments additionally 
increased the surface area presented to the lipase thus increasing the total degradation rate up 
to 1.8% after 30 days of incubation (Fig. 3a). The relationship between degradation rate and 
lipase activity was analyzed in another experiment. In this setup tristearate implants were 
incubated with 100, 200, 300 and 400 U /2ml lipase respectively. As seen in Fig. 3b the 
results indicate that, after an initial a plateau phase, a linear relationship between lipase 
activity and degradation velocity can be assumed over a wide range of the lipase activity. To 
investigate on the amount of lipase involved in the lipid cleavage lipase adsorption studies 
have been conducted as described above.
Figure 3: Results on porous implants: a) Studies on the effect of porosity on the degradation velocity (Average + 
S.D., n = 3). b) Degradation velocity [%/d] of compressed D118 implants versus the lipase activity.
Lipase adsorption studies
Results of these studies show that only a minor percentage of the total lipase used in these 
experiments is involved in the cleavage of the triglyceride. It can be presumed that less than 
0.25 percent of the total lipase content is bound on the lipid surface of a compressed implant 
when applying a lipase activity of 100 U (Fig 4a). Another experiment confirmed the linear 
relationship between lipase adsorption and presented lipid surface (Fig. 4b). 
Figure 4: Lipase adsorption studies: a) Lipase recovery versus surface area. b) Lipase recovery plotted against 
lipase content in buffer media.
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Extrudates degradation study
10 formulations of lipid based extrudates exhibited different degradation rates. Compared to 
the degradation rates of implants extrudate degradation was almost 10 times faster reaching 
up to 4% after 30 days of incubation. In our study we focussed on the influence of the low 
melting lipid component, the high melting lipid component, the effect of the ratio of the 
different lipid components and the effect of pore builder on the degradation behaviour.
Reference extrudates stored in lipase-free buffer media for 2 months remained stable and 
showed no signs of erosion.
Effect of the low melting component: as seen in Fig. 5 extrudates containing trilaurate or 
H12 showed the highest degradation rate, reaching over 3% of lipid mass degradation after 30 
days of incubation, whereas extrudates comprising E85 showed  a lipid mass degradation of 
about 1.5% .
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Figure 5: Extrudate degradation study: influence of the low melting lipid component on the degradation 
velocity (Average + S.D., n = 3).
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Effect of the high melting lipid component: the use of D114 as high melting lipid 
component leads to the highest degradation rate (3.6%) compared with D116 or D118 based 
extrudated implants (Fig. 6). 
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Figure 6: Extrudate degradation study: influence of the high melting lipid component on the 
degradation behaviour (Average + S.D., n = 3).
Effect of the mixing ratio of the lipid composition: Extrudated lipid implants were always 
prepared from mixtures of high and low melting components. As seen in Fig. 7 the 
composition with a mixing ratio of 80:20 showed a degradation of 3.75% of the total lipid 
mass after 30 days and therefore seems superior to 70:30 ( 2.5%) or 90:10 (1.6%). 
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Figure 7: Extrudate degradation study: influence of the ratio of low and high melting component on 
the degradation behaviour (Average + S.D., n = 3).
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Effect of the amount of pore builder: as already confirmed by the experiments with porous 
implants, extrudated lipid rods containing the highest amount of pore builder exhibited the 
highest degradation rate (3.95%). Extrudates without any pre-built pores reached only 1.65% 
of total lipid degradation at the end of the degradation study (Fig. 8). 
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Figure 8: Extrudate degradation study: influence of the PEG content on the degradation behaviour 
(Average + S.D., n = 3).
Surprisingly almost all extrudates –except E1, E4 and E7- lost their physical integrity after a 
few days of lipase incubation resulting in small lipid particles suspended in the buffer media. 
The extrudates of the control group maintained their structure and morphology after 
incubation for more than 2 months in buffer media without lipase solution. Laser light 
diffraction measurements were carried out to analyze the size of the generated particles. As 
seen in Fig. 9 mean particle sizes of the collapsed lipid extrudates were in the µm size range.
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Figure 9: a) SEM photographs of particles generated during lipid matrix collapse of incubated extrudates 
(magnification 1000X). b) Surface morphology of particle generated by matrix collapse of lipid based 
extrudates (magnification 1000X).
c) Typical particle size distribution of particles generated during lipase incubation of lipid based 
extrudates (size distribution of particles from extrudate formulation E6). d) Table of particle size 
distributions: mean particle size range (Average size [µm]).
This breakdown of the lipid matrix is rather unexpected and can be considered as a form of 
bulk erosion. Since polymers typically undergo surface erosion when they are enzymatically 
degraded [33-35] additional experiments have to be carried out in order to explain the reasons 
for the lipid extrudate erosion phenomenon and to analyze the mechanism of the lipid matrix 
breakdown. However, in vivo such degradation behaviour would be highly desirable as the 
generated small particles can be finally washed away by body fluids or can be eliminated by 
phagocytosis and therefore would lead to minimized irritation and foreign body reactions.  
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Conclusion
The presented results lead to the conclusion that depot systems based on single triglycerides 
and triglyceride-mixtures can be degraded by lipolytic enzymes under physiological 
conditions. Although lipid cleavage is a rather slow process, our studies clearly demonstrate 
that this process can be accelerated by using certain materials, implant geometries and 
preparation techniques. For particulate systems it can be stated that with decreasing particle 
sizes lipase degradation is increasing and finally capable to fully degrade such microparticles. 
This finding is consistent with the results of Reithmeier et al. who claimed a reduction of the 
number of implanted microparticles after 7 days of incubation [3]. Thus, if a short term drug 
delivery is necessary lipid microparticles may very well fulfil all the requirements for 
biodegradable controlled release devices. Compared to the microparticles compressed 
implants show only very slow degradation velocity. Presumably this is a result of the minor 
adsorption rate of the enzymes on the monolithic compressed lipid system: since 
microparticles exhibit a higher surface area due to their particulate nature these systems can 
be degraded quicker as monolithic systems with a relative small surface area. Our studies 
indicate that the lipid cleavage is strictly happening on the surface of the implants - a finding 
concordant with several other publications [32, 36]. This surface degradation and erosion 
process prevents interference with the drug release mechanism of such lipid drug delivery 
systems. Nevertheless a complete degradation of these compressed systems is extremely 
unlikely since – assuming a pure enzymatic based degradation – lipid cleavage would take 
more than hundred years. The results on extrudates studies show that it is possible to increase 
the degradation by changing the geometric form and the preparation technique of the depot 
system and thereby increasing the surface area. Using certain lipid components changes the 
degradation behaviour dramatically resulting in “collapsing” extrudates generating lipid 
particles in the µm range. This erosion process can be influenced by the amount of pore 
builder as well as by the sort and the ratio of the used lipid components. Dissolution of the 
pore builder or of the entrapped drugs promotes the generation of an interconnected pore 
network which seems to induce the observed collapse of the lipid structure. The generated 
particles exhibit a higher surface area thus resulting in the following to a faster biodegradation 
compared to an intact depot system based on the same components We can assume, that 
degradation of lipid based drug delivery systems will occur in the human body even if the 
lipase activity levels in vivo are lower than the levels used in these in vitro studies. 
Additionally, we conclude that the observed bulk erosion process may lead to the 
development of fully erodible drug delivery systems. With such systems, both long terms 
sustained release and eventual total biodegradation and bioerosion should be achievable.
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2.3.  Discussion of the results of the in vitro degradation study
For the first time degradation of triglyceride based drug depot systems can be quantifiably 
investigated with the method described in the first part of this chapter. The applied method,
consisting of lipid carrier incubation in lipase containing buffer media, isolation of the 
degradation products, i.e. fatty acids and the quantification of these substances allows the 
evaluation of lipid based drug release carriers with respect to their degradation velocity in the 
presence of lipases. Of course the results of this study have to be considered with some care, 
since the system contains some elements which should be discussed. At first the lipase levels 
applied in the in vitro system are worth some consideration: With respect to the detection 
limit and the time frame of the conducted incubation experiments lipase levels were 
approximately 10000 times higher than the activities known to be present in human tissue. On 
the one hand this extreme amplification of the main parameter in this system may jeopardize 
the plausibility of the generated results. On the other hand one can argue that an enzyme 
system consisting only of 3 different more or less purely isolated enzymes, totally separated 
from normally existing co-enzymes and other factors of biological relevance can hardly 
mimic a controlled and reactive physiological enzyme system. Secondly, one could criticize 
the setup of the applied incubation system. Incubating lipid implants and extrudates in free 
flowing buffer media exhibiting a total absence of physiological substances as albumin, 
collagen surfaces and last but not least a cellular and reactive immunogenic environment isn’t 
a close depiction of the physiological environment an implanted drug depot system would 
face. Tissue fluids and collagenous encapsulation are parameter strongly influencing the 
degradation and erosion behaviour of the implanted systems. In addition to that, as described 
in the review in chapter 1, immunogenic reaction at the implant tissue interface can lead to 
remarkable physical and chemical changes which would surely influence a lipase-induced 
degradation. To avoid such strenuous argumentation one should consider the presented in 
vitro degradation system allows the direct and reproducible comparison of degradation 
processes of such different lipid carrier systems as microparticles and monolithic implants. 
Especially in the simplicity of the applied in vitro systems, in the understatement of its 
parameter lies the advantage. It is hardly imaginable to design an in vivo system capable of 
observing the lipase effects on lipid particles ranging in the micrometer area. When creating 
this system it wasn’t aimed to fully mimic all physiological conditions and to get totally 
independent of animal experiments but it was aimed to concentrate one lipolytic systems of 
the human body and to thoroughly examine the effects of this system without any interference 
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from other biological factors. When dealing with the main points of criticism highlighted 
above, the author was also aware that some other factors in the applied incubation systems 
and incubated samples would need to be dealt with special attention in order to maintain a 
high degree of quality and reproducibility. In the following part additional experiments and 
preparation techniques employed during the development and execution of the lipase 
incubation studies are presented.
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2.4. Lipase stability and lipid microparticle preparation
As described in the first part of this chapter, lipid microparticles and other lipid based drug 
depot systems were incubated in lipase solution, in order to determine lipid degradation rates 
of the applied systems. When working with enzymes such as lipase, it is crucial to thoroughly 
characterize these bio-catalysers in order to achieve a constant and reproducible activity. 
Since enzymes are generally proteins - with an amino acid range from only 62 [1] to several 
hundred or thousand amino acids [2] – these macromolecules comprise the risk of inactivation 
and activity loss. Enzyme activity and catalysis is a result of a complex process, involving 
structural changes thereby exposing the active site of this macromolecule comprising the
amino acids serine, aspartate and histidine which form the catalytic triad [3-5]. Enzyme 
folding and interfacial activation can be impaired by several factors such as ion strength, heat 
or cold and mechanical forces [6]. Therefore, for long term experiments as described in 4.2
enzyme stability has to be evaluated. In the first part of this section the experiments of the 
conducted lipase stability test are outlined. The second part deals with the preparation of lipid 
microparticles featuring a defined particle size.
Materials and methods
Materials
All lipids (Dynasan 118 and Dynasan 116) used in these experiments were purchased from 
Sasol GmbH, Witten, Germany. All lipases and all other chemicals were purchased from 
Sigma–Aldrich, Deisenhofen, Germany.
Methods
Lipase activity assay
Lipase activity was tested with a trioleate emulsion. The emulsion was prepared freshly for 
each test by mixing 4.5 ml aqueous polyvinyl alcohol solution (2%) with 1.5 ml triolein. This 
mixture was then emulsified at 0°C with an Ultra Turrax®  for 2 min at 15,000 rpm. 500µl of 
this emulsion and 400µl PBS buffer 0.01 M pH 7.4 then were incubated in a 2 ml Eppendorf 
cap for 10 min at 37°C in a water bath. 100µl of lipase solution was added and the mixture 
was incubated again at 37°C. After 10 min the reaction was stopped by adding 1 ml of a 
MeOH:acetone:methylene chloride mixture (1:1:1 v/v).  Before derivatization and HPLC 
analysis free fatty acids produced in the triglyceride cleavage were extracted using the method 
already described in the first part of this chapter.  In order to achieve a standardized quality of 
the used trioleate emulsion, oil droplet size was determined with static laser light scattering.
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Stability study
In order to investigate on the stability of the lipases (Lipase amano M, lipoprotein lipase from 
pseudomonas sp, lipase from candida rugosa and lipase from rhizoma oryzae) used for the 
degradation studies lipase solutions of known concentrations were incubated in PBS  pH 7.4 
at 37° for 8 days in TopPac® vials. Every day a specified amount of the incubated solution 
was withdrawn and tested with the trioleate emulsion method described above. Preliminary to 
the start of this study the activity of all lipase was determined and the resulting level of 
activity was set to 100% as a starting point reference.
Lipid microparticle preparation
Lipid based microparticles were prepared as described in chapter 2. As 2 different particle 
sizes were required for the experiments (10µm and 100µm mean particle diameter) process 
conditions, i.e. the rotation speed of the Ultra Turrax® (TP 18/10, Stauffen, Germany) had to 
be adjusted in order to obtain the particle size needed for the experiments. Therefore in 
preliminary experiments the suitability of the applied method has been tested. Rotation speed 
of the Ultra Turrax® was controlled externally with a continuously variable 9-step TRIAC-
controller (Messner, Dettenhausen, Germany). In order to validate the preparation of distinct
particles sizes lipid microparticles were prepared using rotation speed settings from 1 to 9 on 
the TRIAC-controller. Preliminary to the mixing step the rotation tools were adjusted to the 
same temperature as the lipid melt in a temperature controlled water bath in order to avoid 
lipid solidification. Rotation time was set to 30 sec. After stabilizing the obtained particles in 
the ice cold aqueous phase the particles were collected and particle size was determined with 
static light scattering.
Particle size distribution
Size of lipid microparticles and oil droplets of prepared emulsions was determined using a 
Horiba LA 950 particle size distribution analyzer (Retsch Technology GmbH, Haan, 
Germany).
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Results and discussion
Lipase stability
As expected lipase activity was decreasing with increasing time of storage at 37° in aqueous 
media. The tested enzymes exhibited different stabilities. Lipoprotein lipase from 
pseudomonas sp. (LPL) exhibited the highest stability in aqueous media (Fig. 1). After 3 days 
of incubation almost 80% of the initial activity was measured. However after 8 days activity 
level was decreased to 20%.  Comparable to LPL was the obtained stability data for lipase 
from rhizoma oryzae (RO). After 3 days activity was decreased to 80% and after 8 days 20% 
of residual activity was measured. 
Figure 1: Stability data for lipase from pseudomonas sp. (a) and lipase from rhizoma oryzae (b)
Figure 2: Stability data for lipase amano M (a) and lipase from candida rugosa (b)
Lipase amano M was shown to be very unstable under the tested conditions (Fig 2). After 3 
days the activity levels was beneath 20% and after 8 days of incubation no activity was 
measurable anymore. Lipase from candida rugosa (CRG) was slightly better. After 3 days of 
incubation approximately 23% of the primordial activity was detected. After 8 days the 
activity level dropped to values of about 13%.According to the results generated in these 
stability tests, lipoprotein lipase from pseudomonas sp. and lipase from rhizoma oryzae were 
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selected for the long term degradation studies. Further on, as a consequence of these results, it 
was decided to change the lipase-containing buffer media every 3 days in order to maintain 
high lipase activity in the setup. According to these results the lipase activity level are almost 
kept constant for a 3 day cycle. 
Trioleate emulsion
The oil droplet size of the obtained trioleate emulsions was in a narrow size range (0.5 µm to 
25 µm) with an average droplet size of approximately 4 µm. 
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Figure 3: Typical size distribution of oil droplets generated during the preparation of a trioleate emulsion
Microparticle preparation
It was shown that the attached TRIAC-controller enabled the controlled preparation of 
microparticles. As seen in Fig. 4 the particles size and the rotation speed of the emulsification 
tool correlate closely in a certain range. As expected, with lower rotation velocity larger 
particles are obtained. It can be stated that this method it is not suitable to produce particles 
with a mean particle size smaller than 1-2 µm as the particle size didn’t decrease significantly 
when using the settings 7 to 9. Unfortunately, it was not possible to obtain exact data 
concerning the number of revolutions with the TRIAC-controller attached. However it can be 
stated that level 9 corresponds to 20,000 rotations per minute.
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Figure 4: Size of microparticles correlated to settings of the TRIAC controller attached to the emulsification tool
Summary
It was shown that lipases designated for lipid depot system degradation studies exhibit 
different properties concerning their stability in aqueous environment. As a result of these 
experiments lipase from pseudomonas sp and lipase from rhizoma oryzae were employed in 
the degradation experiments described in chapter 1. Accordingly samples were drawn every 
three days in order to quantify the FFA amount and to refresh the lipase in the incubation set 
up. In addition to that a microparticle preparation method was presented which allows 
obtaining microparticles of a certain size range by controlling the rotation speed of the 
emulsification tool. 
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3. Chapter Three: Studies on the mechanisms of lipid matrix disintegration
3.1. Introduction
In chapter 2 the development and preliminary results of a lipase incubation study conducted 
with several lipid based drug depot systems were presented. The results of this study were 
diverging. It was found that most examined simple triglycerides were rather resistant against 
the lipase incubation. Those implants and extrudates remained stable and didn’t change their 
physical structure, a result consistent with the outcome of the animal experiment described in 
chapter 1. It still has to be analyzed whether this insensitivity of glyceryltristearate, -
tripalmitate, and -trimyristate towards the employed enzymes is a result of the observed minor 
accumulation of the lipases at the lipid water interface – a phenomenon which could be a 
consequence of the missing coenzymes and other factors present in physiological systems – or 
if these substance are per se to be considered as stable and inert. Concentrating on the results 
of the incubation experiments conducted with extrudated implants, it seems that especially the 
triglycerides which feature a low melting point influence the behaviour of the implant upon 
lipase incubation. Extrudates consisting of low melting components disintegrated rapidly 
resulting in smaller lipid particles. Considering these results and aiming for lipid depot 
systems featuring such disintegration behaviour in vivo, one should concentrate on the 
analysis of the observed phenomenon. In the following third chapter subsequent experiments 
are described which were conducted in order to analyse the mechanism of lipid system 
disintegration. Looking back on the so far presented data dealing with lipid depot system 
degradation, no clear distinction has been made between degradation and erosion processes. 
However, regarding the phenomenon of extrudate disintegration observed in chapter 2 and 
considering that so far only chemical degradation processes were quantifiably analyzed with 
the employed RP-HPLC method, it may be time to differentiate more clearly between 
degradation and erosion. When speaking of degradation the cleavage of chemical bonds – in 
case of triesters such as the used lipids - the cleavage of the ester bond is understood. Erosion 
is defined as a loss of mass of the analyzed system. In the following these two connected 
processes are analyzed more distinctively. The data presented in the first part of this chapter 
highlights additional analytical methods applied for analyzing the erosion mechanism. 
Subsequently, the last part of this chapter deals with the aspects of preparation technique and 
lipid composition on the degradation of the discussed systems.
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Abstract
It has recently been found that lipid composition appears to have a major influence on the rate 
of lipase-induced degradation of lipid-based drug delivery systems (microparticles, 
compressed implants and extrudated implants). During lipase incubation, most of the lipidic 
extrudates produced for this study lost their physical strength and tended to collapse 
generating lipid particles in the µm-range. The aim of this study was to specify the processes 
leading to collapse of lipid based drug delivery systems during the in vitro lipase incubation. 
Compressed tablet-shaped lipid implants were used as model systems. A pre-column RP-
HPLC derivatization method was used to characterize the degradation behavior of the single 
lipid component used for the preparation of lipidic extrudates. Raman spectroscopy, FT-IR 
spectroscopy and differential scanning calorimetry were used to investigate the physical and 
chemical changes in the tablets upon lipase incubation. This study revealed that the lipid 
component trilaurate plays a major role in the degradation and erosion processes occurring 
during lipase incubation. The production of trilaurate/lauric acid mixtures, with a melting 
point beneath human body temperature, leads to lipid matrices melting and losing their 
physical integrity. 
Key words: lipid based depot systems, biodegradation, erosion, Raman spectroscopy
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Introduction
Recently, there has been substantial interest in lipid-based drug delivery systems for the 
formulation of proteins due to their outstanding performance in stabilizing incorporated 
protein molecules. However, there is currently little known about the fate of lipid-based depot 
devices in the human body. In most of the publications dealing with triglyceride based drug 
delivery systems biodegradation and bioerosion in vivo was not reported [1, 2]. Nevertheless, 
biodegradation and -erosion would be necessary for human use of these drug delivery 
systems.  As lipases play a crucial role in the metabolic system by hydrolyzing triglycerides to 
produce free fatty acids (FFA), which serve as a major source of energy, it is obvious that 
human lipase activity in the subcutaneous fat tissue and the serum could affect the structure 
and the stability of lipid based drug delivery systems. Therefore – in a recent study - we 
conducted in vitro lipase incubation studies with different lipidic delivery devices 
(microparticles, compressed implants and extrudated implants) and investigated the chemical 
degradation rate of these systems. We could report that some of the investigated systems, 
mainly extrudates, tend to disintegrate during the lipase incubation resulting in suspended 
particles in the µm-range. In particular, extrudates containing glyceryltrilaurate as a low 
temperature melting component exhibited the lowest physical stability of the incubated 
extrudates and promoted lipid matrix disintegration. In this study, the chemical degradation 
and erosion behavior of the single lipid components used to produce the different lipidic drug 
depot systems have been analyzed. Raman and infrared spectroscopy, as well as differential 
scanning calorimetry have been used to analyze the process of lipid matrix breakdown.
Materials and Methods
Materials
All lipids (glyceryltristearate (D118), -tripalmitate (D116), -trimyristate (D114) –trilaurate
(D112), lipidmixture E85, lipidmixture H12) used in matrix preparation were purchased from 
Sasol GmbH, Witten, Germany. Lipases (lipoprotein lipase (LPL) from pseudomonas sp. and 
lipase from Rhizoma Oryzae (RO)) and all other chemicals were purchased from Sigma–
Aldrich, Deisenhofen, Germany.
Sample preparation
Implant manufacturing
Lipid tablets were used as lipid based model systems to mimic lipid implants. The tablets 
were prepared from either admixed lipid powder or from melted lipid mixtures.
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Lipid powder mixtures
To simulate an accumulation of lauric acid in D112 matrices, mixtures of these two 
substances were prepared. The powdered components were ground together with liquid 
nitrogen in an agate mortar.  Mixture ratios 1, 5, 10 and 20% lauric acid in D112 were 
prepared. These mixtures were analyzed using differential scanning calorimetry 
measurements. To investigate the influence of lipase incubation on the powder composition 
with Raman spectroscopy tablets were compressed from the obtained mixtures. Compressed 
tablets were prepared using a 5 ton hydraulic press. The components – trilaurate, trimyristate, 
tripalmitate or tristearate- were ground in an agate mortar. The resulting powder was 
compressed with a pressure of 2 tons for 30 seconds. Two sizes of tablets were produced 
using different compression tools. Big tablets consisted of 500 mg of lipid material 
compressed to a tablet exhibiting a diameter of 13 mm an average height of 3.7 mm.
Lipid mixtures prepared by melting
In order to obtain homogenous lipid material blends for analysis with Raman or FT-IR 
spectroscopy lipid mixtures were heated above the melting temperature of the pure 
components. The melt was then cooled down slowly and tempered at 30°C for 24 h to avoid 
polymorphic transformations. These mixtures were then compressed into small tablets using a 
hydraulic press resulting in implants with a diameter of 5 mm, an average weight of 50 mg 
and an average height of approximately 2.3 mm. The tablets were compressed for 30 seconds 
with a pressure of 2 tons. 
Preparation of layered tablets
Lipid tablets consisting of two different lipid layers were prepared using the hydraulic press. 
Briefly, D118 powder was compressed for 30 s with a pressure of 2 tons resulting in a disc 
with a diameter of 13 mm and an average height of 3 mm. These discs were put back in the 
mould and layered with 50mg of D112 powder by compressing the disc for another additional 
30 sec using 2 tons of pressure resulting in a tablet with a top layer of D112. The thickness of 
the applied D112 layer was determined using a calliper. 
Characterisation methods
HPLC analysis 
To investigate the lipase induced degradation of different triglycerides chemical degradation 
studies were carried out. Briefly, the compressed tablets consisting of single components or 
mixtures of different triglycerides were incubated at 37°C in 2.0 ml of isotonic 0.01 M 
phosphate buffer pH 7.4 containing 100 U of lipoprotein lipase and RO-lipase. All tests were 
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run in triplicate. After 3 days the buffer media was completely removed and analyzed for free 
fatty acid contents. New buffer solution was added to the incubated samples. The samples 
were extracted using the modified Dole-extraction [7] method resulting in a free fatty acid 
(FFA) solution ready for derivatization. Phenacyl esters of fatty acids were prepared by the 
method described by Wood and Lee [8] followed by a RP-HPLC method for the separation 
and quantification of the different FFA. A Thermo Separation Products HPLC system 
(Thermo Fisher Scientific, Inc. Waltham, U.S.A.) equipped with a LiChrospere RP C18 
column (4.6 mm i.d. x 250 mm, 5 µm) was used (Merck, Darmstadt, Germany).  Mobile 
phase was a mixture of methanol-acetonitrile-water (80: 10: 10 (v/v). Elution of the generated 
phenacyl esters was monitored by UV absorbance at 254 nm. The detection limit for stearic 
acid was about 5 µgml-1, i.e. approx. 20 nmol of fatty acid. The release of FFA in the buffer 
media (WFFA) was used to quantify the percentage of degradation (D) as follows:
D = FFAWW
×
0
100
(1)
Differential scanning calorimetry (DSC)
Samples of lipid drug delivery devices prior and after derivatization experiments were 
analyzed with a NETZSCH DSC 204 Phoenix® (Selb, Germany) instrument. To determine 
phase transitions of the various compositions samples were heated in the DSC at 10K min-1. 
Samples were heated from -20°C to 100°C.
FT-IR spectroscopy
FT-IR-spectroscopy is a sensitive, quick and reproducible method for structural determination 
of lipids [3], and allows the analysis of changes to the triglycerides used in this study. A 
Bruker Tensor 27 FT-IR Spectrometer with a PIKE MIRacle™ sampling accessory equipped 
with a MIRacle™ micrometer clamp was used to analyse the samples. The diamond/ZnSe 
crystal plate had a surface area of 2.54 mm2. Spectra were the average of 300 scans recorded 
from 4000 to 800 cm-1 with a resolution of 4 cm-1. In order to avoid interference with 
atmospheric humidity sample chamber was purged with dried nitrogen during the 
measurements. Spectra of D112, lauric acid and D118 powders were recorded and tablets of 
these materials were analysed after preparation and subsequent incubation as detailed in the 
Degradation section below.
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Raman spectroscopy
Raman spectroscopy can be used to analyse solid state systems such as lipids [4, 5] in the 
presence of water and buffer substances. The technique was used to investigate the processes 
occurring on the lipid-water interface respectively on the surface of the lipid matrix during 
lipase incubation. Further on Raman-spectroscopy was used to detect changes in lipid 
composition as a result of the enzymatic degradation of lipid drug delivery devices used in 
this study. FT-Raman spectra were recorded from solid samples using a Bruker IFS-55 
Equinox FT-interferometer bench (Bruker Optik GmbH, Ettlingen, Germany) equipped with a 
FRA-106 Raman accessory and a D418-T liquid nitrogen cooled Ge detector. A 1064 nm cw 
Nd:YAG laser (Coherent, Lübech, Germany) was employed; the laser power was set to 490 
mW. OPUS (version 5.5, Bruker Optik GmbH, Ettlingen, Germany) was used to record 
spectral data. Raman spectra were collected using a Bruker Optik SN 73 R361-S3 Raman 
probe coupled to a custom made flow through device.
Raman microscopic data was collected using a Senterra dispersive Raman microscope 
(Bruker Optics, Ettlingen, Germany). OPUS version 6.5 was used to control the microscope. 
An excitation wavelength of 785 nm was used, and a 1200 groove per millimetre grating. The 
resulting resolution was 3-5 cm-1 across the spectrum. Both the Sure_Cal® and Spectral shape 
correction options were implemented within OPUS to ensure wavenumber stability and 
transferability respectively. An Olympus 50x objective with a ??????????????? ??????? was 
used to collect the Raman signal. Each spectrum was collected from 60-1530 cm-1. The laser 
power was set to 100mW. Spectra of D112, lauric acid and D118 were recorded and tablets of 
these materials were analysed after preparation and subsequent incubation as detailed in the 
Degradation section below.
Scanning Electron Microscopy
To investigate whether degradation of lipid drug delivery devices is visible SEM 
measurements were carried out. Samples were analyzed using a Field Emission Scanning 
Electron Microscope Joel JSM-6500F (Joel Inc., Peabody, USA). Therefore samples were 
attached on adhesive carbon tape (BAL-TEC AG, Balzers, Principality of Liechtenstein) to a 
custom made brass stub, carbon-sputtered and analyzed.
Digital microscopy
Changes in implant morphology were analyzed using a VHX-600 digital microscope 
(Keyence, Osaka, Japan). 
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Degradation studies
Chemical degradation
Spectroscopic analysis of the implants
The appearance of lauric acid in the D112 implants was directly measured using IR and 
Raman spectroscopy. Calibrations for the prediction of lauric acid within lipase-incubated 
D112 samples were formed on the basis of infrared and Raman spectral data collected from 
lipid powder mixtures prepared by melting. The calibration curve was constructed from 
binary mixtures of 0, 10, 20, 30 and 50% (w/w) lauric acid combined with D112. Each 
mixture was prepared in triplicate. Raman spectral data was collected using the Raman 
microscope. Both the infrared and Raman spectroscopic calibrations were partial least squares 
(PLS) based data (Unscrambler v. 9.8, CAMO Technologies, Inc, Norway), involved standard 
normal variate preprocessing and the use of a cross-validation procedure which removed one 
sample at a time (i.e. all three spectra per sample were removed at once). The Raman 
spectroscopic calibration used the 400-1530 cm-1 region, while the infrared spectroscopic 
calibration used the 900-1900 cm-1 region. The sample for which lauric acid concentration 
was predicted in the infrared study was a 500mg D112 implant which had been incubated for 
8 h in 5 ml PBS containing 440 U of LPL. The implants were then washed 3 times with water 
in order to remove loosely attached degradation products. After drying of the implants using a 
vacuum chamber at reduced pressure (100mbar) at 25° C for 24 hours the implants were 
analyzed. The lipase-treated tablet was cut using a scalpel in order to analyse the core. The 
samples analysed in the Raman study were 50 mg D112 tablets incubated for 2.5h in 2ml PBS 
containing 100U of LPL and RO. After withdrawal the samples were blotted on absorbent 
paper in order to remove buffer media and loosely attached degradation products.
Erosion of implants
In situ Raman analysis
Since Raman spectra can be recorded from samples immersed in aqueous environments 
without any sample disturbance, a series of Raman spectra were collected in situ from tablets 
immersed in 25 mL PBS buffer containing 14U/ml Lipoprotein at a constant temperature of 
37ºC. The buffer medium was continuously stirred. In order to quantify lipid erosion tablets 
consisting of layered D112 over D118 were analyzed (preparation as described above). Each 
Raman spectrum was recorded over 8.5 min with 6 cm-1 resolution and across the 1010-1150 
cm-1 region. Between each recorded Raman spectrum was a 5 second delay; the total series of 
Raman spectra took approximately 42 hours to collect.
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The Raman spectra were analyzed using multivariate curve resolution (MCR) as implemented 
in the Unscrambler (version 9.8, CAMO Technologies Inc.). The spectra were SNV pretreated 
prior to MCR. Two spectra, pure D112 and pure D118, were input as initial spectral guesses. 
The non-negative concentrations constraint was applied. Ten spectra each of pure D112 and 
D118 were included within the data set analyzed to give a semi-quantitative indication of the 
presence of these two materials.
DSC analysis
Samples for DSC analysis were prepared as followed: D112 tablets (50mg) were incubated 
for 2.5 hours in 2 ml PBS pH 7.4 containing 100 U of LPL and RO lipase. After incubation 
implants were washed 3 times with water to remove loosely attached degradation products. 
After washing implants were blotted. A scalpel was used to cut the implant in half. The 
separated core material was collected and ground in an agate mortar. The resulting lipid mass 
was analyzed with DSC.
Physical analysis of D112 erosion and swelling behaviour
In order to analyze erosion and degradation processes simultaneously compressed D112 
implants with a diameter of 13 mm and an average height of 3.7 mm were incubated in 5ml 
PBS containing 440 U lipoprotein lipase at 37 °C. All tests were run in triplicate. The average 
initial weight was 500 mg. After predetermined time points the implants were withdrawn 
from the medium washed three times in 20 ml water and blotted to remove excess water and 
then weighed (W1). The implants were then dried in a vacuum chamber at reduced pressure 
(100mbar at 25° C) for 24 hours. After the drying procedure implants were weighed (W2) 
using an analytical balance (model UMX2, Mettler–Toledo, Greifensee, Switzerland). Finally, 
the implants were visually characterized using a digital microscope (20X magnification).
The percentage increase in weight due to water uptake and swelling (S) of the lipid was 
determined at each time point from the following equation [9]:
S [%] = 100
0
01 ×
−
W
WW
(2)
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The percentage of erosion processes (ES) was calculated from the following equation:
ES = 2
0
100
W
W
× (3)
The residual buffer media, containing main degradation products was extracted using the 
method described above and the derivatized FFA were analyzed using the RP-HPLC method.
The quantified content of FFA released in the buffer media (WFFA) accounted for the 
percentage of degradation (D) was calculated from equation (1):
D = FFAWW
×
0
100
Results and discussion
Chemical analysis
HPLC analysis
A linear release of fatty acids due to the lipolytic activity of the lipase occurred during the 
degradation of the lipid implants prepared from single components. The degradation rate of 
glyceryltristearate, -tripalmitate and -trimyristate was almost at the same level resulting in 
about 0.3% (w/w) degradation of the saponifiable lipid mass– revealing only slight 
differences in the degradation rate probably according to the chain length [10]. In contrast, 
glyceryltrilaurate (D112) implants exhibited a 15 fold higher degradation rate reaching up to 5 
% percent degradation of the lipid mass after 30 days of incubation (Fig. 1a).
Interestingly, the morphology and structure of the D112 tablets changed dramatically during 
the incubation study. While tablets consisting of D118, D116 and D114 didn’t change after 30 
days of lipase incubation glyceryltrilaurate implants tended to melt during the incubation. 
Macroscopic investigation a few hours after start of the degradation study revealed a 
formation of a porous coat enclosing a dense core consisting of primordial D112. This porous 
coat was extending with increasing time of incubation. Eventually after a few hours the 
implants were melted. This phenomenon was surprising since the melting point of the pure 
component glyceryltrilaurate (46°C) is higher than the temperature of the incubation setup 
i.e., 37°C. Presumably this melting process and the resulting generation of lipid droplets 
enhanced the hydrolytic activity of the lipase probably due to an increase of the total surface 
area. As lipases are surface active enzymes there can be a correlation stated between the 
activity of the enzyme, i.e. the cleavage of substrate and the surface area available [11-13].  
To investigate on the melting process of D112 DSC measurements were carried out. 
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Therefore, glyceryltrilaurate-lauric acid mixtures were analyzed to mimic processes probably 
occurring during incubation with lipase. Further on D112 implants drawn from the 
degradation experiments were analyzed with DSC in order to investigate on the physical 
changes induced by the lipase treatment. The incubation of lipid tablets consisting of D118 
and D112 (mixture ratio 80:20) prepared from powder mixtures resulted in porous tablets. 
During the incubation suspended lipid particles could be noticed in the buffer media. FFA 
analysis revealed a high release of lauric acid generated during lipase incubation, whereas 
stearic acid was released much more slowly in accordance with the results of the experiments 
dealing with the pure components.  Typically, when incubated for several days, these implants 
lost their structural integrity and disintegrated into numerous lipid particles. To analyze the 
effect of the observed preferential cleavage of D112 on the structure of the tablets consisting 
of the D118/D112 tablets were analyzed with DSC prior and after lipase incubation. 
Figure 1: HPLC analysis of lipid degradation: degradation study of D112, D114, D116 and D118 compressed 
tablets over 30 days of incubation in 100 U lipoprotein lipase and 100 U lipase from rhizoma oryzae 
(average + S.D., n = 3).
CHAPTER THREE Studies on the mechanisms of lipid matrix disintegration
___________________________________________________________________________
111
Raman-spectroscopy of lipid implants during lipase incubation
The Raman and infrared spectra of D112 and lauric acid are shown in Figure 2. 
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Figure 2: FT-Raman spectra of D118, D112 and lauric acid powders
Raman-analysis of implant surfaces after lipase incubation showed a distinct shift of the 
normal triglyceride Raman-spectra towards spectra indicating an accumulation of free fatty 
acids on the surface of the implants. This deposition of FFA on the surface of the implants 
after incubation with lipases isn’t surprising as cleavage products of triglyceride hydrolysis 
are interfacial active substances thus tending to adsorb on hydrophobic surfaces [14]. After 
thoroughly washing the surfaces of the lipid implants with water the spectra shifted towards 
the normal triglyceride spectra. This finding indicates a reversible adsorption process of the 
fatty acids at the lipid water interface. The PLS models constructed from the IR spectra and 
Raman spectra of the D112 and lauric acid mixtures both involved two PLS factors. The 
model calibration and validation results are shown in Table 1. Based on these models, the 
incubated samples analysed by infrared spectroscopy contained a mean of 9.4 % ± 0.4 % 
(w/w) lauric acid, while those analysed by Raman spectroscopy contained 14.8 ± 0.8 % (w/w) 
lauric acid. The incubation conditions and times were different for the samples analysed by 
the two techniques since both techniques require different amounts of sample and the 
procedure of analysis is different, and so the results should not be directly compared. 
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However, both results suggest that there is a significant amount of lauric acid production in 
the core of D112 tablets that are incubated in lipase solutions for several hours. 
Table 1: PLS model calibration and validation results from infrared and Raman spectra
Model parameters Infrared Raman
Calibration R2 0.99 0.95
RMSEC 2.02% (w/w) 3.96 % (w/w)
Cross-validation R2 0.91 0.83
RMSECV 6.44% (w/w) 8.75 % (w/w)
Depth profiling of D118, D116 and D114 implants within a depth range of 10 to 100 µm 
below the surface revealed no changes in the spectra of the triglycerides (data not shown). 
Thus it can be stated that for D118, D116 and D114, according to literature [15] degradation 
is strictly happening on the lipid surface. However lipid cleavage through adsorbed lipase can 
lead to pores in the lipid matrix aggravating the diffusion of the cleavage products into the 
surrounding media.
Erosion analysis
In parallel to degradation, erosion of the D112 tablets during the incubation in lipase solution 
was also observed. The incubation time (8h) and lipase activity (440U/5ml) were adjusted to 
avoid complete melting of the lipid tablet. Soon after the incubation was started, suspended 
lipid particles were visible in the buffer media, indicating erosion. As the used analytical
method is highly sensitive towards FFA and shows almost no reactivity towards triglycerides 
strict quantification of the degradation products could be ensured. Interestingly, both 
processes show linear behaviour for the period of analysis. As seen in Fig., 3 a after 8 hours a 
lipid degradation of only 2 % was reached. Erosion of the implant, i.e. the mass loss from the 
initial implant weight was about 12%. This imbalance of erosion and degradation processes 
can be explained as a bulk erosion process with degradation occurring not only at the lipid 
surface but also at lipid water interfaces within the lipid matrix. At the end of the experiment 
the implants showed a distinct swelling behaviour of 4% (Fig. 3b). This may be due to 
softening and melting of the lipid leading to an increased diffusivity of water into the 
matrices. This phenomenon is supported by the DSC described below. Water influx 
presumably is also supported by the generation of pores and the accumulation of cleavage
products such as mono- or diglycerides in the inner part of the lipid tablet. 
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Figure 3: a) Erosion study of D112 tablets incubated for 8 h in 440 U lipoprotein lipase (Average + S.D., n = 3).
b) Swelling behaviour of the incubated D112 tablets (Average + S.D., n = 3).
In situ Raman analysis
Raman spectra were recorded of the layered ??????? ????? ???? ??? ????? ????? ????? ???????
stirring in flowing lipase solution. The MCR analysis provides a semi-quantitative analysis of 
the presence D112 and D118 within the tablet that was sampled by the Raman spectrometer. 
Within the same spectral region, the estimated spectra of D112 and D118 (Figure 4) are 
closely related to the spectra of the pure components (Figure 4). As the D112 was degraded 
over time due to the activity of the lipase, the layer thickness was constantly decreasing 
leading to a shift of the spectral bands towards the bands of the D118 tablet basis. According 
to the semi quantitative analysis, the sample is initially almost exclusively D112, and then the 
D112 content reduces with a simultaneous increase in D118 content. After approximately 800 
min the sample is predominantly D118 and this remains unchanged during the remainder of 
the experiment. Since the D118 was initially underneath the D112, it appears that the D112 
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(together with lauric acid formed) eroded at a relatively steady rate to leave the D118 
exposed. 
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Figure 4: MCR analysis of tablet with D112 layer over D118 with estimated spectra of the two components 
(above) and predicted amount of D112 (black squares) and D118 (white squares) during immersion in lipase 
solution at 37 °C (below)
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DSC Measurements
DSC measurements were conducted to measure changes in lipid composition before and after 
lipase incubation studies. Implants consisting of pure lipid components (D118, D116, and 
D114) showed no changes in the melting temperatures after lipase incubation (data not 
shown). As seen in Fig. 5 tablets prepared from powder mixtures of D118 and D112 (80:20) 
exhibited an almost complete loss of the D112 in the tablet after lipase incubation compared 
to the untreated tablet.
Figure 5:  DSC thermograms of compressed lipid tablets prepared from powder 
(D118/D112 mixture ration 80:20) before (a) and after lipase incubation (b).
As already described above, lipase incubation lead to the formation of a porous coat enclosing 
a core consisting of the intact lipid material. While the core material did not exhibit changes 
in the melting temperature (Fig 6a), a distinctive shift in the melting temperature for the 
coating material revealed a melting process starting at approx, 20°C (Fig. 6b).  
CHAPTER THREE Studies on the mechanisms of lipid matrix disintegration
___________________________________________________________________________
116
Figure 6: DSC thermograms of D112 tablet before (a) and after (b) incubation in lipase solution.
The thermograms indicate a shift of the D112 melting endotherm in combination with a 
decreasing melting enthalpy indicating the presence of less crystalline phases. Such behaviour 
has been described with lipid erosion processes [1]. The change in lipid crystallinity 
presumably can be explained by the accumulation of mixtures of triglyceride and 
corresponding degradation products in the porous coat material. This mixture of trilaurate, 
lauric acid and mono- or glyceryldilaurate-esters produced during the lipid cleavage probably 
exhibit a lower melting point compared to the pure triglyceride. To simulate the production of 
FFA and to elucidate their effect on the melting temperature of D112, mixtures of lauric acid 
and trilaurate were analyzed using DSC. The melting point decreased as the lauric acid 
content increased. As seen in Fig. 7, 1% lauric acid in D112 leads to a distinct shift of the 
melting point compared to the pure D112. However admixing 20% lauric acid in D112 seems 
to be sufficient to lower the melting temperature of this mixture beneath the level of the 
human body temperature. 
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Figure 7: DSC thermograms of D112 and D112/lauric acid mixtures.
This finding may explain the high degradation velocity of the pure component D112 up to a 
certain point.  As the presence of lauric acid within the lipid matrix leads to a shift in the 
melting temperature, eventually the whole implant melts although still consisting of 
triglycerides for the most part. This melting process leads to a generation of fatty droplets in 
the buffer media and therefore to a higher surface area. 
Scanning electron microscopy analysis
SEM of tablets consisting of mixtures of D118 and D112 (80:20) convey the effect of rapid 
trilaurate degradation as observed in the above described degradation study. After incubating 
trilaurate, cleavage leads to a significant change in the structure of these systems. As seen in 
Fig. 8a microscopic pictures of the compressed lipid disc exhibit a smooth surface and no 
visible signs inhomogeneity. After incubation with 100 U of lipase for 2 h the implant 
morphology changed drastically. Pore formation was detected in the matrix of this tablet, 
probably due to the degradation of the entrapped D112. The resulting porous lipid matrix was 
crossed by numerous cracks, indicating a swelling of the D112 component upon erosion (Fig. 
8b). Scanning electron microscopy of the D112 implants treated with lipase solution revealed 
noticeable changes in the implant surface morphology. As shown in Fig 8d the surface of the 
implants shows significant signs of degradation i.e. the formation of a rough and porous 
surface.  When examining the cross section of incubated D112 tablets (Fig 8c) a clear 
distinction could be made between the porous coat and the dense core of the tablet. 
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Figure 8: scanning electron microscopy: compressed lipid tablet prepared from powder (D118/D112 
mixture ration 80:20) before (a) lipase incubation (15X magnification). Tablet after lipase incubation 
(b) (15X magnification). 
(c) D112 implant after lipase incubation: cross section (15X magnification).
(d)D112 implant after lipase incubation: porous implant surface (2000X magnification)
Digital microscopy
The lipid tablets incubated during the erosion and degradation study showed distinct changes 
in surface morphology after lipase treatment. As a result of the detected erosion processes 
pores and rough areas appeared on the formerly smooth tablet surface. The edges of the 
tablets lost their sharpness and eventually the tablet lost its biplane form and showed convex 
morphology. When analyzing the cross section of the tablets an increase in thickness of the 
porous layer was observed over time. After 8 hours a separation of the outer layer from the 
core was visible (Fig. 9). Probably the interface between the two lipid layers was filled with 
water and water pressure forced the layers apart.
CHAPTER THREE Studies on the mechanisms of lipid matrix disintegration
___________________________________________________________________________
119
Figure 9: Digital microscopy: Overview and cross sections of D112 tablets (a) before lipase incubation, (b) after 
3 hours of lipase incubation, (c) after 8 hours of incubation. All pictures with 20X magnification.
Conclusion
Glyceryltrilaurate (D112) was shown to possess degradation characteristics making it suitable 
for the preparation of biodegradable and bioerodible drug carrier systems. While other 
triglycerides like glyceryltristearate – used for the preparation of lipid based drug delivery 
systems – didn’t show detectable signs of degradation in vivo, D112 may fulfil all needs 
required to prepare fully biodegradable depot systems. In our in vitro degradation studies, 
glyceryltrilaurate showed an almost twenty-fold higher degradation rate than other 
comparable triglycerides. This high degradation rate could be explained by an increase in 
lipid surface due to the generation of lipid droplets as a direct consequence of a specific 
melting process. Glyceryltrilaurate starts to melt after incubation with lipase as degradation 
products and primordial trilaurate form mixtures with a melting point beneath the body 
temperature. During degradation, even more pronounced erosion processes occur, leading to 
distinct loss of lipid mass associated with the generation of small lipid particles before the 
total lipid mass has melted. It could be shown that the lipid matrix collapse we observed in 
earlier experiments is a direct consequence of the properties of glyceryltrilaurate used for the 
preparation of lipid based extrudated implants. Upon erosion glyceryltrilaurate starts to swell 
due to an influx of water into the porous lipid matrix. This swelling process damages the 
structure of lipid mixtures consisting of glyceryltrilaurate and other triglycerides and the 
subsequent melting of the trilaurate leads to the generation of a porous network within such 
lipid matrices. Depending on the mixture ratio and the preparation technique systems these 
damaged systems disintegrate. Therefore we propose that the use of glyceryltrilaurate in 
mixture with other triglycerides may allow the custom made design of depot devices with 
predictable and controllable degradation and erosion properties.
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3.3. Discussion of the results of the degradation experiments
In the previous parts of this dissertation the effects of the enzymes on the lipid depot systems 
were always expected to be of chemical nature. It was expected that – due to their physico-
chemical nature – the enzymes would attach on the lipid surface and slowly cleave the ester 
bonds of the outer lipid layer. It was therefore anticipated that degradation processes would 
occur in a classical surface eroding way. When starting with the work on these experiments 
the author didn’t estimate the impact of the lipase incubation to be different from other 
surface-eroding systems described in literature except for the presence of the lipases. After 
examination of the first results the perception slowly arises that some other factors yet 
unregarded may play a greater part in the processes occurring at the lipid-lipase interface. The 
results of the experiments described in the first part of this chapter quickly lead to the 
realization that the influence of the chain length of the employed fatty acids has a big
influence on the physical integrity of the lipid depot systems. This newly gained knowledge 
and the complete clarification of the underlying mechanism is one major milestone on the 
way of developing lipid depot systems with custom made degradation properties. Of course,
at this point one should keep in mind that all the findings of the described experiment were 
produced in an artificial system which was strictly reduced to most necessary parameters. In 
that way it’s self evident that it is impossible to predict if the prepared lipid depot systems 
would act similar in a natural environment, i.e. when incubated into a living organism. 
However, as already highlighted in the previous sections of this dissertation this discrepancy 
between the isolated in vitro system and the unpredictable and hardly reproducible 
surrounding of an in vivo experiment has always to be taken into account. Viewed from 
another point of view, this set of data gives the opportunity to compare the results from in 
vivo and in vitro experiments and to subsequently adjust and affect the prepared drug depot 
systems. Surely, the next step in the development and analysis of lipid drug depot systems 
will be to test the most promising formulations of the presented systems in vivo and compare 
and correlate the results gained from this animal experiment to the data produced so far in 
vitro. But before dealing with such issues the question whether the preparation method has a 
big influence on the degradation method is still open and therefore has to be dealt with. 
Currently, there are two main methods of preparing lipid drug depot systems: the 
discontinuous method of compressing the lipid mass via various compression tools and the 
continuous method of extrudating the lipid mass using a suitable thermo extruder. In the final 
section of this chapter both preparation techniques are compared with regards to their effect 
on the degradation properties. 
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3.4.  Further studies on lipid drug depot degradation
In the first part of this chapter it was shown, that the rapid degradation of D112 in the 
presence of lipases is a consequence of the generation of fatty acid/triglyceride mixtures 
exhibiting a melting point beneath the human body temperature. Since the employed RP-
HPLC described in the previous chapter is capable of separating and quantifying the FFA-
components of all triglycerides used in the described experiments, characterization of the 
degradation behaviour of depot systems consisting of different triglycerides is possible. 
Therefore, in this section, the degradation of an extrudated lipid implant is investigated with 
respect to the amount and the ratio of different FFA released over the time of lipase 
incubation. Scanning electron microscopy was used to characterize the changes in extrudate 
morphology occurring during the incubation. In addition to that, an experiment dealing with 
the comparison of the degradation behaviour of extrudated implants and compressed implants 
with the same surface area is presented. As shown in the previous sections the surface area 
has a great influence on the degradation of lipid based depot systems, since the employed 
enzymes have to adsorb on the lipid surface in order to start lipid cleavage. As a consequence 
of their manufacturing process extrudated implants exhibit a rod-shaped, cylindrical form, 
whereas compressed implants show a more tablet-like shape. It is understood that both 
systems are different concerning their surface area and thus these differences should be taken 
in account when comparing their degradation behaviour. Therefore, compressed implants with 
a similar surface area were prepared in order to compare the degradation of these two 
systems. 
Materials and methods
Implant manufacturing
Implants were prepared by using a 5 ton hydraulic press (Maassen, Eningen, Germany).
The implant components - tristearin powder 80% (D118) and H12 powder- were ground in an 
agate mortar after thoroughly cooling with liquid nitrogen. The resulting mixture was 
compressed with a pressure of 2 tons for 30 seconds. The obtained implants had a diameter of 
5 mm and a height of 7 mm. The dimensions of the prepared implants were measured with a 
digital caliper. According to the dimensions of the implants the surface area was calculated to 
be 1.49 cm2. 
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Extrudate preparation
The extrudated implants were prepared as described in chapter 2 using a Thermo Haake 
MiniLab microcompounder (Thermo Fisher Scientific, Inc. Waltham, U.S.A.). The prepared 
extrudates used for the study consisted of 80% D118 and 20% H12. The produced lipid 
extrudates had a diameter of 1.45 mm and were cut to a length of 32 mm in order to obtain the 
same surface area as the implants described above.
Scanning Electron Microscopy (SEM)
Samples were analyzed using a Field Emission Scanning Electron Microscope Joel JSM-
6500F (Joel Inc., Peabody, USA). The samples were put on adhesive carbon tape (BAL-TEC 
AG, Balzers, Principality of Liechtenstein) and attached to a custom made brass stub, carbon-
sputtered and analyzed.
HPLC analysis
The samples withdrawn from the various degradation experiments were treated and analyzed 
as explicitly described in chapter 2 and 3. Release of the different FFA was analyzed and the 
obtained FFA release was compared to the theoretical values. 
Experimental setup
Implants and extrudates with the same surface area were incubated in 2ml PBS pH 7.4 
containing 100U lipoprotein lipase from pseudomonas sp. After 3 days of incubation the 
buffer media was replenished. FFA were isolated from the drawn samples and, after 
derivatization, analyzed. Another set of extrudates was treated in the same manner after 1, 15 
and 30 days samples were drawn and analyzed with SEM. All experiments were run in 
triplicate.
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Results and discussion
Surface are
Analysis of the tested implants and extrudates exhibiting the same surface area revealed that 
both systems exhibit the same degree of degradation at least for the first days of incubation as 
seen in Fig. 1.
Extrudates and compressed implants with the same surface area
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Figure 1: Implants and extrudates with a surface area of 1.49 cm2 incubated in lipase containing buffer 
(Average + S.D., n = 3).
After day 15 the lipid structure of the extrudate collapsed resulting in different degradation 
behaviour (Fig.2). Presumably due to the preparation process and its dimensions the 
compressed implant maintained its structure and showed no signs of structural damage 
Figure 2: SEM pictures of an extrudated lipid implant incubated for different periods of time in lipase solution. 
a) extrudated lipid implant incubated for 1 day (50X magnification) b) lipid extrudate after 15 days of lipase 
incubation: loss of structural integrity (50X magnification) c) fragments derived from the lipid matrix collapse of 
the extrudated implants, drawn after 30 days of incubation (50X magnification)
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However after 30 days of incubation the surface of the compressed implant showed distinct 
signs of degradation in addition to that the diameter and length of the implant was 
significantly reduced. As seen in Fig.3 porous regions were visible when examining the 
implant with scanning electron microscopy. Presumably these porous regions are a 
consequence of the rapid degradation of the contained H12 component.
Figure 3: SEM photographs of the compressed implant incubated in lipase solution. a) Overview (50X 
magnification) b) porous area on the implant surface (150X magnification)
As a result it can be concluded that, concerning the first 15 days, manufacturing technique has 
no major influence on the degradation of lipid based drug delivery systems. Although a 
pressure of 2 tons was applied during the preparation of the compressed implants these 
systems showed no difference in the degradation rate compared to depot systems prepared by 
twin screw extrusion. Nevertheless the preparation technique especially the application of 
high pressure seems to stabilize the lipid matrix. As the detected lipid matrix collapse is 
highly desirable with regard to bioerosion processes the so far observed stability of the 
compressed lipid matrix would interfere with the requirement for bioerodible drug depot 
systems.
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HPLC-Analysis of extrudate degradation
Free fatty acids (FFA) generated during the degradation of lipid extrudate formulation E1 
(80:20 D118/H12) were separated and quantified with RP-HPLC as seen in Fig. 4. 
Figure 4: HPLC chromatogram of an extrudate degradation study. 1) lauric acid 2)myristic acid 3) palmitic acid 
4) stearic acid.
After the first 3 days of incubation it was found that the release of lauric acid and myristic 
acid was almost 2 times higher than theoretically expected whereas the release of the stearic 
acid, i.e. the corresponding fatty acid of the main component, was significantly below the 
expected level (Fig. 5).
Figure 5: Theoretical and experimentally obtained FFA values after 3 days of lipase incubation
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Figure 6: Theoretical and experimentally obtained FFA values after 12 days of lipase incubation
After 12 days of lipase incubation the amount of low melting fatty acids released from the 
extrudate was decreased, however it was still on a slightly higher level than theoretically 
expected (Fig. 6). According to this finding the release of stearic acid was increased and 
almost reaching the theoretical level. This decrease in low melting fatty acids indicates a 
depletion of H12 in the outer areas of the extrudate since the H12 erodes quickly as seen in 
the experiments described in the previous sections of this chapter. This decreasing trend for 
low melting fatty acids was continued regarding the FFA release data of day 30 (Fig. 7). 
Lauric acid release was decreased by two thirds of the theoretical level, whereas myristic acid 
release was still slightly increased. Concerning the release of stearic acid from the incubated 
extrudate the obtained values were almost identical to the theoretically expected values. Once 
again, these findings are in accordance to the results of 3.2 indicating a quick and preferential 
cleavage of the low melting component H12 -consisting mainly of triglycerides esterified with 
lauric acid – and a subsequent constant release of the main component stearic acid. 
Figure 7: Theoretical and experimentally obtained FFA values after 30 days of lipase incubation
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Conclusion
It was shown that the degradation of lipid based drug delivery systems isn’t affected 
significantly by the preparation method of the lipid depot systems. In short, depot systems 
with a similar surface area exhibit similar degradation rates. However, as a consequence of 
the applied high pressure when using the hydraulic press as production method, compressed 
implants maintain their structure and show only minor changes in morphology upon 
degradation. Therefore since lipid matrix collapse is desirable extrusion methods should be 
chosen in order to obtain erodible drug depot systems. In addition to that the presented results 
of RP-HPLC analysis clearly show that the phenomenon of lipid matrix breakdown of certain 
extrudates – proposed in chapter 3- is a direct consequence of the heterogeneous FFA release 
during lipase incubation. Firstly, lauric acid release is high, leading to the formation of lauric 
acid/triglyceride mixtures which promote the erosion of the lipid matrix, then, after this initial 
phase, the lipid matrix is depleted on lauric acid and D118 degradation is mainly occurring. 
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4. Chapter Four: Investigations on spider silk proteins
4.1. Introduction
The following sections are dedicated to a material which is well-known to mankind since
hundreds of years but relatively new to the science community and the scientific investigation 
of this material has only started some 10 years ago: spider silk proteins. Especially silk 
proteins from other organisms like the silk worm bombyx mori are used since centuries for 
clothing and many other purposes probably due to the fact that the silk worms can be easily 
bred and the harvest of the silk is relatively easy. In contrast to that, spider silk proteins have 
always been more precious since the cobweb exhibits only a very small amount of this flimsy
material. Today the situation is somewhat similar. While silk worm silk is still easily available 
and cheap, spider silk still needs to be collected from the living spider which is a tricky 
undertaking as these animals show a distinct territorial behaviour and therefore must be held 
in solitary confinement. Normally such circumstances would influence the use and 
disposability of these materials in a way that, subsequently the interest on spider silk proteins 
and their use in science would fade away. However, since silk proteins from bombyx mori
contain compounds which can lead to inflammation and immunogenic reactions, whereas 
spider silk doesn’t exhibit such negative features, the interest on spider silk is still 
unquenched. With the rise of modern genetic engineering, finally the obstacle of harvesting 
the spider silk proteins from living spiders was overcome. Today it is possible to produce 
batch wise several hundred grams of this material in high quality and pureness. Eventually,
the investigation on spider silk proteins for their use in pharmaceutical technology, i.e. their 
employment in the development of parenteral drug depot systems has started. The following 
sections detailedly describe the characterisation of this genetically engineered material, the 
preparation of spider silk proteins micro and nanospheres and finally the performance of these 
particles with regards to drug loading and drug release in in-vitro experiments. This fourth 
chapter is divided in two parts: the first parts consists of a set of data already published and 
deals with the reproducible and controlled preparation of spider silk particles usable as 
parenteral drug carriers, the second part of this chapter is understood as a little discussion of 
the presented data and serves as transition to the next chapter which is dedicated different 
drug release experiments.
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Abstract
Spider silk is a material consisting of very large (>200 kDa) proteins and has a high potential 
for biomedical applications as a result of its biocompatibility and biodegradability. We report 
on the influence of physicochemical factors on structure formation of the engineered spider 
silk protein eADF4 (C16), which mimics the known sequence of the dragline protein ADF4 
from the spider Araneus diadematus. Under certain experimental conditions, eADF4 (C16) 
forms stable microspheres that have been analyzed with respect to sphere size, size 
distribution, and surface inertness upon different preparation methods (dialysis, pipette and 
micromixing). As a result of their material strength, biocompatibility, and the possibility of 
functionalization, spider silk microspheres have a high potential for the development of 
targeted drug-delivery systems.
Key words: spider silk proteins, micro particles, biodegradation, preparation method
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Introduction
Numerous biopolymers have been optimized over millions of years during evolution with 
respect to distinct applications. For instance spider silk exhibits a combination of 
extraordinary mechanical and chemical properties due to a high strength and resistance 
required for function as a trap for prey. Spider silk is a material consisting of very large 
proteins (> 200 kDa) with unique structural stability, mechanical toughness and elasticity 
which even exceeds the mechanical properties of Kevlar, one of the most stable and toughest 
synthetic fibers [1, 2]. Along with their biocompatibility and biodegradability, silk materials 
have a high potential for biomedical applications [3,4]. Especially in the area of new 
innovative and effective drug delivery systems spider silk proteins are very well suited 
because of their possible functionalization and coupling of active agents [5]. Spider silk 
proteins are very well suited to develop and create morphologies that can meet the demanding 
requirements of specificity and efficiency for the delivery of active ingredients such as drugs 
and pharmaceutical proteins [6, 7]. Conformational conversion of spider silk proteins can be 
triggered by potassium phosphate which is an important issue regarding the biocompatibility 
of the drug delivery device considering not only the material but also its processing [8-11]. 
Here we report on the influence of physicochemical factors on structure formation of 
engineered spider silk protein eADF4 (C16), mimicking the known sequence of the dragline 
compound ADF4 from the spider Araneus diadematus in addition to the biochemical analysis 
by Slotta et al (back-to-back contribution). Generally protein aggregation is driven by a shift 
of the thermodynamic equilibrium state caused by factors like temperature and ionic strength 
[12]. We detected, that under certain experimental conditions eADF4 C16) forms stable 
microspheres which were analyzed with respect to sphere size, size distribution and surface 
inertness for different preparation methods (dialysis, pipette and micro mixing). Based on our 
results the properties of spider silk microspheres can be controlled by varying parameters such 
as protein and potassium phosphate concentration as well as mixing intensity during the 
salting out process of spider silk protein.  
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Materials and methods 
Materials
All materials used for protein dialysation, and sphere preparation were purchased from 
Sigma–Aldrich, Deisenhofen, Germany.
Preparation methods
Engineering of eADF4 (C16): The amino acid sequence of eADF4 (C16) was adapted from 
natural sequence of ADF4 from Araneus diadematus. The repetitive part of ADF4 is generally 
composed of a single conserved repeat unit displaying only slight variations. Repetitive 
elements in the sequence of ADF4 display a polyalanine-rich motif with high glycine content, 
which was named C. Our previously established engineering approach allowed the 
combination and multimerization of the single motifs, resulting in the eADF4 (C16) protein 
which comprises 16 repeats of the sequence GSSAAAAAAAASGPGG 
YGPENQGPSGPGGYGPGGP resulting in a molecular mass of 48 kDa [9].
Protein dialysis: lyophilized protein eADF4 (C16) was dissolved in 6 M guanidinium 
thiocyanate. Dialysis was performed against 10 mM 
tris(hydroxymethyl)aminomethane(Tris)/HCl, pH 8, at 4°C using membranes with a 
molecular weight cut-off 6000-8000 Da (Spectrum Laboratories, Rancho  Dominguez, USA).
Preparation of eADF4 (C16) microspheres: Four different preparation methods for 
inducing salting out were employed: 1) simple mixing (pipette) of 2M potassium phosphate
(pH8) with eADF4 (C16) solution 2) mixing of 2M potassium phosphate (pH8) with eADF4
(C16) solution in a micromixing device under laminar flow conditions (2 ml/min, Re = 85). 3) 
mixing of 2M potassium phosphate (pH8) with eADF4 (C16) in a micro mixing device under 
turbulent flow conditions (50 ml/min, Re = 2122). 4) Dialysis of eADF4 (C16) solution 
against 1M potassium phosphate (pH8).
Micromixing Device: Constant volume flows of educt solutions (potassium phosphate (pH8) 
and eADF4 (C16) solution) were generated by two identical syringe pumps (Model 100DX, 
Teldyne Isco, Inc., USA). Pumps were operated by a digital controller (ISCO Series D, 
Teldyne Isco, Inc., USA). Mixing and precipitation was performed in a T-shaped mixing 
???????????????????????? ??????????????????????????????????????????????????-728 Threads 10-
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other. In order to characterize the flow through the mixing element, a mixing Reynolds 
number is defined according to
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viscosity of water and Q is the volumetric flow rate. In the discussed experiments mixing was 
conducted at flow rates of 2 ml/min and 50 ml/min which correspond to Reynolds numbers of 
Re = 85 and Re = 2122. The flow inside the mixing zone can be considered turbulent due to 
the impinging of the two solutions. The generated suspensions were collected in 1.5 ml 
Eppendorf tubes. 
Analytical methods
Determination of protein concentration: The concentrations of obtained eADF4 (C16) 
solutions were determined by UV measurements at 20°C using Cary100 spectrophotometer 
(Varian Medical Systems, Palo Alto, USA). The molar extinction coefficient of eADF4 (C16)
(40974 M-1cm-1) at 276 nm and 20°C was employed. 
Determination of sphere size: Particles sizes and their distributions were determined with 
Laser diffraction spectrometry (Horiba, Partica LA-950, Japan). Refractive indices of 1.33 for 
water and 1.60 for protein were taken for computation of particle sizes. In addition, a dry 
specimen of each preparation was analyzed by SEM to confirm sphere formation and sphere 
sizes.
Scanning electron microscopy (SEM): eADF4 (C16) microspheres were immobilized on 
Thermanox plastic cover slips (Nagle Nunc, USA), which had been coated with gold by 
sputtering under vacuum and analyzed by a JSM 5900 LV scanning electron microscope 
(JEOL Ltd., Japan at 20 kV).
Results
Salting out of eADF4 (C16) depends on ion concentration and temperature
eADF4 (C16) was incubated in Tris (10mM, pH 8) at 0.5 mg/ml or 1 mg/ml in presence of 
500 mM or 1 M potassium phosphate (pH 8). It was determined that the required time for 
aggregation of 50% of eADF4 (C16) (t50) was t50 = 50 s in the case of 500 mM potassium 
phosphate (pH 8) and t50 = 30 s in the case of 1 M potassium phosphate (pH 8) (Figure 1a). 
Independent of the starting protein concentration the limit of solubility is only dependent on 
potassium phosphate concentration and a constant amount of protein remained soluble in each 
????????????????????????????????????????????????????????????????????????????????????????
???????????ed in case of incubation with 1 M potassium phosphate (Figure 1a and data not 
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shown).Further on, the influence of potassium phosphate concentration in combination with 
temperature was analyzed in greater detail. 50% of the protein was salted out with potassium 
phosphate after 1 hour of incubation at 381 ± 4.2 mM and 10°C, 205.5 ± 4.3 mM and 30°C 
and 85.2 ± 1.7 mM and 60°C respectively.
a) b)
Figure 1: Aggregation assay of eADF4 (C16) protein. a) Aggregation behaviour of eADF4 (C16) as a function 
of time at 25°C at protein and potassium phosphate concentrations as indicated. b) eADF4 (C16) aggregation as 
a function of potassium phosphate concentration and temperature after 1 hour of incubation. At lower salt 
concentrations the aggregation is enhanced with increasing temperature. 50% of the protein is aggregated at 381 
± 4.2 mM and 10 °C, at  205.5 ± 4.3 mM and 30°C and at 85.2 ± 1.7 mM and 60°C respectively.
Morphology of aggregates
Next the morphology of the aggregates was investigated. Above a potassium phosphate 
concentration of 500 mM the quantitative formation of microspheres could be detected (see 
also Slotta et al). Several different methods were employed for mixing eADF4 (C16) with 
potassium phosphate such as dialysis, simple mixing with pipette and micromixing within a 
T-mixing element. Upon mixing the samples were analyzed with laser diffraction 
spectrometry and scanning electron microscopy (SEM). Accordingly, different sphere 
characteristics with respect to sphere sizes, size distributions and formation of sphere clusters 
could be detected depending on the method of preparation. At 500 mM potassium phosphate 
(pH 8) silk spheres formed clusters at all examined preparation methods (dialysis, pipette, 
micromixing at 2 ml/min (Reynolds number: Re = 85, see Experimental Section) and 50 
ml/min (Re = 2122)).  Figure 2a shows a typical SEM picture of silk spheres produced by 
salting out with 500 mM potassium phosphate (pH 8). The picture illustrates that spheres with 
a diameter of approximately 500 nm build larger clusters of aggregates. In contrast, in salting 
out experiments performed with 1 M potassium phosphate (pH 8) mainly fully developed 
microspheres could be observed (Figure 2b). Micromixing with higher mixing intensities led 
to the formation of smaller spheres than salting out with dialysis or simple mixing with 
pipette. The SEM picture in Figure 2c depicts spheres produced by micromixing with 2 
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ml/min and Figure 2d spheres produced by mixing with a flow rate of 50 ml/min. Strikingly, 
sphere production by dialysis which reflects the slowest mixing conditions resulted in the 
??????????????????????????????????????????????????Figure 2b).
a) b)
c) d)
Figure 2:  SEM images of microspheres produced by different methods. a) Micromixing of 500 mM potassium 
phosphate (pH8) with 0.5 mg/ml eADF4 (C16) solution with a flow rate of 50 ml/min. b) Dialysis of eADF4
(C16) solution with a protein concentration of 1 mg/ml against 1 M potassium phosphate (pH 8). c) Micromixing 
of 1M potassium phosphate (pH8) with 1 mg/ml eADF4 (C16) solution at a flow rate of 2ml/min.  d) Micro 
mixing of 1M potassium phosphate (pH8) with 1 mg/ml eADF4 (C16) solution at a flow rate of 50 ml/min. 
Size distribution of microspheres
For quantification of size distributions, as qualitatively observed by SEM, all samples without 
larger aggregates were analyzed by laser diffraction spectrometry. Thus, we analyzed all 
samples prepared by salting out with 1 M potassium phosphate (pH 8). Figure 3a shows the 
size distribution of spheres produced by mixing of 1 M potassium phosphate (pH 8) with 1 
mg/ml eADF4 (C16) solutions with pipette as well as with micromixing at a rate of 2 ml/min 
and 50 ml/min. Figure 3b illustrates the size distribution of spheres salted out by dialysis of 
0.5 mg/ml and 1 mg/ml eADF4 (C16) solution against 1 M potassium phosphate (pH 8). As 
seen by sharp peaks, controlled mixing with a micromixing device leads to a smaller size 
distribution compared to mixing with pipette or salting out by dialysis. Simple mixing with 
pipette at eADF4 (C16) concentrations of 0.5 mg/ml and 1 mg/ml led to stable micro spheres 
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with average diameters of 350 nm and 510 nm respectively (Figure 3c). By controlled mixing 
at a flow rate of 2 ml/min microspheres with an average size of 290 nm (0.5 mg/ml) and 370 
nm (1 mg/ml) were formed, whereas at a flow rate of 50 ml/min smaller microspheres with an 
average diameter of 250 nm and 320 nm could be detected (Figure 3c). Dialysis yielded stable 
???????? ????? ???????? ?????? ??? ???? ??? ???? ???? ???? ?????????????? ????? ?? ??????? ?????? ?????
distribution (Figure 3c).
a) b)
c) 
Figure 3: Size analysis of microspheres salted out with 1M potassium phosphate (pH 8). a) Size distribution of 
eADF4 (C16) microspheres prepared by different methods: simple mixing with pipette and controlled mixing 
with a micromixing device at flow rates of 2 ml/min and 50 ml/min b) Size distribution of eADF4 (C16) 
microspheres prepared by dialysis. c) Calculated mean sphere size of eADF4 (C16) microspheres prepared by 
different methods as indicated.
CHAPTER FOUR Investigations on spider silk proteins
___________________________________________________________________________
138
Stability 
To investigate the conformational stability of microspheres, sphere size distributions were 
measured with laser spectrometry over a time period of ten minutes with constant mixing to 
prevent sedimentation of microspheres. At low potassium phosphate concentration (500 mM, 
pH 8) aggregates were formed which could be separated by the induced shear stress provided 
by stirring (Figure 4). With 1M potassium phosphate (pH 8), stable microspheres could be 
produced independent of protein concentration or mixing condition (Figure 2c, Figure 2d, 
Figure 3c and Figure 4).
Figure 4: Conformational stability of microspheres produced by micromixing of 0.5 mg/ml eADF4 (C16) with 
potassium phosphate (pH 8) at a flow rate of 2 ml/min. Upon protein salting out with 1M potassium phosphate 
(pH 8) stable inert spheres are formed. After 10 min of stirring no decrease or increase in particle size could be 
detected. In the case of micromixing of 500 mM potassium phosphate (pH 8) with 0.5 mg/ ml eADF4 (C16), 
particles were formed which decreased in size upon stirring. 
Figure 5: Influence of protein concentration on microspheres size produced dialysis of eADF4 (C16)  solution 
against 1M potassium phosphate (pH 8). Employed eADF4 (C16) concentration from left to right: 0.1 mg/ml, 1 
mg/ml and 10 mg/ml.
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Conclusion
We conclude that for the production of spider silk microspheres by salting out a high 
concentration of potassium phosphate is required to obtain stable inert spheres. Generally, 
with increasing protein concentration sphere size is increased (Figure 5). The sphere size can 
be further adjusted by controlled micromixing inside a T-mixing element of eADF4 (C16) 
with 1M potassium phosphate (pH 8). The obtained microspheres represent a new class of 
biomimetic materials which are an alternative to microcapsules for incorporation of active 
ingredients such as therapeutic proteins. In contrast to spider silk microcapsules, the 
production of microspheres is much simpler since no formation of vesicles is required [6, 7] 
Incorporation of active ingredients into spider silk microspheres can be realized by adding a 
solution with the desired molecules before microspheres formation by addition of potassium 
phosphate. Presumably mechanical stability of the newly detected microspheres is much 
higher than that of the previously described microcapsules. In combination with material 
strength, biocompatibility and the possibility of functionalization, spider silk microspheres 
have a high potential for the development of targeted drug delivery devices. 
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4.3. Discussion of the presented data
In the above presented publication a production method for the preparation of micro sized
spider silk particles is shown. The produced spider silk particles are formed by admixing 
spider silk protein solution with aqueous potassium phosphate solution. These two aqueous 
solutions are admixed via a micromixing device which allows the control of the mixing 
parameters. At a first glance the applied preparation technique is a simple precipitation 
method and therefore doesn’t seem to stand out the mass of different techniques used for the 
preparation of polymer particles. However, the total absence of organic solvents in this 
preparation method and the use of physiological salts make this preparation technique special. 
Surveying literature one would find only few polymeric materials which allow the use of such 
harmless substances as potassium phosphate implemented in the preparation process and even 
less methods would allow such a high degree of controllability and reproducibility. Most 
often precipitation techniques of polymers such as PLGA involve the use of organic solvents. 
As already outlined detailedly in the introduction of this dissertation, the use of organic 
solvents is very often the driving force in drug especially therapeutic protein instability. But 
even if the drug intended to be encapsulated during the precipitation process shows up to be 
stable residual solvent content is a major issue to be dealt with when talking about application 
of such prepared systems into humans. It seems now that not only spider silk proteins seem to 
display a high degree of biocompatibility but also they uniquely feature the possibility of 
physio-compatible production methods. Considering the data so far the question arises 
whether the prepared spider silk protein particles are suitable for the controlled release of 
bioactive substance. Of course this question was the main impetus for the experiments 
described in 6.2 and normally one would assume that this question would have been dealt 
with within the first experiments conducted. However since the this produced material was 
relatively new  to the research team there was so far no experience concerning the properties 
of this material with respect to controlled release. It was therefore our first aim to thoroughly 
characterize the production process and the resulting spheres before proceeding into another 
area of research. In addition to that we worked with very small amounts of this engineered 
material so that experiments which required higher quantities had to wait in line. Eventually 
the experience gained with these tentative experiments and the implementation of larger batch 
sizes lead to the start of the first drug release experiments. These experiments and their results 
are thoroughly highlighted in the next chapter dedicated to the application of this material in 
drug release.
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5. Chapter Five: In vitro release studies of spider silk microparticles
5.1. Introduction
In the previous chapter we became acquainted with the preparation of genetically engineered 
spider silk protein spheres. A solvent free and easily controllable preparation method was 
shown and the resulting particles were analyzed with respect to their size, their surface 
morphology and their physical stability. Of course this set of data was understood as 
introduction in a very fascinating research area, essentially concentrating on the investigation 
of these semi-artificial spider proteins with special respect to their application as drug depot 
carrier. Apart from a preparation technique which allows their employment in physiological 
systems Chapter 4 so far didn’t exhibit any hints that these proteins would feature special 
characteristics specially qualifying them for the preparation of controlled release systems. To 
close this gap, subsequently different experiments were conducted. After an early stage, when 
the first experiments lead to promising results the spectra of the analytical methods was 
expanded in order to examine the mechanism of drug loading and drug release from the 
prepared microspheres. The produced results – intended for publication – represent the main 
part of this chapter. The following manuscript therefore deals with the questions which need 
to be addressed when dealing with the implementation of a new drug depot system. After a 
little discussion about the presented manuscript additional data produced in subsequent
experiments close this chapter and may serve as prospective view in the future research of this 
very fascinating material.
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5.2. Spider silk particles for controlled drug delivery
Andreas Lammel1*, Martin Schwab3*,Gerhard Winter3, Thomas Scheibel2
1Lehrstuhl Biotechnologie, Lichtenbergstraße 4, Technische Universität München, D-85747 
Garching, Germany
2Lehrstuhl Biomaterialien, Universitätsstraße 30, Universität Bayreuth, D-95440 Bayreuth, 
Germany
3Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-
Maximilians-Universität, D-81377 Munich, Germany
* These Authors contributed equally to that work
Intended for publication in: Journal of Controlled Release
Abstract
We investigated the applicability of engineered spider silk protein eADF4 (C16) particles as 
drug delivery carriers. Spider silk particles have been produced by employing a precipitation 
method at ambient conditions with a particle formation yield above 99%. Particles 
morphology and sizes have been determined by Scanning Electron Microscopy (SEM) and 
Laser Diffraction Spectrometry (LDS) showing spherical shape and diameters in the range of 
170 nm to 700 nm. We showed that eADF4 (C16) particles are colloidal stable in solution and 
thus are well suited as parenteral drug delivery devices. A detailed investigation of loading 
efficiencies of twelve small molecular model drugs with different chemical properties 
revealed that the obtainable loading efficiency correlates with the distribution coefficient 
(logD) of small molecules of alkaline nature. We could show that eADF4 (C16) particles can 
be uniformly loaded by diffusion of molecules into the spider silk protein matrix driven by 
electrostatic interactions. Release studies revealed that sustained pH sensitive release with 
constant release rates at physiological conditions can be realized for a period of two weeks. 
Enzymatic degradation studies of spider silk particles showed that they are fully degradable 
and undergo surface erosion. 
Keywords: Biomimetics, biodegradation, controlled release, drug loading, proteins 
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Introduction
Since many drugs need to be administered regularly in order to achieve constant therapeutic 
relevant drug plasma levels drug depot systems have been developed to overcome drawbacks 
of multiple drug administration. Especially colloidal micro- and nanoparticulate carriers have 
extensively been investigated as a platform for targeted controlled drug delivery to realize a 
predictable systematic delivery of pharmaceutical agents [1-3]. The advantages of delivery 
systems compared to conventional administration forms are improved cellular uptake, 
increased bioavailability, a reduction of toxic side effects and improved patient compliance 
[4-7]. The employed material for controlled release should generally offer control of structure 
and function, while also exhibiting good mechanical stability, and be easily fabricated into 
desired morphologies [8]. Biodegradable and biocompatible polymers are preferred for such 
applications since they retain their properties for a limited period of time and then gradually 
degrade into soluble non-toxic products that can be excreted from the body. Many synthetic 
(aliphatic polyesters, PGA, PLA, PLGA etc.) and natural (polysaccharides, chitin, chitosan, 
proteins) polymers have been employed to produce degradable vehicles for encapsulation, 
incorporation or binding of active compounds [9-13]. While synthetic polymers have the 
advantage of sustaining the release of the encapsulated therapeutic agent over a period of days 
to several weeks they are in general limited by the use of organic solvents and relatively harsh 
formulation conditions [14]. Biocompatibility may be limited due to remaining toxic solvents. 
This has been tried to overcome by natural polymers which can be processed at ambient mild 
conditions. Most biopolymers investigated are hydrophilic which show relatively short 
duration of drug release. In spite of the possible advantages of natural polymers being 
biocompatible and processable at ambient conditions, most biopolymers present a main 
drawback of a rapid solubilization in aqueous environments, thus resulting in fast drug release 
profiles [15]. In order to overcome this problem, chemical cross-linking procedures (e.g. 
glutaraldehyde and formaldehyde treatment) have been considered [16-18]. Unfortunately, the 
presence of residual cross linking agents could lead to toxic side effects, in addition, 
unwanted reactions between the drug and cross-linker could result in the formation of toxic or 
inactivated derivatives [19. 20]. In contrast, a hydrophobic polymeric system has the 
capability of yielding sustained drug release [12]. Silk proteins as material unify all afore 
discussed properties necessary for its usage as a biomaterial in drug delivery systems 21, 22]. 
A special feature and advantage of silk proteins compared to other biopolymers is that the 
secondary structure of silk proteins can be triggered from a ?-helical water soluble structure 
CHAPTER FIVE In vitro release studies of spider silk microparticles
___________________________________________________________________________
145
into a ?-sheet rich water insoluble structure by addition of lyotropic salts. Due to its unique 
properties and high potential as biomaterial, silk proteins especially bombyx mori fibroin but 
also silk proteins from spider species have been investigated for various biomedical 
applications including drug delivery [23, 24]. In the area of particulate drug carriers, silk 
fibroin microspheres with diameters of several microns using lipid vesicles as templates with 
microsphere yields of 55% and loading efficiencies of 21% have been reported [25]. Recently 
Wenk et al reported on the fabrication of fibroin spheres using a laminar jet break up 
technique by which they obtained encapsulation efficiencies close to 100% but with the trade 
off of sphere sizes from 100 to 440 µm in diameter. Nevertheless, the applied preparation 
techniques are quite sophisticated but exhibit a low up-scalability and sometimes involve 
organic solvents to stabilize the resulting silk fibroin preparations [23]. In our study we 
employed recombinantly produced engineered spider silk protein eADF4 (C16) mimicking 
the amino acid sequence from natural sequence of ADF4 from Araneus diadematus [26,29]. 
Detailed studies of the thermodynamic assembly process of eADF4 (C16) revealed that stable 
microspheres are formed by addition of high concentrations (>400mM) of lyotropic salts like 
potassium phosphate. Analysis of morphology and structure of obtained microspheres showed 
that they have a smooth surface and are solid with high ?-sheet content (>60%) and no 
apparent sub microstructure [27]. Further studies of the process parameters of eADF4 (C16) 
sphere formation showed that sphere size (250 nm to 3µm) and size distribution can be 
controlled by mixing intensity and concentration of potassium phosphate and eADF4 (C16) 
solution [28]. The goal of the study was to investigate the applicability of engineered spider 
silk protein nanoparticles as drug carriers for parenteral applications. Spiders silk particles 
were fabricated by the above mentioned precipitation method under mild processing 
conditions suitable for the encapsulation of sensitive drugs. Several model drugs were applied 
and loading efficiencies were determined to elucidate the effect of drug molecule properties 
such as partition coefficient P and dissociation constant Ka on the loading efficiencies. In the 
following we report on the mechanism of drug loading, drug release behaviour and 
biodegradation of eADF4 (C16) particles.
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Materials and methods
Materials
Engineering of recombinant spider silk protein eADF4 (C16): The amino acid sequence of 
eADF4 (C16) was adapted from the natural sequence of ADF4 from Araneus diadematus. The 
repetitive part of ADF4 is generally composed of a single conserved repeat unit displaying 
only slight variations. Repetitive elements in the sequence of ADF4 display a polyalanine-rich 
motif with high glycine content, which was named C. Our previously established engineering 
approach allowed the combination and multimerization of the single motifs, resulting in the 
eADF4 (C16) protein which comprises 16 repeats of the sequence 
GSSAAAAAAAASGPGGYGPENQGPSGPGGYGPGGP resulting in a molecular mass of 
48 kDa [26,29]. The protein was purified as described previously to yield a purity of over 
98% [29]. Due to its amino acid composition eADF4 (C16) features a theoretical isoelectric 
point at pH 3.48, which indicates that this protein is mainly negatively charged at a 
physiological pH of 7.4.
Small molecular model drugs: In order to investigate on the influence of different molecular 
parameters on the loading efficiency, 12 different small molecular drugs were used in this 
study. All drugs were dissolved in water with a drug molarity of 0.21 µmol. Drug substances 
and their featured properties are depicted in table 1. The main parameters focused on were the 
solubility in aqueous media expressed by the octanol/water partition coefficient (logP), the 
acid dissociation constant (pKa for protonated bases (BH+) or from acidic function (HA)) and 
the resulting charge in aqueous media (predominant or permanent charge). As molecular 
diffusivity is depending on molecular mass the molecular weight of each substance was taken 
into account.
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Table 1: List of small molecular model drugs used for eADF4 (C16) nanosphere loading study. Values for 
molecular weight, dissociations constants (pKa) and partition coefficients (LogP) are taken from literature. The 
partition coefficient (logP) accounts for the unprotonated form of drug. The absorbtion wavelength ?Abs was 
determined experimentally for each substance. All substances were purchased from Sigma-Aldrich 
(Deisenhofen, Germany).
Model drug Molecular 
weight 
[Da]
?????
[nm]
Dissociation 
constant of 
BH+ (pKa)
Dissociation 
constant of 
HA (pKa)
Log P Predominant 
charge at pH7
Permanently
charged
Chlorthalidone 338 276 --- 8,9 -0.03 uncharged no
Nipagin 152 254 --- 8.3 1.86 uncharged no
Acetaminophen 151 272 8,0 0.38 uncharged no
Phenol red 354 510 --- 1.7; 7.7 3.0 negative yes
Tetracaine*HCl 282 310 8.2 --- 4.0 positive no
Procaine*HCl 272 290 8.05 --- 2.4 positive no
Papaverine*HCl 376 248 8.07 --- 3.5 positive no
Ephedrine*HCl 165 256 9.6 --- 1.30 positive no
Propranolol *HCl 295 290 9.1 --- 3.18 positive no
Biperiden*HCl 347 210 9.6 --- 3.5 positive no
Ethacridine lactate 343 365 11 --- 2.5 positive no
Methyl violet 407 590 --- --- 3.2 positive yes
Thiamine 
chloride* HCl
337 240 4.8 4.8 -3.90 positive
no
Preparation of eADF4 (C16) particles
Lyophilized protein eADF4 (C16) was dissolved in 6M guanidiniumthiocyanate. Dialysis was 
performed against 10 mM tris(hydroxymethyl)aminomethane(Tris)/HCl, pH 8, at 4°C using 
membranes with a molecular weight cut-off at 6000-8000 Da (Spectrum Laboratories, Rancho 
Dominguez, USA).The concentration of eADF4 (C16) solution was determined by UV-Vis-
spectrometry at 20°C using a Cary100 spectrophotometer (Varian Medical Systems,Palo Alto, 
USA). The molar extinction coefficient of eADF4 (C16) at 276 nm and 20°C was employed 
(? = 46400 M-1cm-1). eADF4 (C16) particles were prepared using a phase separation 
procedure as described previously. Briefly, aqueous eADF4 (C16) (c = 1.0 mg/ml) solution 
was admixed with potassium phosphate solution (2M, pH8) in volumetric ratio of 1:10 using 
a pipette. The resulting particles were centrifuged for 10 min at 10.000 g and washed three 
times with purified water.  Obtained particles were redispersed in water and nanoparticle 
concentration was determined gravimetrically. A stock dispersion of known protein particle 
concentration was used for all experiments.
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Drug loading of eADF4 (C16) particles
Drug loading of spider silk particles was conducted as followed: 100 µl of spider silk particle 
suspension containing 1.0 mg silk protein were admixed with 1.0 ml of model drug solution. 
In order to obtain comparable results a molar ratio of eADF4 (C16) : model drug = 1:10  was 
realized for all model drugs employed. After 10 min of incubation at room temperature 
samples were centrifuged for 10 min with 10.000 g and the supernatant was analyzed for 
residual drug concentration with UV-Vis spectrometry. Standard calibration curves of model 
drugs by plotting the concentration versus absorbance were highly reproducible and used for 
drug quantification. A control group of samples containing only 100 µl water admixed with 
1.0 ml of model drug solution was prepared for each experiment. Drug concentrations from 
control and sample supernatant were used to calculate the amount of drug loaded on the spider 
silk particles. All experiments were performed in triplicate. Encapsulation efficiency and 
loading were determined by using equation (1) and (2), respectively:
(1)
(2)
In vitro release studies
Drug loaded eADF4 (C16) particles were washed with distilled water and suspended in 1 ml 
PBS (pH 7.4) and incubated at 37 °C while constant shaking. Each vial contained 2 mg of 
drug loaded spider silk protein particles. Medium from each sample was periodically removed 
and replaced with fresh PBS (pH 7.4). The model drug content in the medium was analyzed 
using UV-Vis- spectrometry at regular time intervals. The percentage of cumulative model 
drug release (% w/w) was investigated as a function of incubation time. Each experiment was 
performed in triplicate. To study the effect of different pH values on the release behaviour of 
drug loaded eADF4 (C16) particles we incubated ethacridine lactate loaded nanospheres (1 
mg) in 1.0 ml PBS with 5 different pH values (2, 4, 6, 7.4 and 8.8) for 5 days. The incubation 
media was withdrawn daily and the particles were redispsersed in fresh media. Supernatants 
of drawn samples were analyzed with UV-Vis spectrometry for drug content determination.
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In vitro degradation of eADF4 (C16) particles
In order to simulate the degradation and cleavage of engineered spider silk protein eADF4
(C16) based drug depot systems we employed a mixture of two in the human body naturally 
occurring proteases namely elastase and trypsin. In our studies we incubated 1.0 mg of silk 
microspheres in 1.0 ml PBS containing 0.80 µg elastase and 12.5 µg trypsin. After 1, 2, 3, 4 
and 5 days samples were centrifuged, the supernatant was carefully removed and analyzed 
with SDS-PAGE. The pellet containing the eADF4 (C16) particles was redispersed in distilled 
water and washed three times for further size and morphology analysis by laser diffraction 
spectrometry and scanning electron microscopy. Elastase and trypsin from hog pancreas were 
supplied by Sigma Aldrich (St. Louis, USA)
Characterization methods
Scanning electron microscopy
The  eADF4 (C16) particles were immobilized on Thermanox plastic cover slips (Nagle 
Nunc, USA), dried at room temperature and coated with gold by sputtering under vacuum, 
and analyzed with a JSM 5900 LV scanning electron microscope (JEOL Ltd., Japan, at 20 
kV).
Laser diffraction spectrometry
Particles sizes and size distributions were determined with laser diffraction spectrometry 
(Horiba, Partica LA-950, Japan). Refractive indices of 1.33 for water and 1.60 for protein 
were taken for computation of particle sizes. In addition, a dry specimen of each preparation 
was analyzed by scanning electron microscopy (SEM) to confirm spherical shape and sphere 
sizes.
Fourier transform infrared spectroscopy (FTIR)
Fourier transform infrared (FTIR) spectra were collected using a Bruker Equinox 55 FTIR 
spectrometer. The samples were prepared by putting a drop of eADF4 (C16) particle 
suspension on CaF2 disks and subsequent air-drying.  Absorbance spectra of eADF4 (C16) 
particle ensemble were recorded in the spectral range between 400 and 4000 cm-1 with 
unpolarized light with a resolution of 4 cm-1. An accumulation of 32 spectra ensured a high 
signal to noise ratio. The measurements were carried out at 25°C and 30% relative humidity. 
To analyze the secondary structure of eADF4 (C16) protein particles secondary structure we 
used the amide I band (1600–1700 cm-1). Peaks at 1648-1660 cm-1, 1625-1640 cm-1 and 
1660-1668 cm-1 can be assigned to ?-helical, ?-sheet and ?-turn structures respectively [30].
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UV-Vis spectrometry
Ultraviolet–visible spectrometry using a Cary100 spectrophotometer (Varian Medical 
Systems, Palo Alto, USA) has been employed for determination of model drug content in 
supernatants for the calculation of loading efficiencies and release behaviour. Calibration 
curves for all model drugs investigated have been obtained by using five different 
concentrations of all stock solutions. The absorption wavelengths used for determination of 
drug concentration are summarized in Table 1.
Zetapotential Analysis
In order to elucidate and characterize the loading mechanism of eADF4 (C16) particles with 
model drugs, zeta potential measurements have been conducted as a function of added amount 
of model drug. The zeta potential was determined using a Nanoseries Malvern Zetasizer 
(Malvern, Worcestershire, UK). Automatic titration was conducted with a Malvern 
Multipurpose Titrator MPT-2. Experiments have been performed in distilled water (pH 7) at 
25°C. Each measurement was performed in triplicate. 
SDS gel electrophoresis 
Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) as a sensitive 
method for protein species analysis was used for the determination of protein cleavage. 
Samples drawn from the degradation studies were diluted in SDS-running buffer, heated for 
50 min at 95° C before loading on the gel. Gels were run with 40 mA for approximately 1.5 
hours. Silver staining was used for visualization of separated protein bands. All materials 
were supplied by Invitrogen (Carlsbad, CA, USA).
Results and discussion
Spider silk protein eADF4 (C16) particle characterization
To characterize the morphology and quantify the sizes of obtained eADF4 (C16) particles the 
prepared stock dispersion used for further experiments was examined employing SEM and 
laser diffraction spectrometry. Figure 1a) shows that particles of spherical shape with 
diameters from 170 nm to 700 nm have been obtained. The determined average diameter of 
particles ensemble was davg = 332 ± 95 nm with a polydispersity index of 0.72. The yield of 
nanoparticle formation by salting out was above 99% meaning that literally all protein 
initially in solution was transformed into particles. The colloidal stability of eADF4 (C16) 
particles in suspension was studied by adding 1.0 mg of particles to 1.0 ml of Na2SO4 
solutions of varying concentration (0–2.0 M), and measuring the turbidity at a wavelength of 
400 nm after 15 min. The onset of electrolyte induced flocculation in dilute dispersions can be 
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detected by a dramatic increase in turbidity of the dispersion at 400nm [31]. We found that 
eADF4 (C16) particles are colloidal stable within the complete studied concentration range 
from 0 to 2.0 M Na2SO4 (Figure 1b).
a) b)
Figure 1: Spider silk protein eADF (C16) particle characterization: a) Size distribution of obtained eADF4
(C16) particles analyzed with laser diffraction spectrometry. The inset shows an scanning electron micrograph of 
corresponding eADF4 (C16) particles. b) Investigation of colloidal stability assessed by the turbidity method.
Loading efficiencies & loading mechanism
Due to its negative charge at pH 7 eADF4 (C16) has the potential to form complexes with 
positively charged molecules due to electrostatic interactions. Considering the tertiary 
structure of proteins, charged amino acid residues are mainly located on the surface of 
proteins whereas hydrophobic groups are buried in the closely packed interior [32]. Thus we 
concluded that loading and entrapment of drug molecules into eADF4 (C16) protein particles 
is mainly driven by the following three parameters. First, the charge of the drug molecule 
expressed by its proton dissociation constant Ka (accounted for BH+ or HA). Secondly, the 
octanol water partition coefficient (logPo/w), as an indicator for the solubility of the model 
drug employed. And third, the molecular weight (MW) of model drugs which plays an 
important role in diffusion driven mass transport processes. Our aim was to correlate these 
dominating chemical parameters (pKa, logP and MW) with experimentally obtained loading 
properties of eADF4 (C16) particles to understand the underlying mechanisms important for 
effective and successful loading. The distribution between a lipophilic and a hydrophilic 
phase of two different species of a specific drug, i.e. the native and the protonated form, can 
be described by its distribution coefficient (logD). The distribution coefficient (logD) for 
acids and bases was calculated with equation (3) and (4) respectively [33].
( 3 )
( 4 )
The logP and pKa values of individual species used for calculation of logD are listed in 
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Table 1. Table 2 summarizes the determined loading efficiencies, theoretical and actual 
amount of entrapped drug content as well as the calculated distribution coefficient (logD) for 
all model drugs investigated. 
Table 2: List of model drugs investigated classified according to their chemical nature. The table provides an 
overview of theoretical and actual model drug content (expressed as percentage of wt drug/ wt spider silk protein 
particles), corresponding encapsulation efficiencies and calculated distribution coefficients (logD) for model 
drugs as listed.
All loading experiments were conducted at pH 7. We found that protonated weak organic 
bases could be loaded onto eADF4 (C16) particles with efficiencies ranging from 20.7 % up 
to 53.0 %. For this class of small molecular model drugs we found that the quotient of 
calculated logD divided by the molecular mass of individual molecule correlates linear with 
the obtained loading efficiencies (Figure 2). This linear relationship clearly indicates that the 
combination of charge and solubility (expressed by logD) and diffusion processes (expressed 
by the inverse proportionality of molecular weight) are the dominating factors responsible for 
effective loading of small molecular basic model drugs on eADF4 (C16) particles. 
Model drug MW 
[Da]
Chemical 
nature
Theoretical 
drug content 
[w/w%]
Actual drug 
content 
[w/w%]
Encapsulation 
efficiency     
[%]
Log D
Ephedrin*HCl 165 base 3.38 0.7 20.7 -1.321
Procain*HCl 273 base 5.70 2.16 38.0 0.396
Biperiden*HCl 347 base 6.97 2.93 42 0.899
Propranolol*HCl 295 base 5.55 2.5 45.0 1.197
Papaverine*HCl 376 base 7.56 3.55 47 2.395
Tetracaine*HCL 282 base 5.67 3.01 53 2.773
Ethacridine lactat 343 strong base 7.33 7.2 98.2 2.899
Acetaminophen 151 weak acid 3.16 0.06 0.2 0.378
Chlortalidon 338 weak acid 7.22 0.7 9.7 -0.315
Nipagin 152 weak acid 3.47 0.6 17.3 0.544
Phenol red 354 strong acid 7.12 0.0 0.0 -
Methyl violet 407 --- 8.72 8.7 98.1 -
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Figure 2: Loading efficiencies for model drug of basic nature plotted over 1/MW · logD.
Strong basic molecules like ethacridine lactate showed a loading efficiency of even more than 
98 %. By investigating molecules with permanent charge we found that positively charged 
molecules such as methyl violet were most successfully encapsulated whereas negatively 
charged molecules such as phenol red could not be encapsulated into spider silk protein 
particles at all. Model drugs exhibiting acidic nature exhibited relatively low loading 
efficiencies from 0.2 to 17.3 %. Despite the relatively high logD of acetaminophen 
(comparable to Nipagin) a loading efficiency of only 0.2 % has been determined which might 
be explained by its structure acting as weak phenolic base leading to the appearance of 
negatively charged acetaminophen species. We suspect that due to electrostatic repulsion of 
the negative charges these species cannot diffuse into the spider silk protein matrix. In order 
to proof the concept of drug permeation into the protein nanoparticle interior we used glass 
beads with a highly negative surface charge (-50mV) as control, assuming that permeation 
processes of drug molecules into the dense glass matrix cannot occur.  Due to the high 
negative surface charge of glass beads the loading efficiency for glass beads should be higher 
than that for spider silk particles if no diffusion into the protein matrix would occur.  For this 
experiment we employed methyl violet which was identified to have a loading efficiency 
above 98% for a molar ratio of methyl violet : eADF4 (C16) = 10:1. Figure 3a shows the 
obtained loading and loading efficiencies as a function of molar ratio. Up to a molar ratio of 
methyl violet : eADF4 (C16) = 10 the loading scales linear with the amount of methyl violet 
added. Above a molar ratio of 10 the loading efficiency decreases and the loading follows a 
saturation curve. Online zeta potential measurements during methyl violet loading revealed 
that zeta potential change upon sphere loading is a triphasic process (Figure 3b). First, the 
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potential changes gradually after addition of methyl violet solution to spider silk protein 
sphere suspension. After an initial constant slope, the zeta potential curve exhibits a plateau 
phase indicating no change of surface loading while increasing methyl violet concentration. 
Interestingly after reaching the concentration corresponding to the molar ratio of methyl violet 
: eADF4 (C16) = 10 a further increase of the zeta potential could be observed. We propose 
that the reduction of the zeta potential as seen in the titration curve is a direct consequence of 
the interaction with molecules of opposite charge. The initial lowering of surface charge can 
be explained by the charge compensation due to the addition of opposite charged methyl 
violet molecules. The plateau region indicates an equilibrium state of drug adsorbed at the 
solid-liquid particle interface and a diffusion of molecules into the hydrophobic core of the 
protein sphere. After the core matrix is saturated the influx of methyl violet molecules is 
reduced and eventually terminated, at that point the zeta potential starts to decrease again as 
can be seen by the second slope in Figure 3b.
a) b)
Figure 3: Characterization of loading mechanism: a) Loading and loading efficiency of methyl violet on eADF4
(C16) particles as a function of molar ratio. b) Zeta-Potential of eADF4 (C16) particles as a function of added 
methyl violet. For comparison the inlay shows the Zeta-potential of glass beads with methyl violet.
In contrast to loading experiments conducted with glass microparticles showed distinctive 
differences. The zeta potential curve during methyl violet addition showed no distinctive 
change. The only observation which can be stated is that the zeta potential of glass beads 
increased slightly and constantly during titration upon addition of methyl violet. The initial 
assumption that methyl violet cannot permeate into the glass particle matrix was confirmed by 
UV-Vis analysis of supernatant after completed titration. While the surface charge of glass 
particles is approximately two times higher compared to silk particles the determined loading 
efficiency was only 0.03%.  Furthermore the loading of methyl violet could be easily washed 
off the surface by three washing steps with purified water. 
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According to our results we propose that distribution coefficient logD can be used to estimate 
the obtainable loading efficiency for weak organic bases without permanent charge. 
Molecules with permanent charge cannot be included in this model as it is not possibility to 
calculate the corresponding logD value. Furthermore we propose that for an effective loading 
of spider silk protein particles, drug molecules ideally should feature a positive charge 
combined with a certain degree of lipophilicity and a molecular weight enabling it to diffuse 
freely into the spider silk protein matrix.
In vitro release studies 
Encapsulated drugs (methyl violet and ethacridine lactate) were released in a constant manner 
for more than 30 days. Most interestingly loaded particles showed no signs of drug burst, i.e. 
an initial high drug release within the first 24 hours of incubation.  The release of ethacridine 
lactate and methyl violet within the first 24 hours was 11% of the total amount encapsulated. 
Subsequently eADF4 (C16) particles released approx. 5% of the entrapped molecules per day 
within the first week (Figure 4a,b). To characterize the release behaviour the semi empirical 
power law equation introduced by Siepmann and Peppas [34] was used 
nt kt
M
M
=
∞ (5)
where Mt/M?? ??? ???? ??????????? ??????? ??? ???? ????? ????????? ??? ????? ??? ?? ??? ?? ???????????????
constant of the system, and exponent n is related to the geometrical shape of the formulation 
and describes the kinetics and release mechanism. Thus, for spherical systems n is equal to 
0.43 and 0.85, when pure Fickian diffusion or pure Case II transport is operating, respectively. 
Case II transport reflects the influence of polymer relaxation on molecules’ movement in the 
matrix. When n is in the interval between n = 0.43 and n = 0.85 a superposition of both 
transport processes occurs which is known as anomalous transport. In order to obtain a linear 
fit for the drug release data, equation (5) was modified by taking the logarithm as shown in 
equation (6) 
)log()log()log( tnk
M
M t +=
∞ (6)
where n can be obtained from the slope of the log-log plot of release Mt/M???????????????????
linear fitting (Figure 4d). We identified three time intervals with different dominating release 
mechanisms. To distinguish between different time intervals we used the criterion that the 
coefficient r2 had to be above 0.99 for the individual linear fits. The values of release 
exponent (n), correlation coefficient (r2), and characteristic constants (k) obtained are 
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summarized in Table 3. For validation of the determined release parameters we compared the 
experimental release data with the semi-empirical power law and found very good agreement 
from post-initial burst stage (>24 hours) stage up to 100% release (Figure 4a).
a) b)
c) d)
Figure 4: Release studies of ethacridine lactate and methyl violet: a) Experimental and theoretical release 
kinetics of model drugs as indicated over a period of 35 days. b) Experimental and theoretical release kinetics in 
the  initial burst region (release < 11%). c) Release of ethacridine lactate as a function of pH as indicated d) 
Experimental release data of  ethacridine lactate and methyl violet  based on the power law model. A linear fit 
with a correlation parameter (r2) above 0.99 was determined for three distinct time intervals. The linear fit for 
the interval from day 1 to day 13 is depicted in the main plot, whereas the inset shows the data and linear fits for 
the time intervals from day 14 to day 20 (no filling) and day 21 to day 35 (black filling) respectively.
Table 3: Drug release parameters (n: release exponent; r2: correlation coefficient; k: characteristic constant) for 
methyl violet and ethacridine lactate for defined release intervals as indicated.
Model drug time [d] Release [%] N R2 k
0-13 ???? 0.692 0.998 1.17
14-20 60 - 82 0.6079 0.994 1.92
Methyl violet
>20 ???? 0.3537 0.993 9.20
0-13 ???? 00.6754 0.998 1.25
14-20 60 - 73 0.5083 0.994 3.18
Ethacridine lactate 
>20 ???? 0.2641 0.992 14.4
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Within the first two weeks of release both exponents n for ethacridine lactate and methyl 
violet are almost identical and clearly above 0.43 (nel = 0.6754, nmv = 0.692) indicating an 
anomalous diffusional release. In the second identified time interval from day 14 to day 20 we 
found that release profiles diverge from each other where the release exponent of ethacridine 
lactate drops to 0.51 and that of methyl violet decreases less to a value of 0.61. This shows 
that for ethacridine lactate fickian transport begins to dominate. After 20 days release 
exponent n values for methyl violet and ethacridine lactate fall below the limiting value of 
0.43 indicating a Fickian release behavior. Release experiments with ethacridine lactate 
loaded eADF4 (C16) nanosparticles incubated in PBS at 37°C and different pH values 
showed a strong pH influence on the release rates (Figure 4c). We observed that an acidic 
environment accelerates the drug release. Almost 80% of the loaded drug was released after 
24 hours from silk nanospheres incubated in pH 2 buffer media. For silk particles incubated at 
pH4 an initial release rate of almost 40% was obtained after the first day of incubation. 
Particles incubated in pH 6 buffer showed an accelerated but similar release to pH 7.4 and 8.8. 
No significant difference between the release of nanospheres incubated in pH7.4 and pH 8.8 
was observed. The observed results confirm the predicted importance of electrostatic 
interactions between eADF4 (C16) and drug molecules. Presumably an influx of protons into 
the biopolymer leads to a displacement of drug molecules from the matrix. In addition to that 
the decreased pH influences the distribution of charged drug species by shifting the 
equilibrium towards the charged species. As these species are driven towards the negatively 
charged surface of the protein they can easily be washed away by the surrounding media.
In vitro degradation
Degradation of drug depot systems is highly desirable as non degradable drug depot systems 
carry the risk of inflammation and intoxication and therefore need to be removed surgically 
[35,36]. As many natural occurring polymers feature the ability of enzymatic degradation [37] 
thus we conducted degradation studies using proteases [38, 39] naturally occurring in the 
human body to simulate the degradation of our eADF4 (C16) drug carriers. Results from the 
degradation study revealed that eADF4 (C16) microspheres undergo degradation in the 
presence of proteases. Soluble degradation products were verified with SDS-PAGE (Figure 
6a).  Interestingly, the molecular weight of eADF4 (C16) degradation products decreases over 
time. The phenomenon can be explained by the protease activity at different sites of the 
eADF4 (C16) peptide chain. Elastase and trypsin, i.e. serine proteases can cleave peptide 
bonds on the carboxy side of small, hydrophobic amino acids such as glycine, alanine, and 
valine [40]. Due to the relative high content of glycin and alanin in eADF4 (C16) (~ 50 
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percent of the total amino acid composition) such proteases may cleave peptide bonds at 
several sites in the amino acid backbone of eADF4 (C16). The resulting fragments of eADF4
(C16) exhibit a molecular weight of about 18 kD. When soluble eADF4 (C16) was incubated 
with proteases, degradation products with a molecular weight of 6 kD were generated (Figure 
6a, lane 3). We presume that the degradation of spider silk particles would continue upon 
incubation for a longer period of time resulting in soluble fragments comparable to those 
observed in the degradation experiment with eADF4 (C16) solution. Size analysis of particles 
drawn from the degradation experiments at specific time points showed a continuous decrease 
of 50 nm in mean particle diameter within five days (Figure 5 a, b).  As enzymatic 
degradation is a process controlled by the interfacial activation of the enzymes and 
considering the decrease in particles size one can assume the silk nanospheres undergo 
surface erosion. Results obtained by scanning electron microscopy show a distinct reduction 
in particle size; however particle morphology appears to be conserved (Figure 5 c, d). The 
incubated particles still exhibit a smooth surface. If spider silk protein particles would 
undergo bulk erosion particle morphology would be altered and particle size presumably 
would increase as bulk erosion is accompanied with polymer swelling. 
a) b)
c) d)
Figure 5: Characterization of eADF4 (C16) particles upon enzymatic degradation: a) Size distribution of 
nanosparticles upon degradation at timepoints as indicated b) Mean diameter of eADF4 (C16) spheres upon 
degradation over time. c) SEM image of eADF4 (C16) nanospheres before degradation d) SEM image of eADF4
(C16) nanospheres after degradation with elastase (c = 4µg/ml ) and trypsin (c = 50 µg/ml) for 5 days.
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FTIR analysis of eADF4 (C16) particles upon enzymatic degradation revealed that the 
percental ?-sheet content increases whereas the ?-helical content decreases. This can be most 
effectively seen by changes of the second derivative of FTIR spectra at the wavenumbers 
1648-1660 cm-1 and 1625-1640 cm-1 assigned ?-helical and ?-sheet structures respectively 
(Figure 6b). The result that ?- helical structures are degraded faster than ?-sheet structures is 
advantageous for the long term stability and release behaviour of eADF4 (C16) particles at 
physiological conditions. ?-sheet-structures are not soluble in aqueous environments and thus 
a hydrophobic core of the particles is maintained important for desired surface erosion. 
a) b)
Figure 6: Degradation analysis of eADF4 (C16) particles:  a) SDS Page of degradation products of eADF4
(C16) particles. 1: Marker (Mark 12, Invitrogen); 2: eADF4 (C16) solution (c = 0.05 mg/ml) used for nanosphere 
preparation; 3: Degradation of eADF4 (C16) solution (c = 0.05 mg/ml) with elastase (c = 150 µg/ml) and trypsin 
(c = 600 µg/ml) for 1 h at 25°C; 4:  elastase (c = 150 µg/ml) and trypsin (c = 600 µg/ml) without any substrate; 
5-9: Degradation of 1 mg eADF4 (C16) nanospheres with  elastase (c = 4µg/ml ) and trypsin (c = 50 µg/ml) 5: 
after 1 day, 6: after 2 days, 7: after 3 days, 8: after 4 days, 9: after 5 days. b) Second derivative of FTIR spectra 
of eADF4 (C16) particles upon degradation at time points as indicated.
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Conclusion
Our results show the potential utility of engineered spider silk protein eADF4 (C16) particles 
for sustained controlled drug delivery. Our detailed investigation of the loading procedure 
including the parameters like the octanol/water partition coefficient (logP) and dissociation 
constants (pKa) of twelve different investigated model drugs showed that the presented 
encapsulation procedure can efficiently applied  for weak organic bases which represent the 
majority of drug molecules available today. Additionally, using an online zeta potential 
measurement during particle loading allows monitoring of the loading processes and 
facilitates determination of loading endpoint. Especially for high potential drugs used in 
cytostatics therapy such as Doxorubicin*HCl this particulate carrier system may be ideal due 
to its ease of preparation. Furthermore as shown eADF4 (C16) particles can be produced and 
loaded within an all-aqueous process under ambient conditions which is a major advantage 
considering encapsulation of labile compounds and the biocompatibility of the product. Due 
to its size eADF4 (C16) particles are applicable for drug targeting, since the diameter of the 
microspheres is appropriate for phagocytosis by macrophages or cellular uptake by carcinoma 
cells [41,42]. For biomedical application especially engineered spider silk proteins seem to be 
ideal. Due to the biotechnological production process no degumming process as for bombyx 
mori silk is rquired to get rid of the sericin which was identified as a source of immunogenic 
reactions in vivo [43]. Our results show that eADF4 (C16) particles undergo surface erosion 
which can be explained by the fact that the interior of the particles is hydrophobic enough to 
keep water from penetrating and degrading the interior of the materials faster than the surface 
layer erodes. The property of surface erodible eADF4 (C16) particles supports the 
applicability as drug delivery systems since bulk erosion processes lead to a massive 
interference with the drug release mechanism resulting in accelerated and uncontrolled 
release. We conclude that engineered spider silk particles have the potential for diverse 
applications where controlled release from biocompatible, mechanically tough, and slowly 
biodegradable carriers is desirable.
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5.3. Discussion of the presented data
In the previous section it was shown that spider silk protein particles are very suitable for the 
employment as drug release carriers. Since they carry a permanent negative charge in aqueous 
media of pH 7 they can interact with conversely loaded drug molecules thus determinating the 
observed highly efficient loading phenomenon and the well defined drug release rates. 
Additionally, the observed surface erosion process and the expected high biocompatibility is 
another promotional argument for the application of the genetically engineered material in 
pharmaceutical technology. However, when talking about the well defined release and the 
release period exceeding one month, on should keep in its mind that due to the small size of 
these particles the entrapped drug molecules have to diffuse only short distances. It is 
therefore appropriate to question whether the observed diffusion controlled release 
mechanism would be transferable to release systems featuring larger dimension, i.e. implants 
which exhibit unlike longer distances to be traversed by the entrapped drug molecules. 
Another question which needs to be answered deals with the preparation techniques of such 
larger release systems consisting of spider silk proteins. It has been previously shown that the 
employed spider silk proteins can be successfully transferred into films either by casting from 
organic solvents or from aqueous solution. However, preliminary experiments - as reported 
previously in the general introduction of this dissertation - showed that the casting process 
from aqueous solution isn’t capable of producing films larger than a few square millimetres
and exhibiting a thickness of only a few micrometers. This incapability is presumably a 
consequence ??? ???? ??????????? ??? ?-helical protein structure into ß-sheet rich structure 
occurring inhomogeneously during water evaporation. Therefore, in order to prepare larger 
films and implants organic solvents have to be introduced in the preparation process. 
Unfortunately the spectrum of solvents capable of dissolving spider silk proteins is not very 
broad. Apart from concentrated formic acid - a component which is not suitable for the 
preparation of drug depot systems due to its extreme pH – only hexafluoroisopropanol (HFIP) 
is capable of dissolving the engineered proteins in a reasonable amount of time. According to 
what we already learned about organic solvents such as HFIP- a polar solvent, miscible with 
water - we would now assume that this component jeopardizes the stability of the 
encapsulated proteins by inactivating them via water- HFIP interfaces. Eventually, the final 
part of this chapter highlights experiments dealing with the questions of spider silk film 
preparation and protein stability issues associated with the applied preparation techniques.
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5.4. Characterization of eADF4 (C16)-films for their application in drug release 
systems
Introduction
As seen in the previous part of this chapter recombinant produced spider silk protein eADF4
(C16) enables diffusion controlled release from nanoparticulate systems. The featured higuchi 
kinetic of the release profiles is consistent with the proposed structure of the genetically 
engineered silk material as a hydrophobic densely packed protein matrix.
Concerning the known properties of this unique material, the question arises, if C16 is 
applicable as release controlling layer, i.e. as coating material for various biomedical 
applications like stents or drug releasing implants. For silk fibroin we know of successful 
application as coating material for stents continuously releasing smooth muscle cell inhibitors 
such as clopidogrel and paclitaxel [1]. Theophyllin release from tablets was significantly 
reduced when coating the tablets with silk fibroin resulting in protein layers with an average 
thickness of about 50µm [2]. When preparing drug loaded silk fibroin films a biphasic release 
pattern was achieved by Hofmann et al. An initial release phase without burst effect was 
followed by a lag phase and continuous drug release between day 3 and 11[3]. The results of 
this experiment confirm that films and matrices consisting of high molecular fibroin –
exhibiting a molecular of about 60 kD[4] – are suitable as a release modifying material due to 
the diffusion of the drug molecule though the matrix. Therefore it was the aim of the 
presented experiments to characterize films prepared from recombinant spider silk protein 
eADF4 (C16) for their application as drug release controlling matrix material. 
Films were characterized using FT-IR spectroscopy (FT-IR), Scanning Electron Microscopy 
(SEM), Differential scanning Calorimetry (DSC) and tested for their permeability of various 
drugs.
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Materials and methods
Materials
Rh-??????????? ?-2a-(rh-?????? ?????? ????????????? ?????????? ????????? ?????in conc. 1.7 
mg/ml in a 25 mM acetate buffer of pH 5.0, 120 mM sodium chloride) was lyophilized in a 
1:3 ratio with hydroxypropyl-?-cyclodextrin (HP-?-CD, Merck, Darmstadt, Germany).
GCSF (Stada AG, Bad Vilbel, Germany; protein concentration 4.04mg/ml in a 20mM acetate 
buffer of pH 4) was lyophilized in 1:4 ratio with trehalose and 0.01% Tween 20. 
Lyophilized bovine serum albumin (BSA) and all other chemicals and solvents used in the 
presented experiments were purchased from Sigma-Aldrich, Steinheim, Germany. 
Methods
Preparation of silk films
Spider silk films were prepared using a casting method. 
Solutions of recombinant spider silk protein eADF4 (C16) were cast on a custom made PTFE 
plate with drilled moulds with an average diameter of 26mm and an average depth of 4mm 
(Fig. 1). Films made of aqueous or hexafluoroisopropanol (HFIP) eADF4 (C16)- solutions 
were post-cast treated with methanol or potassium phosphate solution to stabilize the film,  
i.e. to make them water insoluble. Films cast from formic acid solutions were already water 
insoluble after solvent evaporation. 
Figure 1: a) Custom made Teflon moulds b) cast film after solvent 
evaporation and removed from mould.
a b
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Silk films for examination with differential scanning Calorimetry
To determine the effect of different solvents on the properties of spider silk protein films were 
prepared from HFIP, formic acid and water. The silk content of the different solutions is listed 
in Table 1.
Solvent Silk content in solvent [%]
HFIP 10
Formic acid 10
Water 2
Table 1:  Solvents and silk concentrations in solutions for film casting
Spider silk protein eADF4 (C16) fibrils form spontaneously in aqueous solution, formation is 
concentration dependent. Silk concentration in aqueous solution was therefore limited to 2% 
since protein concentration is increasing when water is evaporating. As films from eADF4
(C16) are very sensitive towards changes in atmospheric humidity especially towards drying 
out, resulting in brittleness and fragility, the effect of  plasticizer was analyzed with DSC. 
Triacetin was used as plasticizer and applied in a concentration of 10% in HFIP solutions.
Silk film preparation for permeability experiments
Solutions prepared for film casting were dilutions of stock solutions. 
For casting procedure 330µl of stock solution (silk content 150mg/ml) were admixed in the 
casting mould with 250µl of pure solvent to allow the solution to bedew the surface of the 
mould. This final silk solution had a silk content of 5%. Cast solutions were stored over night 
in order to evaporate the solvent. After solvent evaporation the dried films were carefully 
removed from the mould and stored in a refrigerator for later use. 
Film thickness determination
Thickness of the prepared films was determined with light microscopy (data were collected 
through a Leica DFC 320 camera (Leica Microsystems, Wetzlar, Germany) mounted on an 
Orthoplan microscope (Leica, Wetzlar, Germany). and by using a digital calliper.
For microscopic thickness determination films were cut in slices of approximately 1 mm 
width by using a scalpel. These slices were mounted on microscopic glass slides using Scotch 
Tape. Thickness of the fixed slice was calculated with calibrated computer software (LUCIA 
Screen Measurement Version 3.52a)
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Karl-Fischer measurements
The residual moisture of spider silk films and lyophilized powder was analyzed using a Karl-
Fischer titrator AQUA 40.00 with headspace module. Samples of freshly prepared films and 
freshly lyophilized spider silk protein were sealed in vials with rubber stoppers. These vials 
were then used for water determination.
Scanning Electron Microscopy
To investigate surface structure and morphology, films cast from HFIP, water and formic acid 
were analyzed using a Field Emission Scanning Electron Microscope Joel JSM-6500F (Joel 
Inc., Peabody, USA). Films were fixed with adhesive carbon tape (BAL-TEC AG, Balzers, 
Principality of Liechtenstein) to a custom made brass stub, carbon-sputtered and analyzed.
FT-IR spectroscopy
In order to investigate on the structural changes prior and after the treatment of films cast 
from water and HFIP a Bruker Tensor 27 FT-IR Spectrometer with a PIKE MIRacle™ 
sampling accessory equipped with a MIRacle™ micrometer clamp was used to analyse the 
samples. The diamond/ZnSe crystal plate had a surface area of 2.54 mm2. Samples were 
spread on the crystal surface and compressed with the attached micrometer clamp in order to 
optimize the spectral quality. Spectra were recorded from 4000 to 800 cm-1 with a resolution 
of 4 cm-1
Differential scanning Calorimetry
Samples of eADF4 (C16) films cast from different solvents with or without plasticizer were 
analyzed with a NETZSCH DSC 204 Phoenix® instrument. Films derived from HFIP or 
aqueous solution were methanol treated in order to initiate structural conversion. To 
determine the glass transition temperature and the decomposition temperature samples were 
heated in the DSC at 10K min-1. Starting temperature was -20°C; end temperature was 
200°C.
SDS-PAGE
To investigate whether HFIP has detrimental effects on therapeutic proteins, HFIP and 
mixtures of HFIP and water were prepared and lyophilized therapeutic proteins (rh-INF, 
GCSF) were suspended respectively dissolved in the prepared mixtures. In order to mimic 
long term contact, i.e. residual solvents in spider silk matrices and solvent evaporation over a 
longer period of time, samples of the prepared protein-solvent mixtures were stored for one 
weak and analyzed thereafter. Samples drawn from the stored and from freshly prepared 
solutions were diluted in SDS-running buffer, heated for 50min at 95° C before loaded on the 
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gel. Gels were run with 40mA for approx. 1.5 h. Silver staining was used to visualize the 
protein bands, a mark 12TM protein standard was run in duplicate in order to determine the size 
of the analyzed samples. All materials were supplied by Invitrogen (Carlsbad, CA, USA).
SEC-HPLC
Protein stability of the samples was examined with a SEC-HPLC method. rh-?????????????
were analyzed using a Thermo Separation Products HPLC system equipped with a Tosoh 
TSK-Gel G3000 SWxl column. 120 mM disodium hydrogen phosphate dehydrate, 20 mM 
sodium dihydrogen phosphates and 4 g/L sodium chloride, adjusted with hydrochloric acid to 
a pH of 5 was used as mobile phase. The flow rate was set to 0.6 mL/min, UV detection was 
performed at 210 nm wavelength. GCSF was analyzed with the same instrument and column, 
as mobile phase a mixture of acetonitrile water (60:40) with an addition of 1ml trifluoro acetic 
acid per liter was used. Flow rate was adjusted to 1ml and the detection wavelength was 
225nm. In order to quantify protein concentration of the samples calibration curves with 
known protein concentrations were generated.
Permeation experiments
Physical properties of the model drugs used are listed in Table 2. The permeability 
coefficients of these drugs were determined using diaphragm diffusion cells made of two 
custom made Plexiglas compartments (donor and acceptor) divided by the silk film to be 
investigated serving as diaphragm. The area of the orifice was 2.21 cm2 and the capacity of 
both cells was approximately 1.2 ml each thus the solution in the two compartments was 
constantly exchanged by fresh media to maintain the diffusion pressure due to concentration 
differences on both sides of the diaphragm. The overall volume of the donor and the acceptor 
media was 50.0 ml. The measurement of permeability was performed in 10mM phosphate 
buffer at a pH of 7.4. Prior to an experiment, the hydrated membrane mounted between the 
two diffusion cells was swollen in the buffer solutions without diffusion solutes for about 2 h. 
Table 2: List of model drugs and their physical properties.
Model drug Isoelectric 
point
Dominant 
charge at 
pH 7.4
Permanently 
charged
Molecular 
weight [Da]
????
Nipagin ----- uncharged no 152 254
Phenol Red ----- negative yes 354 510
Methyl violet ----- positive yes 407 590
rh-INF 6 positive no 19.23k 280
BSA 4.8 negative no 66.3K 210
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The permeability coefficients of the model drugs then can be calculated by the following 
equation [5, 6]: t
t P
V
A
C
C
*2
2
1ln
0
=





− (1)
Whereas, Ct is the drug concentration in the receiving cell at time t, C0 the initial drug 
concentration in the source cell, V the solution volume in the two cells and A is the effective 
area of permeation. By plotting ??V/2A)×ln(1??Ct/C0) versus time t, the permeability 
coefficient can be calculated from the slope. All experiments were run in triplicate.
UV Vis-Spectroscopy
Ultraviolet–visible spectrometry using a Cary100 spectrophotometer (Varian Medical 
Systems,Palo Alto, USA) and for BSA determination a CS-930-1PC plate reader (Shimadzu, 
Kyoto, Japan). was employed for determination of model drug content in the donor and the 
acceptor compartment for the calculation of the permeability coefficient. Calibration curves 
for all model drugs investigated have been obtained by using 5 different concentrations of a 
stock solution. The wavelengths used for drug concentration are listed in Table2. 
Drug concentration in donor media was as followed for the different drugs:
Nipagin (1mg/ml), Methyl violet (0,03mg/ml), Phenol red (0,6 mg/ml), rhINF(1mg/ml) and 
BSA (0,4mg/ml).
Results and discussion
Karl-Fischer
Although using analytical grade solvents, i.e. 99-100% purity, films cast from Formic acid 
and from HFIP featured water contents comparable to the residual water content of films cast 
from aqueous solution. Probably these solutions were hygroscopic and adsorbed atmospheric 
water. The water contents of the films and the lyophilized C16 powder are listed in Table3.
Sample Residual water content  [%]
Film cast from HFIP 4.56
Film cast from Formic acid 6.73
Film cast from Water 7.21
Lyophilized eADF4 (C16) 3.42
Table 3: Residual water content in eADF4 (C16) films and powder
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Film thickness
Examination of the prepared film slices could confirm a uniform thickness of about 20µm of 
all cast films. Microscopic surface analysis revealed a glassy translucent film surface with few 
imprints probably derived from the casting mould. The cross section of the films didn’t differ 
significant from the analyzed surface morphology 
Figure 2: Light microscopy; a) film surface with mould imprints (50*magnification) b) cross section of a film 
prepared from HFIP solution (100x magnification) c) Formic acid derived film (100x magnification)
Scanning electron microscopy
SEM analysis of all prepared films revealed no significant difference in surface morphology 
and detectable microstructure. All films showed a pore free surface, cracks or other 
abnormalities in the morphology couldn’t be detected. Although the applied SEM technique 
requires water free samples no detrimental effect of the drying within the evacuated SEM 
observation chamber was detected. Analysis of cross sections of the films could confirm the 
pore less structure of the film matrix. Films prepared from aqueous solutions (Fig. 2) 
exhibited a slightly rougher surface than films prepared from HFIP (Fig. 3), or Formic acid 
(Fig. 4).
This phenomenon can be explained by the concentration effect of the solution due to water 
evaporation. Upon water evaporation the resulting higher concentrated eADF4 (C16) triggers 
the conversion of the random coil conformation to ß-sheet rich fibrils which are insoluble and 
therefore precipitate before water evaporation was complete. Nevertheless the cross section of 
this film shows no negative side effect of this phenomenon, i.e. no brittle and porous structure 
due to high fibril content.
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Figure 3:  SEM photographs of eADF4 (C16) cast from aqueous solution. A) On the left side of the picture: film 
surface revealing the fibrous surface structure (900X magnification) b)cutting edge of the same film with smooth 
microstructure (1800X magnification) c)Fine structured cross section of aqueous eADF4 (C16) film (23000X 
magnicfication)
Figure 4: SEM photographs of eADF4 (C16) cast from HFIP solution. a):Smooth  film surface with dust particle 
(11000X magnification) b)cutting edge of the same film (3700X magnification) c)Close up of the cutting site 
(14000X magnicfication)
Figure 5: eADF4 (C16) films cast from formic acid solution. a) film surface (3000X magnification) b) cutting
edge of the same film (850X magnification) c) Close up of the cutting site (13000X magnicfication)
DSC measurements 
Similar to conventional polymers such as PLGA spider silk protein films exhibited a second 
order phase transition and a corresponding relaxation peak at temperatures between 40 and 
55°C (Fig. 6). Presumably this phase transition can be explained as protein unfolding, i.e. a 
??????????? ??? ????????? ?-helical structure into ß-sheet. As seen in Fig. 6a the addition of 
triacetin as plasticizer decreases this phase transition temperature presumably unfolding is 
facilitated when the amount of water in the protein film is increased. Overall there is no major 
difference in this phase transition temperature for all films except for films prepared from 
aqueous solutions. These films showed no distinct phase transition, probably due to the 
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arrangement of proteins upon water evaporation and the formation of insoluble fibrils within 
the aqueous solution. When increasing the temperature of the oven all samples showed an 
endothermic event at about 130°C. 
This phenomenon indicates an irreversible folding process and the start of protein 
decomposition. 
Figure 6: Phase transition of protein films derived from a) HFIP with a decrease of phase transition temperature 
for films with 10% triacetin content ( lower Thermogram) b) Formic acid c) and films prepared from aqueous 
solution c).
Figure 7: Protein decomposition for films prepared from a) HFIP b) Formic acid c) water.
FT-IR measurements
FT-IR measurements were conducted with films before and after methanol treatment in order 
??? ???????? ???? ??????????? ???????? ???? ??? ?????????? ???? ???????? ??? ?-helical, respectively ß-
sheet structure. In contr?????????????????????????????????????????????-helical structure (Fig. 8 
blue line), treated films (Fig. ?? ???? ?????? ?????? ???????? ???????????? ???????? ??? ?-helical 
structured domains as seen in the second derivative of the spectral range from 1580 cm-1 and 
1720 cm-1. These domains can undergo structural conversion into ß-sheet when treated with 
heat as seen in the thermograms depicted in Fig. 7. In addition to that there was no significant 
change in ß-sheet or a-helical structure concerning films treated either with methanol of with 
potassium phosphate (Data not shown).
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Figure 8: 2nd derivative of FT-IR spectra of native and methanol treated films.
Permeation studies of eADF4 (C16) films
Except for the negatively charged Phenol red, all tested drugs permeated through the spider 
silk protein films. Experiments with Methyl violet lead to a dark dyed spider silk film and a 
quick permeation through the films, thus confirming the electrostatic interaction of both 
molecules. According to equation (1) permeation coefficients were calculated from the linear 
part of the slope since transport parameters can be recovered more accurately in this region 
(Fig. 9).All obtained permeation coefficients were normalized for a membrane thickness of 1 
µm. The permeation coefficients are listed in Table.4. As expected rh-INF? permeation was 
triggered by its isoelectric point and the resulting positive charge at the employed pH milieu 
of 7.4. Compared to that the measured permeation coefficient for the small molecule Nipagin 
was on a similar level and only slightly higher, presumably permeation of this uncharged 
molecule was unaltered due to the loss of electrostatic interaction with C16. The 66 kD 
molecule BSA featured the lowest permeation coefficient presumably as a result of both, its 
high molecular weight and its negative charge at pH 7.4. This finding is in accordance to 
experiments conducted with silk microcapsules tested for their permeability for FITC-dextran 
with different molecular weights. While the membrane was easily permeable for small 
molecules it was found that capsules showed no permeation of 60 kD FITC-dextran after 
incubation for 12h at room temperature [7].
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Table 4: Permeation coefficients P of different model drugs
Figure 9: Permeability studies of model drugs: Determination of permeation coefficient P.
SDS-PAGE
As HFIP and Formic acid are the only known solvents to dissolve ß-sheet structured eADF4
(C16) their effect on the stability of drugs during the preparation of drug loaded depot systems 
has to be investigated thoroughly. Investigation was mainly concentrating on HFIP since 
Formic acid is known to have detrimental effects on various drugs due to its extreme pH level 
of 1.2 resulting in drug hydrolysis and protein denaturation.
Model drug P (cm?s-1/µm).
Nipagin 1,63*10-3
Phenol Red impermeable
Methyl violet 1,9*10-2
rh-???? 1,1*10-3
BSA 2.56*10-5
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Figure 10: SDS-PAGE of rh-INf (a) and GCSF (b)
a) lane 1&8 marker, lane 2 rh-????? ?????????? ??????? ??-??????????????? ???????? ????????????? ??????? ??-?????
stored in HFIP:water (1:1) for 2 hours, lane 5 rh-?????????????????????????????????????????????????????????????-????????????????????????????????????????????????????????????????????????????????????????????????????????????????
b)  lane 1&8 marker, lane 2 GCSF standard, lane 3 GCSF dispersed in HFIP for 14 days at 5°C, lane 4 GCSF 
stored in HFIP:water (1:1) for 14  days at 5°C, lane 5 GCSF in aqueous solution stored at 5°C for 14 days, lane 6 
GCSF dispersed in HFIP stored for 2 hours, lane 7 GCSF stored in HFIP:water (1:1) for 2 hours.
As seen in Figure 10 gel-electrophoresis did not show strong destabilizing effects on protein 
stability for samples either suspended in HFIP or dissolved water, even after storage for 14 
days. However, HFIP/water mixtures seem to have negative effect on protein stability as 
proteins stored in this solution exhibited traceable aggregates, i.e. dimers. Additional 
experiments with HFIP/water mixtures could show that theses mixtures featured an acidic pH 
of about 3. Presumably this low pH levels in the prepared HFIP/water mixtures initiated 
protein aggregation.
SEC-HPLC
Results from chromatographic analysis of the protein samples prepared for SDS-PAGE 
analysis confirm the negative effect of HFIP/water mixtures on the protein stability. Whereas 
rh-INF and GCSF incubated in pure water or pure HFIP maintained their stability, analysis of 
samples incubated in HFIP/water mixtures for 14 days clearly revealed the presence of 
dimers. For rh-????? ???????? ?? ?????? ???????? ??? ????? ???? ??????????? ???? ???? ????????
incubated for 14 days in HFIP/water solutions. GCSF samples stored for the same amount of 
time in HFIP/water mixtures exhibited 4.7% Dimers (Figure 11b). This finding is in 
accordance with literature stating that traces of water in organic solvents have tremendous 
effect on protein stability and activity [8, 9].
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Figure 11: ???????????????????????????????????????????????????????????
So far SEC-HPLC analysis is consistent with the results of SDS-PAGE experiments. 
Surprisingly a negative effect on protein stability of pure HFIP cannot be stated, especially for 
proteins applied as lyophilized powder. This material wasn’t soluble in the organic solvent, 
thus protein solvent interactions as described in literature couldn’t occur [10].
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Conclusion
Results of the presented experiments attest the high potential of genetically engineered spider 
silk protein eADF4 (C16) for the application in pharmaceutical technology. Especially for the 
preparation of drug depot systems such as drug releasing films or coated implants, 
microparticles and biomedical devices likes stents. Due to the permeability properties 
membrane diffusion controlled systems for small drug molecules are achievable. For larger 
drugs or proteins with a molecular weight higher than 60kD the application as diffusion 
controlling membrane might be possible by rendering the membrane permeability properties 
by means of pore formation upon film preparation. eADF4 (C16) films can be easily prepared 
using simple casting techniques. Plasticizers can be added in order to achieve a higher 
flexibility of the films. It was shown that films prepared from aqueous solutions exhibit a 
fibrous surface and thermo analytical measurements of these films revealed changes in phase 
inversion properties. Usually these films were brittle and fragile. To obtain thicker films 
prepared from aqueous solutions subsequent casting and stabilization steps have to be applied 
resulting in sandwich structured film. However, the employment of HFIP as good solvent for 
eADF4 allows the quick and reproducible preparation of stable films without pores. Results of 
our stability studies showed that it is possible to integrate proteins as lyophilized powder in 
HFIP-based silk solution without any detrimental effects on protein stability. However, 
contamination of HFIP- eADF4 (C16)-drug solution with traces of water or a accumulation of 
water from atmospheric humidity has to be prevented, as small amounts of water endanger 
drug stability in these solutions.
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III. FINAL SUMMARY & CONCLUSION
The presented thesis deals with 2 main objectives treated in five chapters of this publication. 
Firstly, this work focuses on lipid based drug delivery systems for the long term delivery of 
bioactive substances e.g. therapeutic proteins and, in particular the degradation and erosion 
behaviour of these systems. In the introduction the current state of the art concerning the 
preparation of these systems was highlighted. Despite the long period of experience – starting 
already in the 70ies of the last century – until today data dealing with those systems in respect 
of their degradation behaviour in vivo is still insufficient. In order to learn more about the fate 
of lipid drug depot systems an animal experiment with rh-INF-releasing Tristearin implants 
was conducted which is the main topic of chapter 1. This animal experiment proved the high 
applicability of compressed implants consisting of Tristearin since the release mechanism in 
vivo wasn’t affected by tissue reactions and immune response of the animal organism. A high 
causal correlation between the observed in vivo release data and in vitro release data could be 
stated for the employed implants. No fever or other signs of inflammation and foreign tissue 
reaction were observed during the animal experiment. After sacrification of the animals the 
implants were surgically removed. First examinations revealed no significant degree of 
bioerosion; the implants maintained their physical structure. At the first glance this result was
somewhat disappointing since it was nearly expected that the employed implants would 
undergo biodegradation. However scanning electron microscopy analysis gives evidence that 
the lipid structure of the implants wasn’t unaffected by the onslaught of the immune cells 
occurring always when foreign material comes in contact with living tissue. A change in lipid 
matrix crystallinity and structure was detectable. Anyway the question whether these detected 
changes would have resulted in significant lipid implant erosion could not be answered in the 
scope of the presented data. To be more independent of animal experiments and to fully 
characterize degradation and erosion processes presumably happening during bio-incubation 
an in vitro model for the simulation of biodegradation processes was developed. The 
developed model and the employed analytical methods allowed for the first time a qualitative 
and quantitative analysis of the lipid degradation process upon incubation with lipases. In 
chapter 2 theses experiments dealing with different types of lipids and different particulate or 
monolithic systems derived thereof are presented. It could be shown that certain triglycerides 
can be hydrolyzed easily by natural enzymes and depot systems consisting of these 
triglycerides materials degrade fast, eventually collapsing into small and innocuous lipid
particles which are even more susceptible to lipid hydrolysis. It was also shown that, when 
using small lipid microparticles instead of large compressed implants the degradation velocity 
was substantially accelerated. This was previously observed in animal experiments when 
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injecting a lipid microparticle suspension. To learn more about these interesting phenomena
and to investigate on the underlying mechanism of rapid lipid degradation and implant 
erosion, additional experiments were conducted. This time, the analytical spectrum was 
extended and so far untouched aspects, i.e. especially the lipid erosion was covered. The 
results of these experiments are described in the scope of chapter 3. Here it could be clearly 
shown that certain physical properties of the employed materials such as the melting point, the 
miscibility with degradation products and the crystallinity are main factors determinating the 
degradation behaviour. It was found that the water uptake of lipid matrices which is very low 
for pure triglycerides is enhanced after treatment with lipases. This finding is not unexpected, 
since the hydrolyzed molecules feature one or more hydroxyl functions capable of interacting 
with water molecules. Furthermore this effect was found to substantially enhance the lipid 
erosion. The water penetrating into the lipid matrix presumably interferes with the lipid 
crystal lattice. The generated pores serve as gateway for lipase molecules which presumably 
can diffuse into the weakened matrix. The produced degradation products of the triglycerides 
- mainly fatty acids and mono- and diglycerides - subsequently promote the erosion process. 
These substances accumulate within the pore network inside the lipid matrix. This 
accumulation of substances featuring a lower melting point can eventually lead to the 
generation of an eutectic mixture exhibiting a melting point beneath the melting temperature 
of the single substances involved in this system. The subsequent melting process of the lipid 
structure destroys the physical stability of the compressed implant or extrudate. It can 
therefore be stated that the observed processes leading to lipid implant disintegration are of
both, chemical and physical nature and both pathways are synergistically amplifying each 
other. As already mentioned, this statement is only valid for triglyceride substances featuring 
a low melting point slightly above the body temperature of the human body such as 
glyceryltrilaurate. This may explain why the applied tristearate implants didn’t shown 
significant signs of degradation neither in the animal experiments nor in the first in vitro 
lipase incubation studies. Since glyceryltristearate exhibits a melting point significantly higher 
than the human body temperature it was not susceptible to the observed erosion process and 
only minor degradation was detected with the applied analytical methods. After presenting 
this set of data the author would like summarize that the chapters 1- 3 emblaze the 
applicability of these fascinating natural and ubiquitous materials for the production of highly 
biocompatible drug depot systems. Based on the presented data it should be possible to 
design, prepare and characterize triglyceride based depot systems with predefined degradation 
and erosion properties. These systems could be used for example for a long term delivery of 
bioactives e.g. for a period of several months to a few years depending on the employed lipid 
composition and on the system prepared. For instance when preparing lipid microparticles a 
FINAL SUMMARY & CONCLUSION
183
short shelf life in living animals can be assumed due to the observed size effects which boost 
the degradation velocity. When applying larger monolithic implants it can be assumed that 
total degradation doesn’t take place before the delivery phase has run. However it will be 
possible to design the implant in a way that the lipid system eventually fully degrades within 
the scope of several months.
The second part of the presented dissertation concentrates on the application of genetically 
engineered spider silk in the field of pharmaceutical technology and drug delivery. A 
comprehensive aggregation of this interesting research theme is included in the general 
introduction of this work. Since the research concentrating on proteins derived from spiders or 
silk worms is a relative new chapter in the book of biotechnology science there are only few 
data available dealing with the application of spider for the preparation of drug delivery 
systems. However, it is generally understood that these proteins exhibit properties which 
make them ideal for the preparation of tissue scaffold and drug delivery systems. Especially 
the high degree of biocompatibility is a major factor promoting their application in 
bioscience. Furthermore, experiments have shown that spider silk proteins promote healing 
processes and seem even capable of supporting the regeneration of nerve cells. Due to 
cooperation with the University of Bayreuth, especially with the research team of the 
department of biomaterial science it was possible to conduct research on newly prepared semi 
synthetic spider silk proteins. In contrast to other natural proteins which very often exhibit an
irregular composition of amino acids these genetically engineered spider silk proteins were 
available in qualities of high purity. Since these proteins were so far not examined for their 
application in the area of pharmaceutical technology their basic properties with respect to the 
preparation of drug depot systems were analyzed. In chapter 4 for the first time the 
preparation and characterization of semi synthetic spider silk microspheres and methods to 
control the particle size of the resulting particles are presented. It was found that these 
proteins can be processed easily into stable microparticles with a narrow particle size 
distribution. The preparation process is based on a precipitation mechanism involving the 
?????????????????????????????-helical rich proteins into ß-sheet rich, water insoluble proteins. 
This transition is achieved upon the addition of lyotropic salts such as potassium phosphate. 
In summary, a solvent free easily up scalable method was presented. The conducted method 
additionally features an almost 100% yield of protein spheres, an important issue for high 
price material. It is obvious that described preparation method is ideal in terms of 
biocompatible production of drug depot systems since all applied materials and solvents are 
absolutely physiologically uncritical. Subsequently the generated spider silk particles were 
analyzed and investigated for their use as particulate drug carrier.
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Chapter 5 is dedicated to the analysis of these particles with regards to the loading 
mechanism and the resulting drug release for small molecules. Drug loading efficiencies of up 
to 98% were achieved for positively charged drug molecules. Surprisingly it is not necessary 
to include the drug loading process into the process of particle preparation. In fact it is 
possible to prepare the particles, subsequently concentrate them by centrifugation and 
eventually subject them to the drug loading step. As the semi synthetic spider silk particles are 
negatively charged at neutral pH-levels due to the isoelectric point of their amino acid 
composition they can attract positively charged drug molecules. It was further on shown using 
on-line analysis methods during drug loading processes that the attracted positively charged 
drug molecules enter the interior of the protein particles and accumulate within. When 
investigating more than 10 different drug molecules with respect to their loading performance 
it was found that it is possible to correlate molecular parameters such as drug charge 
(calculated from the acid dissociation constant pKa) and the distribution coefficient D with 
the achieved loading efficiency. Interestingly the high hydrophobicity within the interior of 
the spider silk particles allows as well a high degree of drug loading for uncharged water 
soluble drugs, whereas negatively charged drugs are almost impossible to encapsulate into the 
spider protein particles. In terms of the release of the entrapped drug molecules from the 
spider silk particles release periods exceeding one month were achieved. The observed release 
kinetics was characterized. Drug release from these systems is characterized as anomalous 
diffusional release within the first weeks. After that period Fickian release behaviour is 
predominant. In another set of experiments the biodegradation of this silk molecule was 
investigated. These experiments could clearly show that the spider silk particles are erodible 
in the presence of physiological proteases such as Elastase. As expected when incubating the 
particles in enzyme-containing buffer media surface erosion processes were observed via 
SEM and particles size analysis. Additional data highlighting the applicability of spider silk
macro layers and films usable for the release of drugs or the modulation of drug release from 
implants is presented in the additional data closing chapter 5. In summary genetically 
engineered spider silk proteins especially the employed eADF4 are of very high potential for 
the application in pharmaceutical technology due to their unique properties regarding 
applicable preparation techniques, drug loading, and drug release and due to their expected 
biodegradation in physiological surroundings.
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